#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Altered functional connectivity of the nucleus accumbens subdivisions in amphetamine-type stimulant abusers: a resting-state fMRI study
#Text=Background
#Text=The growing abuse of amphetamine-type stimulants leads to new challenges to human health.
1-1	0-7	Altered	_	
1-2	8-18	functional	_	
1-3	19-31	connectivity	_	
1-4	32-34	of	_	
1-5	35-38	the	_	
1-6	39-46	nucleus	_	
1-7	47-56	accumbens	_	
1-8	57-69	subdivisions	_	
1-9	70-72	in	_	
1-10	73-89	amphetamine-type	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse[1]	
1-11	90-99	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse[1]	
1-12	100-107	abusers	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse[1]	
1-13	107-108	:	_	
1-14	109-110	a	_	
1-15	111-124	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
1-16	125-129	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
1-17	130-135	study	_	
1-18	136-146	Background	_	
1-19	147-150	The	_	
1-20	151-158	growing	_	
1-21	159-164	abuse	_	
1-22	165-167	of	_	
1-23	168-184	amphetamine-type	_	
1-24	185-195	stimulants	_	
1-25	196-201	leads	_	
1-26	202-204	to	_	
1-27	205-208	new	_	
1-28	209-219	challenges	_	
1-29	220-222	to	_	
1-30	223-228	human	_	
1-31	229-235	health	_	
1-32	235-236	.	_	

#Text=A possible addiction mechanism has been proposed by altered functional architecture of the nucleus accumbens (NAc) during resting state.
2-1	237-238	A	_	
2-2	239-247	possible	_	
2-3	248-257	addiction	_	
2-4	258-267	mechanism	_	
2-5	268-271	has	_	
2-6	272-276	been	_	
2-7	277-285	proposed	_	
2-8	286-288	by	_	
2-9	289-296	altered	_	
2-10	297-307	functional	_	
2-11	308-320	architecture	_	
2-12	321-323	of	_	
2-13	324-327	the	_	
2-14	328-335	nucleus	_	
2-15	336-345	accumbens	_	
2-16	346-347	(	_	
2-17	347-350	NAc	_	
2-18	350-351	)	_	
2-19	352-358	during	_	
2-20	359-366	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[3]	
2-21	367-372	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[3]	
2-22	372-373	.	_	

#Text=NAc contains different subdivisions and they may play different roles in addiction.
3-1	374-377	NAc	_	
3-2	378-386	contains	_	
3-3	387-396	different	_	
3-4	397-409	subdivisions	_	
3-5	410-413	and	_	
3-6	414-418	they	_	
3-7	419-422	may	_	
3-8	423-427	play	_	
3-9	428-437	different	_	
3-10	438-443	roles	_	
3-11	444-446	in	_	
3-12	447-456	addiction	_	
3-13	456-457	.	_	

#Text=The aim of the present study was to examine whether there are common or distinct patterns of functional connectivity of the NAc subdivisions in amphetamine-type stimulant abusers (ATSAs).
4-1	458-461	The	_	
4-2	462-465	aim	_	
4-3	466-468	of	_	
4-4	469-472	the	_	
4-5	473-480	present	_	
4-6	481-486	study	_	
4-7	487-490	was	_	
4-8	491-493	to	_	
4-9	494-501	examine	_	
4-10	502-509	whether	_	
4-11	510-515	there	_	
4-12	516-519	are	_	
4-13	520-526	common	_	
4-14	527-529	or	_	
4-15	530-538	distinct	_	
4-16	539-547	patterns	_	
4-17	548-550	of	_	
4-18	551-561	functional	_	
4-19	562-574	connectivity	_	
4-20	575-577	of	_	
4-21	578-581	the	_	
4-22	582-585	NAc	_	
4-23	586-598	subdivisions	_	
4-24	599-601	in	_	
4-25	602-618	amphetamine-type	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse[4]	
4-26	619-628	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse[4]	
4-27	629-636	abusers	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse[4]	
4-28	637-638	(	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse[4]	
4-29	638-643	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse[4]	
4-30	643-644	)	_	
4-31	644-645	.	_	

#Text=Methods
#Text=The present study recruited 17 male ATSAs and 22 healthy male controls.
5-1	646-653	Methods	_	
5-2	654-657	The	_	
5-3	658-665	present	_	
5-4	666-671	study	_	
5-5	672-681	recruited	_	
5-6	682-684	17	_	
5-7	685-689	male	_	
5-8	690-695	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse	
5-9	696-699	and	_	
5-10	700-702	22	_	
5-11	703-710	healthy	_	
5-12	711-715	male	_	
5-13	716-724	controls	_	
5-14	724-725	.	_	

#Text=All the subjects underwent resting-state functional magnetic resonance imaging (fMRI) with their eyes closed.
6-1	726-729	All	_	
6-2	730-733	the	_	
6-3	734-742	subjects	_	
6-4	743-752	underwent	_	
6-5	753-766	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
6-6	767-777	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
6-7	778-786	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
6-8	787-796	resonance	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
6-9	797-804	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
6-10	805-806	(	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
6-11	806-810	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
6-12	810-811	)	_	
6-13	812-816	with	_	
6-14	817-822	their	_	
6-15	823-827	eyes	_	
6-16	828-834	closed	_	
6-17	834-835	.	_	

#Text=The NAc was divided into core-like and shell-like subdivisions.
7-1	836-839	The	_	
7-2	840-843	NAc	_	
7-3	844-847	was	_	
7-4	848-855	divided	_	
7-5	856-860	into	_	
7-6	861-870	core-like	_	
7-7	871-874	and	_	
7-8	875-885	shell-like	_	
7-9	886-898	subdivisions	_	
7-10	898-899	.	_	

#Text=We used seed-based resting-state functional connectivity (RSFC) analyses to identify differences in brain functional architecture between ATSAs and healthy controls (HCs).
8-1	900-902	We	_	
8-2	903-907	used	_	
8-3	908-918	seed-based	_	
8-4	919-932	resting-state	_	
8-5	933-943	functional	_	
8-6	944-956	connectivity	_	
8-7	957-958	(	_	
8-8	958-962	RSFC	_	
8-9	962-963	)	_	
8-10	964-972	analyses	_	
8-11	973-975	to	_	
8-12	976-984	identify	_	
8-13	985-996	differences	_	
8-14	997-999	in	_	
8-15	1000-1005	brain	_	
8-16	1006-1016	functional	_	
8-17	1017-1029	architecture	_	
8-18	1030-1037	between	_	
8-19	1038-1043	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse	
8-20	1044-1047	and	_	
8-21	1048-1055	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
8-22	1056-1064	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
8-23	1065-1066	(	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
8-24	1066-1069	HCs	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
8-25	1069-1070	)	_	
8-26	1070-1071	.	_	

#Text=Results
#Text=ATSAs had lower positive RSFCs with all of the NAc subdivisions over the left orbital part of superior frontal gyrus and higher positive RSFCs with the NAc subdivisions over the left opercular part of inferior frontal gyrus than HCs, which indicates common abnormalities across the NAc subdivisions in ATSAs.
9-1	1072-1079	Results	_	
9-2	1080-1085	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse	
9-3	1086-1089	had	_	
9-4	1090-1095	lower	_	
9-5	1096-1104	positive	_	
9-6	1105-1110	RSFCs	_	
9-7	1111-1115	with	_	
9-8	1116-1119	all	_	
9-9	1120-1122	of	_	
9-10	1123-1126	the	_	
9-11	1127-1130	NAc	_	
9-12	1131-1143	subdivisions	_	
9-13	1144-1148	over	_	
9-14	1149-1152	the	_	
9-15	1153-1157	left	_	
9-16	1158-1165	orbital	_	
9-17	1166-1170	part	_	
9-18	1171-1173	of	_	
9-19	1174-1182	superior	_	
9-20	1183-1190	frontal	_	
9-21	1191-1196	gyrus	_	
9-22	1197-1200	and	_	
9-23	1201-1207	higher	_	
9-24	1208-1216	positive	_	
9-25	1217-1222	RSFCs	_	
9-26	1223-1227	with	_	
9-27	1228-1231	the	_	
9-28	1232-1235	NAc	_	
9-29	1236-1248	subdivisions	_	
9-30	1249-1253	over	_	
9-31	1254-1257	the	_	
9-32	1258-1262	left	_	
9-33	1263-1272	opercular	_	
9-34	1273-1277	part	_	
9-35	1278-1280	of	_	
9-36	1281-1289	inferior	_	
9-37	1290-1297	frontal	_	
9-38	1298-1303	gyrus	_	
9-39	1304-1308	than	_	
9-40	1309-1312	HCs	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
9-41	1312-1313	,	_	
9-42	1314-1319	which	_	
9-43	1320-1329	indicates	_	
9-44	1330-1336	common	_	
9-45	1337-1350	abnormalities	_	
9-46	1351-1357	across	_	
9-47	1358-1361	the	_	
9-48	1362-1365	NAc	_	
9-49	1366-1378	subdivisions	_	
9-50	1379-1381	in	_	
9-51	1382-1387	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse	
9-52	1387-1388	.	_	

#Text=In addition, the RSFCs between the NAc subdivisions and the left orbital part of superior frontal gyrus were negatively correlated with the addiction severity in ATSAs.
10-1	1389-1391	In	_	
10-2	1392-1400	addition	_	
10-3	1400-1401	,	_	
10-4	1402-1405	the	_	
10-5	1406-1411	RSFCs	_	
10-6	1412-1419	between	_	
10-7	1420-1423	the	_	
10-8	1424-1427	NAc	_	
10-9	1428-1440	subdivisions	_	
10-10	1441-1444	and	_	
10-11	1445-1448	the	_	
10-12	1449-1453	left	_	
10-13	1454-1461	orbital	_	
10-14	1462-1466	part	_	
10-15	1467-1469	of	_	
10-16	1470-1478	superior	_	
10-17	1479-1486	frontal	_	
10-18	1487-1492	gyrus	_	
10-19	1493-1497	were	_	
10-20	1498-1508	negatively	_	
10-21	1509-1519	correlated	_	
10-22	1520-1524	with	_	
10-23	1525-1528	the	_	
10-24	1529-1538	addiction	_	
10-25	1539-1547	severity	_	
10-26	1548-1550	in	_	
10-27	1551-1556	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse	
10-28	1556-1557	.	_	

#Text=Conclusion
#Text=These results provide evidence that there are common RSFC patterns of the NAc subdivisions in ATSAs.
11-1	1558-1568	Conclusion	_	
11-2	1569-1574	These	_	
11-3	1575-1582	results	_	
11-4	1583-1590	provide	_	
11-5	1591-1599	evidence	_	
11-6	1600-1604	that	_	
11-7	1605-1610	there	_	
11-8	1611-1614	are	_	
11-9	1615-1621	common	_	
11-10	1622-1626	RSFC	_	
11-11	1627-1635	patterns	_	
11-12	1636-1638	of	_	
11-13	1639-1642	the	_	
11-14	1643-1646	NAc	_	
11-15	1647-1659	subdivisions	_	
11-16	1660-1662	in	_	
11-17	1663-1668	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse	
11-18	1668-1669	.	_	

#Text=The abnormality indicated by disrupted functional connectivity between the NAc subdivisions and prefrontal cortex suggests abnormal interaction between the rewarding process and cognitive control in ATSAs.
12-1	1670-1673	The	_	
12-2	1674-1685	abnormality	_	
12-3	1686-1695	indicated	_	
12-4	1696-1698	by	_	
12-5	1699-1708	disrupted	_	
12-6	1709-1719	functional	_	
12-7	1720-1732	connectivity	_	
12-8	1733-1740	between	_	
12-9	1741-1744	the	_	
12-10	1745-1748	NAc	_	
12-11	1749-1761	subdivisions	_	
12-12	1762-1765	and	_	
12-13	1766-1776	prefrontal	_	
12-14	1777-1783	cortex	_	
12-15	1784-1792	suggests	_	
12-16	1793-1801	abnormal	_	
12-17	1802-1813	interaction	_	
12-18	1814-1821	between	_	
12-19	1822-1825	the	_	
12-20	1826-1835	rewarding	_	
12-21	1836-1843	process	_	
12-22	1844-1847	and	_	
12-23	1848-1857	cognitive	_	
12-24	1858-1865	control	_	
12-25	1866-1868	in	_	
12-26	1869-1874	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse	
12-27	1874-1875	.	_	

#Text=Our results shed insight on the neurobiological mechanisms of ATSA and suggest potential novel therapeutic targets for treatment and intervention of ATSAs.
13-1	1876-1879	Our	_	
13-2	1880-1887	results	_	
13-3	1888-1892	shed	_	
13-4	1893-1900	insight	_	
13-5	1901-1903	on	_	
13-6	1904-1907	the	_	
13-7	1908-1923	neurobiological	_	
13-8	1924-1934	mechanisms	_	
13-9	1935-1937	of	_	
13-10	1938-1942	ATSA	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse	
13-11	1943-1946	and	_	
13-12	1947-1954	suggest	_	
13-13	1955-1964	potential	_	
13-14	1965-1970	novel	_	
13-15	1971-1982	therapeutic	_	
13-16	1983-1990	targets	_	
13-17	1991-1994	for	_	
13-18	1995-2004	treatment	_	
13-19	2005-2008	and	_	
13-20	2009-2021	intervention	_	
13-21	2022-2024	of	_	
13-22	2025-2030	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse	
13-23	2030-2031	.	_	

#Text=Background
#Text=Drug addiction is one of the major health problems in the current society.
14-1	2032-2042	Background	_	
14-2	2043-2047	Drug	_	
14-3	2048-2057	addiction	_	
14-4	2058-2060	is	_	
14-5	2061-2064	one	_	
14-6	2065-2067	of	_	
14-7	2068-2071	the	_	
14-8	2072-2077	major	_	
14-9	2078-2084	health	_	
14-10	2085-2093	problems	_	
14-11	2094-2096	in	_	
14-12	2097-2100	the	_	
14-13	2101-2108	current	_	
14-14	2109-2116	society	_	
14-15	2116-2117	.	_	

#Text=The main feature of drug addiction is the inability to resist one's urge to obtain and take addictive drugs even though it can cause serious negative consequences.
15-1	2118-2121	The	_	
15-2	2122-2126	main	_	
15-3	2127-2134	feature	_	
15-4	2135-2137	of	_	
15-5	2138-2142	drug	_	
15-6	2143-2152	addiction	_	
15-7	2153-2155	is	_	
15-8	2156-2159	the	_	
15-9	2160-2169	inability	_	
15-10	2170-2172	to	_	
15-11	2173-2179	resist	_	
15-12	2180-2185	one's	_	
15-13	2186-2190	urge	_	
15-14	2191-2193	to	_	
15-15	2194-2200	obtain	_	
15-16	2201-2204	and	_	
15-17	2205-2209	take	_	
15-18	2210-2219	addictive	_	
15-19	2220-2225	drugs	_	
15-20	2226-2230	even	_	
15-21	2231-2237	though	_	
15-22	2238-2240	it	_	
15-23	2241-2244	can	_	
15-24	2245-2250	cause	_	
15-25	2251-2258	serious	_	
15-26	2259-2267	negative	_	
15-27	2268-2280	consequences	_	
15-28	2280-2281	.	_	

#Text=Worldwide, the abuse of amphetamine-type stimulants is a global and growing phenomenon.
16-1	2282-2291	Worldwide	_	
16-2	2291-2292	,	_	
16-3	2293-2296	the	_	
16-4	2297-2302	abuse	_	
16-5	2303-2305	of	_	
16-6	2306-2322	amphetamine-type	_	
16-7	2323-2333	stimulants	_	
16-8	2334-2336	is	_	
16-9	2337-2338	a	_	
16-10	2339-2345	global	_	
16-11	2346-2349	and	_	
16-12	2350-2357	growing	_	
16-13	2358-2368	phenomenon	_	
16-14	2368-2369	.	_	

#Text=In China, the proportion of amphetamine-type stimulants abusers (ATSAs) is continuously increasing over the past several years.
17-1	2370-2372	In	_	
17-2	2373-2378	China	_	
17-3	2378-2379	,	_	
17-4	2380-2383	the	_	
17-5	2384-2394	proportion	_	
17-6	2395-2397	of	_	
17-7	2398-2414	amphetamine-type	_	
17-8	2415-2425	stimulants	_	
17-9	2426-2433	abusers	_	
17-10	2434-2435	(	_	
17-11	2435-2440	ATSAs	_	
17-12	2440-2441	)	_	
17-13	2442-2444	is	_	
17-14	2445-2457	continuously	_	
17-15	2458-2468	increasing	_	
17-16	2469-2473	over	_	
17-17	2474-2477	the	_	
17-18	2478-2482	past	_	
17-19	2483-2490	several	_	
17-20	2491-2496	years	_	
17-21	2496-2497	.	_	

#Text=Drug addiction is often related to altered functional architecture in the brain, which results in hypersensitivity to the drug and drug-related cues and further ensures the compulsive drug-seeking behavior.
18-1	2498-2502	Drug	_	
18-2	2503-2512	addiction	_	
18-3	2513-2515	is	_	
18-4	2516-2521	often	_	
18-5	2522-2529	related	_	
18-6	2530-2532	to	_	
18-7	2533-2540	altered	_	
18-8	2541-2551	functional	_	
18-9	2552-2564	architecture	_	
18-10	2565-2567	in	_	
18-11	2568-2571	the	_	
18-12	2572-2577	brain	_	
18-13	2577-2578	,	_	
18-14	2579-2584	which	_	
18-15	2585-2592	results	_	
18-16	2593-2595	in	_	
18-17	2596-2612	hypersensitivity	_	
18-18	2613-2615	to	_	
18-19	2616-2619	the	_	
18-20	2620-2624	drug	_	
18-21	2625-2628	and	_	
18-22	2629-2641	drug-related	_	
18-23	2642-2646	cues	_	
18-24	2647-2650	and	_	
18-25	2651-2658	further	_	
18-26	2659-2666	ensures	_	
18-27	2667-2670	the	_	
18-28	2671-2681	compulsive	_	
18-29	2682-2694	drug-seeking	_	
18-30	2695-2703	behavior	_	
18-31	2703-2704	.	_	

#Text=Recent neuroimaging studies have indicated the significant functions of the reward system in drug addiction.
19-1	2705-2711	Recent	_	
19-2	2712-2724	neuroimaging	_	
19-3	2725-2732	studies	_	
19-4	2733-2737	have	_	
19-5	2738-2747	indicated	_	
19-6	2748-2751	the	_	
19-7	2752-2763	significant	_	
19-8	2764-2773	functions	_	
19-9	2774-2776	of	_	
19-10	2777-2780	the	_	
19-11	2781-2787	reward	_	
19-12	2788-2794	system	_	
19-13	2795-2797	in	_	
19-14	2798-2802	drug	_	
19-15	2803-2812	addiction	_	
19-16	2812-2813	.	_	

#Text=One of the main brain regions underlying addiction is the nucleus accumbens (NAc), a brain nucleus well recognized as a center of rewarding processes.
20-1	2814-2817	One	_	
20-2	2818-2820	of	_	
20-3	2821-2824	the	_	
20-4	2825-2829	main	_	
20-5	2830-2835	brain	_	
20-6	2836-2843	regions	_	
20-7	2844-2854	underlying	_	
20-8	2855-2864	addiction	_	
20-9	2865-2867	is	_	
20-10	2868-2871	the	_	
20-11	2872-2879	nucleus	_	
20-12	2880-2889	accumbens	_	
20-13	2890-2891	(	_	
20-14	2891-2894	NAc	_	
20-15	2894-2895	)	_	
20-16	2895-2896	,	_	
20-17	2897-2898	a	_	
20-18	2899-2904	brain	_	
20-19	2905-2912	nucleus	_	
20-20	2913-2917	well	_	
20-21	2918-2928	recognized	_	
20-22	2929-2931	as	_	
20-23	2932-2933	a	_	
20-24	2934-2940	center	_	
20-25	2941-2943	of	_	
20-26	2944-2953	rewarding	_	
20-27	2954-2963	processes	_	
20-28	2963-2964	.	_	

#Text=Elevated dopamine transmission in the NAc is thought to be a primary mediator of drug addiction.
21-1	2965-2973	Elevated	_	
21-2	2974-2982	dopamine	_	
21-3	2983-2995	transmission	_	
21-4	2996-2998	in	_	
21-5	2999-3002	the	_	
21-6	3003-3006	NAc	_	
21-7	3007-3009	is	_	
21-8	3010-3017	thought	_	
21-9	3018-3020	to	_	
21-10	3021-3023	be	_	
21-11	3024-3025	a	_	
21-12	3026-3033	primary	_	
21-13	3034-3042	mediator	_	
21-14	3043-3045	of	_	
21-15	3046-3050	drug	_	
21-16	3051-3060	addiction	_	
21-17	3060-3061	.	_	

#Text=Besides, the NAc is a major input structure of the basal ganglia, thus it can integrate information from cortical and limbic regions and further modulate goal-directed behaviors.
22-1	3062-3069	Besides	_	
22-2	3069-3070	,	_	
22-3	3071-3074	the	_	
22-4	3075-3078	NAc	_	
22-5	3079-3081	is	_	
22-6	3082-3083	a	_	
22-7	3084-3089	major	_	
22-8	3090-3095	input	_	
22-9	3096-3105	structure	_	
22-10	3106-3108	of	_	
22-11	3109-3112	the	_	
22-12	3113-3118	basal	_	
22-13	3119-3126	ganglia	_	
22-14	3126-3127	,	_	
22-15	3128-3132	thus	_	
22-16	3133-3135	it	_	
22-17	3136-3139	can	_	
22-18	3140-3149	integrate	_	
22-19	3150-3161	information	_	
22-20	3162-3166	from	_	
22-21	3167-3175	cortical	_	
22-22	3176-3179	and	_	
22-23	3180-3186	limbic	_	
22-24	3187-3194	regions	_	
22-25	3195-3198	and	_	
22-26	3199-3206	further	_	
22-27	3207-3215	modulate	_	
22-28	3216-3229	goal-directed	_	
22-29	3230-3239	behaviors	_	
22-30	3239-3240	.	_	

#Text=The NAc plays a pivotal role in refining action selection and mediating the rewarding effects of drugs abuse.
23-1	3241-3244	The	_	
23-2	3245-3248	NAc	_	
23-3	3249-3254	plays	_	
23-4	3255-3256	a	_	
23-5	3257-3264	pivotal	_	
23-6	3265-3269	role	_	
23-7	3270-3272	in	_	
23-8	3273-3281	refining	_	
23-9	3282-3288	action	_	
23-10	3289-3298	selection	_	
23-11	3299-3302	and	_	
23-12	3303-3312	mediating	_	
23-13	3313-3316	the	_	
23-14	3317-3326	rewarding	_	
23-15	3327-3334	effects	_	
23-16	3335-3337	of	_	
23-17	3338-3343	drugs	_	
23-18	3344-3349	abuse	_	
23-19	3349-3350	.	_	

#Text=Therefore, it is generally thought that chronic exposure to addictive drugs disrupts the plasticity of the NAc, producing a pathologic motivation for addictive drug seeking.
24-1	3351-3360	Therefore	_	
24-2	3360-3361	,	_	
24-3	3362-3364	it	_	
24-4	3365-3367	is	_	
24-5	3368-3377	generally	_	
24-6	3378-3385	thought	_	
24-7	3386-3390	that	_	
24-8	3391-3398	chronic	_	
24-9	3399-3407	exposure	_	
24-10	3408-3410	to	_	
24-11	3411-3420	addictive	_	
24-12	3421-3426	drugs	_	
24-13	3427-3435	disrupts	_	
24-14	3436-3439	the	_	
24-15	3440-3450	plasticity	_	
24-16	3451-3453	of	_	
24-17	3454-3457	the	_	
24-18	3458-3461	NAc	_	
24-19	3461-3462	,	_	
24-20	3463-3472	producing	_	
24-21	3473-3474	a	_	
24-22	3475-3485	pathologic	_	
24-23	3486-3496	motivation	_	
24-24	3497-3500	for	_	
24-25	3501-3510	addictive	_	
24-26	3511-3515	drug	_	
24-27	3516-3523	seeking	_	
24-28	3523-3524	.	_	

#Text=Resting-state functional connectivity (RSFC) is shown to provide a measure of the brain’s functional organization.
25-1	3525-3538	Resting-state	_	
25-2	3539-3549	functional	_	
25-3	3550-3562	connectivity	_	
25-4	3563-3564	(	_	
25-5	3564-3568	RSFC	_	
25-6	3568-3569	)	_	
25-7	3570-3572	is	_	
25-8	3573-3578	shown	_	
25-9	3579-3581	to	_	
25-10	3582-3589	provide	_	
25-11	3590-3591	a	_	
25-12	3592-3599	measure	_	
25-13	3600-3602	of	_	
25-14	3603-3606	the	_	
25-15	3607-3612	brain	_	
25-16	3612-3613	’	_	
25-17	3613-3614	s	_	
25-18	3615-3625	functional	_	
25-19	3626-3638	organization	_	
25-20	3638-3639	.	_	

#Text=Some researchers have studied the RSFC in substance-dependent populations, including individuals addicted to heroin, nicotine, and cocaine.
26-1	3640-3644	Some	_	
26-2	3645-3656	researchers	_	
26-3	3657-3661	have	_	
26-4	3662-3669	studied	_	
26-5	3670-3673	the	_	
26-6	3674-3678	RSFC	_	
26-7	3679-3681	in	_	
26-8	3682-3701	substance-dependent	_	
26-9	3702-3713	populations	_	
26-10	3713-3714	,	_	
26-11	3715-3724	including	_	
26-12	3725-3736	individuals	_	
26-13	3737-3745	addicted	_	
26-14	3746-3748	to	_	
26-15	3749-3755	heroin	_	
26-16	3755-3756	,	_	
26-17	3757-3765	nicotine	_	
26-18	3765-3766	,	_	
26-19	3767-3770	and	_	
26-20	3771-3778	cocaine	_	
26-21	3778-3779	.	_	

#Text=These resting-state fMRI findings provide evidence that regions related to reward and cognitive control are involved in addiction.
27-1	3780-3785	These	_	
27-2	3786-3799	resting-state	_	
27-3	3800-3804	fMRI	_	
27-4	3805-3813	findings	_	
27-5	3814-3821	provide	_	
27-6	3822-3830	evidence	_	
27-7	3831-3835	that	_	
27-8	3836-3843	regions	_	
27-9	3844-3851	related	_	
27-10	3852-3854	to	_	
27-11	3855-3861	reward	_	
27-12	3862-3865	and	_	
27-13	3866-3875	cognitive	_	
27-14	3876-3883	control	_	
27-15	3884-3887	are	_	
27-16	3888-3896	involved	_	
27-17	3897-3899	in	_	
27-18	3900-3909	addiction	_	
27-19	3909-3910	.	_	

#Text=A possible mechanism for drug addiction has been proposed by disrupted functional connectivity of the NAc in resting state.
28-1	3911-3912	A	_	
28-2	3913-3921	possible	_	
28-3	3922-3931	mechanism	_	
28-4	3932-3935	for	_	
28-5	3936-3940	drug	_	
28-6	3941-3950	addiction	_	
28-7	3951-3954	has	_	
28-8	3955-3959	been	_	
28-9	3960-3968	proposed	_	
28-10	3969-3971	by	_	
28-11	3972-3981	disrupted	_	
28-12	3982-3992	functional	_	
28-13	3993-4005	connectivity	_	
28-14	4006-4008	of	_	
28-15	4009-4012	the	_	
28-16	4013-4016	NAc	_	
28-17	4017-4019	in	_	
28-18	4020-4027	resting	_	
28-19	4028-4033	state	_	
28-20	4033-4034	.	_	

#Text=It has been shown that the RSFC of NAc, especially its interaction with the prefrontal cortices, was related to impulsive behavior.
29-1	4035-4037	It	_	
29-2	4038-4041	has	_	
29-3	4042-4046	been	_	
29-4	4047-4052	shown	_	
29-5	4053-4057	that	_	
29-6	4058-4061	the	_	
29-7	4062-4066	RSFC	_	
29-8	4067-4069	of	_	
29-9	4070-4073	NAc	_	
29-10	4073-4074	,	_	
29-11	4075-4085	especially	_	
29-12	4086-4089	its	_	
29-13	4090-4101	interaction	_	
29-14	4102-4106	with	_	
29-15	4107-4110	the	_	
29-16	4111-4121	prefrontal	_	
29-17	4122-4130	cortices	_	
29-18	4130-4131	,	_	
29-19	4132-4135	was	_	
29-20	4136-4143	related	_	
29-21	4144-4146	to	_	
29-22	4147-4156	impulsive	_	
29-23	4157-4165	behavior	_	
29-24	4165-4166	.	_	

#Text=Exposures to addictive cues could decrease its RSFC to the prefrontal lobe.
30-1	4167-4176	Exposures	_	
30-2	4177-4179	to	_	
30-3	4180-4189	addictive	_	
30-4	4190-4194	cues	_	
30-5	4195-4200	could	_	
30-6	4201-4209	decrease	_	
30-7	4210-4213	its	_	
30-8	4214-4218	RSFC	_	
30-9	4219-4221	to	_	
30-10	4222-4225	the	_	
30-11	4226-4236	prefrontal	_	
30-12	4237-4241	lobe	_	
30-13	4241-4242	.	_	

#Text=Further, the disrupted RSFC of NAc and prefrontal cortical regions has been reported in substance use disorder.
31-1	4243-4250	Further	_	
31-2	4250-4251	,	_	
31-3	4252-4255	the	_	
31-4	4256-4265	disrupted	_	
31-5	4266-4270	RSFC	_	
31-6	4271-4273	of	_	
31-7	4274-4277	NAc	_	
31-8	4278-4281	and	_	
31-9	4282-4292	prefrontal	_	
31-10	4293-4301	cortical	_	
31-11	4302-4309	regions	_	
31-12	4310-4313	has	_	
31-13	4314-4318	been	_	
31-14	4319-4327	reported	_	
31-15	4328-4330	in	_	
31-16	4331-4340	substance	_	
31-17	4341-4344	use	_	
31-18	4345-4353	disorder	_	
31-19	4353-4354	.	_	

#Text=These findings demonstrate that drug addiction might be associated with altered functional connectivity between the NAc that involved in rewarding process and prefrontal cortical regions that involved in cognitive behavioral control processes.
32-1	4355-4360	These	_	
32-2	4361-4369	findings	_	
32-3	4370-4381	demonstrate	_	
32-4	4382-4386	that	_	
32-5	4387-4391	drug	_	
32-6	4392-4401	addiction	_	
32-7	4402-4407	might	_	
32-8	4408-4410	be	_	
32-9	4411-4421	associated	_	
32-10	4422-4426	with	_	
32-11	4427-4434	altered	_	
32-12	4435-4445	functional	_	
32-13	4446-4458	connectivity	_	
32-14	4459-4466	between	_	
32-15	4467-4470	the	_	
32-16	4471-4474	NAc	_	
32-17	4475-4479	that	_	
32-18	4480-4488	involved	_	
32-19	4489-4491	in	_	
32-20	4492-4501	rewarding	_	
32-21	4502-4509	process	_	
32-22	4510-4513	and	_	
32-23	4514-4524	prefrontal	_	
32-24	4525-4533	cortical	_	
32-25	4534-4541	regions	_	
32-26	4542-4546	that	_	
32-27	4547-4555	involved	_	
32-28	4556-4558	in	_	
32-29	4559-4568	cognitive	_	
32-30	4569-4579	behavioral	_	
32-31	4580-4587	control	_	
32-32	4588-4597	processes	_	
32-33	4597-4598	.	_	

#Text=Although functional connectivity of the NAc has been examined in drug addiction, no study has been conducted to investigate the functional connectivity of the NAc subdivisions.
33-1	4599-4607	Although	_	
33-2	4608-4618	functional	_	
33-3	4619-4631	connectivity	_	
33-4	4632-4634	of	_	
33-5	4635-4638	the	_	
33-6	4639-4642	NAc	_	
33-7	4643-4646	has	_	
33-8	4647-4651	been	_	
33-9	4652-4660	examined	_	
33-10	4661-4663	in	_	
33-11	4664-4668	drug	_	
33-12	4669-4678	addiction	_	
33-13	4678-4679	,	_	
33-14	4680-4682	no	_	
33-15	4683-4688	study	_	
33-16	4689-4692	has	_	
33-17	4693-4697	been	_	
33-18	4698-4707	conducted	_	
33-19	4708-4710	to	_	
33-20	4711-4722	investigate	_	
33-21	4723-4726	the	_	
33-22	4727-4737	functional	_	
33-23	4738-4750	connectivity	_	
33-24	4751-4753	of	_	
33-25	4754-4757	the	_	
33-26	4758-4761	NAc	_	
33-27	4762-4774	subdivisions	_	
33-28	4774-4775	.	_	

#Text=Numerous studies confirmed multi-aspect heterogeneity of the NAc, resulting the most intensely investigated shell-core dichotomy in animal models.
34-1	4776-4784	Numerous	_	
34-2	4785-4792	studies	_	
34-3	4793-4802	confirmed	_	
34-4	4803-4815	multi-aspect	_	
34-5	4816-4829	heterogeneity	_	
34-6	4830-4832	of	_	
34-7	4833-4836	the	_	
34-8	4837-4840	NAc	_	
34-9	4840-4841	,	_	
34-10	4842-4851	resulting	_	
34-11	4852-4855	the	_	
34-12	4856-4860	most	_	
34-13	4861-4870	intensely	_	
34-14	4871-4883	investigated	_	
34-15	4884-4894	shell-core	_	
34-16	4895-4904	dichotomy	_	
34-17	4905-4907	in	_	
34-18	4908-4914	animal	_	
34-19	4915-4921	models	_	
34-20	4921-4922	.	_	

#Text=In human neuroimaging, multimodal connectivity-based parcellation also reveals a shell-core dichotomy of the human NAc.
35-1	4923-4925	In	_	
35-2	4926-4931	human	_	
35-3	4932-4944	neuroimaging	_	
35-4	4944-4945	,	_	
35-5	4946-4956	multimodal	_	
35-6	4957-4975	connectivity-based	_	
35-7	4976-4988	parcellation	_	
35-8	4989-4993	also	_	
35-9	4994-5001	reveals	_	
35-10	5002-5003	a	_	
35-11	5004-5014	shell-core	_	
35-12	5015-5024	dichotomy	_	
35-13	5025-5027	of	_	
35-14	5028-5031	the	_	
35-15	5032-5037	human	_	
35-16	5038-5041	NAc	_	
35-17	5041-5042	.	_	

#Text=The shell-like and core-like subdivisions of NAc were both found to facilitate the selection of the best reward functionally, but promote different patterns of behavior.
36-1	5043-5046	The	_	
36-2	5047-5057	shell-like	_	
36-3	5058-5061	and	_	
36-4	5062-5071	core-like	_	
36-5	5072-5084	subdivisions	_	
36-6	5085-5087	of	_	
36-7	5088-5091	NAc	_	
36-8	5092-5096	were	_	
36-9	5097-5101	both	_	
36-10	5102-5107	found	_	
36-11	5108-5110	to	_	
36-12	5111-5121	facilitate	_	
36-13	5122-5125	the	_	
36-14	5126-5135	selection	_	
36-15	5136-5138	of	_	
36-16	5139-5142	the	_	
36-17	5143-5147	best	_	
36-18	5148-5154	reward	_	
36-19	5155-5167	functionally	_	
36-20	5167-5168	,	_	
36-21	5169-5172	but	_	
36-22	5173-5180	promote	_	
36-23	5181-5190	different	_	
36-24	5191-5199	patterns	_	
36-25	5200-5202	of	_	
36-26	5203-5211	behavior	_	
36-27	5211-5212	.	_	

#Text=The shell-like subdivision, located in the ventromedial NAc, plays a role in the selection of the best reward by suppressing non- or less rewards stimuli that may obstruct with the best reward predicting stimuli.
37-1	5213-5216	The	_	
37-2	5217-5227	shell-like	_	
37-3	5228-5239	subdivision	_	
37-4	5239-5240	,	_	
37-5	5241-5248	located	_	
37-6	5249-5251	in	_	
37-7	5252-5255	the	_	
37-8	5256-5268	ventromedial	_	
37-9	5269-5272	NAc	_	
37-10	5272-5273	,	_	
37-11	5274-5279	plays	_	
37-12	5280-5281	a	_	
37-13	5282-5286	role	_	
37-14	5287-5289	in	_	
37-15	5290-5293	the	_	
37-16	5294-5303	selection	_	
37-17	5304-5306	of	_	
37-18	5307-5310	the	_	
37-19	5311-5315	best	_	
37-20	5316-5322	reward	_	
37-21	5323-5325	by	_	
37-22	5326-5337	suppressing	_	
37-23	5338-5341	non	_	
37-24	5341-5342	-	_	
37-25	5343-5345	or	_	
37-26	5346-5350	less	_	
37-27	5351-5358	rewards	_	
37-28	5359-5366	stimuli	_	
37-29	5367-5371	that	_	
37-30	5372-5375	may	_	
37-31	5376-5384	obstruct	_	
37-32	5385-5389	with	_	
37-33	5390-5393	the	_	
37-34	5394-5398	best	_	
37-35	5399-5405	reward	_	
37-36	5406-5416	predicting	_	
37-37	5417-5424	stimuli	_	
37-38	5424-5425	.	_	

#Text=The core-like subdivision, located in the dorsolateral NAc, plays a role in the selection of the best reward by selectively stimulating incentive stimuli that are associated with the best reward.
38-1	5426-5429	The	_	
38-2	5430-5439	core-like	_	
38-3	5440-5451	subdivision	_	
38-4	5451-5452	,	_	
38-5	5453-5460	located	_	
38-6	5461-5463	in	_	
38-7	5464-5467	the	_	
38-8	5468-5480	dorsolateral	_	
38-9	5481-5484	NAc	_	
38-10	5484-5485	,	_	
38-11	5486-5491	plays	_	
38-12	5492-5493	a	_	
38-13	5494-5498	role	_	
38-14	5499-5501	in	_	
38-15	5502-5505	the	_	
38-16	5506-5515	selection	_	
38-17	5516-5518	of	_	
38-18	5519-5522	the	_	
38-19	5523-5527	best	_	
38-20	5528-5534	reward	_	
38-21	5535-5537	by	_	
38-22	5538-5549	selectively	_	
38-23	5550-5561	stimulating	_	
38-24	5562-5571	incentive	_	
38-25	5572-5579	stimuli	_	
38-26	5580-5584	that	_	
38-27	5585-5588	are	_	
38-28	5589-5599	associated	_	
38-29	5600-5604	with	_	
38-30	5605-5608	the	_	
38-31	5609-5613	best	_	
38-32	5614-5620	reward	_	
38-33	5620-5621	.	_	

#Text=All these researches indicate the dissociable roles of the NAc subdivisions to some extent.
39-1	5622-5625	All	_	
39-2	5626-5631	these	_	
39-3	5632-5642	researches	_	
39-4	5643-5651	indicate	_	
39-5	5652-5655	the	_	
39-6	5656-5667	dissociable	_	
39-7	5668-5673	roles	_	
39-8	5674-5676	of	_	
39-9	5677-5680	the	_	
39-10	5681-5684	NAc	_	
39-11	5685-5697	subdivisions	_	
39-12	5698-5700	to	_	
39-13	5701-5705	some	_	
39-14	5706-5712	extent	_	
39-15	5712-5713	.	_	

#Text=For now, no study has investigated the functional roles that different subdivisions of NAc may play in ATSA.
40-1	5714-5717	For	_	
40-2	5718-5721	now	_	
40-3	5721-5722	,	_	
40-4	5723-5725	no	_	
40-5	5726-5731	study	_	
40-6	5732-5735	has	_	
40-7	5736-5748	investigated	_	
40-8	5749-5752	the	_	
40-9	5753-5763	functional	_	
40-10	5764-5769	roles	_	
40-11	5770-5774	that	_	
40-12	5775-5784	different	_	
40-13	5785-5797	subdivisions	_	
40-14	5798-5800	of	_	
40-15	5801-5804	NAc	_	
40-16	5805-5808	may	_	
40-17	5809-5813	play	_	
40-18	5814-5816	in	_	
40-19	5817-5821	ATSA	_	
40-20	5821-5822	.	_	

#Text=Thus, it is not clear whether there are common changes of the RSFC across the different NAc subdivisions or distinct changes for each subdivision underlying the mechanism of addiction.
41-1	5823-5827	Thus	_	
41-2	5827-5828	,	_	
41-3	5829-5831	it	_	
41-4	5832-5834	is	_	
41-5	5835-5838	not	_	
41-6	5839-5844	clear	_	
41-7	5845-5852	whether	_	
41-8	5853-5858	there	_	
41-9	5859-5862	are	_	
41-10	5863-5869	common	_	
41-11	5870-5877	changes	_	
41-12	5878-5880	of	_	
41-13	5881-5884	the	_	
41-14	5885-5889	RSFC	_	
41-15	5890-5896	across	_	
41-16	5897-5900	the	_	
41-17	5901-5910	different	_	
41-18	5911-5914	NAc	_	
41-19	5915-5927	subdivisions	_	
41-20	5928-5930	or	_	
41-21	5931-5939	distinct	_	
41-22	5940-5947	changes	_	
41-23	5948-5951	for	_	
41-24	5952-5956	each	_	
41-25	5957-5968	subdivision	_	
41-26	5969-5979	underlying	_	
41-27	5980-5983	the	_	
41-28	5984-5993	mechanism	_	
41-29	5994-5996	of	_	
41-30	5997-6006	addiction	_	
41-31	6006-6007	.	_	

#Text=The recently proposed data-driven NAc subdivision template in humans makes it possible to evaluate the RSFC of each NAc subdivision in patients with ATSA, which will be important to shed light on the mechanisms of ATSA.
42-1	6008-6011	The	_	
42-2	6012-6020	recently	_	
42-3	6021-6029	proposed	_	
42-4	6030-6041	data-driven	_	
42-5	6042-6045	NAc	_	
42-6	6046-6057	subdivision	_	
42-7	6058-6066	template	_	
42-8	6067-6069	in	_	
42-9	6070-6076	humans	_	
42-10	6077-6082	makes	_	
42-11	6083-6085	it	_	
42-12	6086-6094	possible	_	
42-13	6095-6097	to	_	
42-14	6098-6106	evaluate	_	
42-15	6107-6110	the	_	
42-16	6111-6115	RSFC	_	
42-17	6116-6118	of	_	
42-18	6119-6123	each	_	
42-19	6124-6127	NAc	_	
42-20	6128-6139	subdivision	_	
42-21	6140-6142	in	_	
42-22	6143-6151	patients	_	
42-23	6152-6156	with	_	
42-24	6157-6161	ATSA	_	
42-25	6161-6162	,	_	
42-26	6163-6168	which	_	
42-27	6169-6173	will	_	
42-28	6174-6176	be	_	
42-29	6177-6186	important	_	
42-30	6187-6189	to	_	
42-31	6190-6194	shed	_	
42-32	6195-6200	light	_	
42-33	6201-6203	on	_	
42-34	6204-6207	the	_	
42-35	6208-6218	mechanisms	_	
42-36	6219-6221	of	_	
42-37	6222-6226	ATSA	_	
42-38	6226-6227	.	_	

#Text=In brief, the RSFC of the NAc subdivisions in drug addiction has not been previously studied in addictive individuals.
43-1	6228-6230	In	_	
43-2	6231-6236	brief	_	
43-3	6236-6237	,	_	
43-4	6238-6241	the	_	
43-5	6242-6246	RSFC	_	
43-6	6247-6249	of	_	
43-7	6250-6253	the	_	
43-8	6254-6257	NAc	_	
43-9	6258-6270	subdivisions	_	
43-10	6271-6273	in	_	
43-11	6274-6278	drug	_	
43-12	6279-6288	addiction	_	
43-13	6289-6292	has	_	
43-14	6293-6296	not	_	
43-15	6297-6301	been	_	
43-16	6302-6312	previously	_	
43-17	6313-6320	studied	_	
43-18	6321-6323	in	_	
43-19	6324-6333	addictive	_	
43-20	6334-6345	individuals	_	
43-21	6345-6346	.	_	

#Text=Therefore, this study aimed at investigating whether there are any addiction related alterations in RSFC of the NAc subdivisions by acquiring resting-state fMRI data from ATSAs and healthy controls (HCs).
44-1	6347-6356	Therefore	_	
44-2	6356-6357	,	_	
44-3	6358-6362	this	_	
44-4	6363-6368	study	_	
44-5	6369-6374	aimed	_	
44-6	6375-6377	at	_	
44-7	6378-6391	investigating	_	
44-8	6392-6399	whether	_	
44-9	6400-6405	there	_	
44-10	6406-6409	are	_	
44-11	6410-6413	any	_	
44-12	6414-6423	addiction	_	
44-13	6424-6431	related	_	
44-14	6432-6443	alterations	_	
44-15	6444-6446	in	_	
44-16	6447-6451	RSFC	_	
44-17	6452-6454	of	_	
44-18	6455-6458	the	_	
44-19	6459-6462	NAc	_	
44-20	6463-6475	subdivisions	_	
44-21	6476-6478	by	_	
44-22	6479-6488	acquiring	_	
44-23	6489-6502	resting-state	_	
44-24	6503-6507	fMRI	_	
44-25	6508-6512	data	_	
44-26	6513-6517	from	_	
44-27	6518-6523	ATSAs	_	
44-28	6524-6527	and	_	
44-29	6528-6535	healthy	_	
44-30	6536-6544	controls	_	
44-31	6545-6546	(	_	
44-32	6546-6549	HCs	_	
44-33	6549-6550	)	_	
44-34	6550-6551	.	_	

#Text=Previous studies emphasized the importance of the abnormal interactions between the NAc that process reward and prefrontal cortical regions that govern the cognitive-behavioral control in the mechanism of addiction, thus we hypothesized that the RSFCs between the NAc subdivisions and the prefrontal cortices were consistently altered among ATSAs.
45-1	6552-6560	Previous	_	
45-2	6561-6568	studies	_	
45-3	6569-6579	emphasized	_	
45-4	6580-6583	the	_	
45-5	6584-6594	importance	_	
45-6	6595-6597	of	_	
45-7	6598-6601	the	_	
45-8	6602-6610	abnormal	_	
45-9	6611-6623	interactions	_	
45-10	6624-6631	between	_	
45-11	6632-6635	the	_	
45-12	6636-6639	NAc	_	
45-13	6640-6644	that	_	
45-14	6645-6652	process	_	
45-15	6653-6659	reward	_	
45-16	6660-6663	and	_	
45-17	6664-6674	prefrontal	_	
45-18	6675-6683	cortical	_	
45-19	6684-6691	regions	_	
45-20	6692-6696	that	_	
45-21	6697-6703	govern	_	
45-22	6704-6707	the	_	
45-23	6708-6728	cognitive-behavioral	_	
45-24	6729-6736	control	_	
45-25	6737-6739	in	_	
45-26	6740-6743	the	_	
45-27	6744-6753	mechanism	_	
45-28	6754-6756	of	_	
45-29	6757-6766	addiction	_	
45-30	6766-6767	,	_	
45-31	6768-6772	thus	_	
45-32	6773-6775	we	_	
45-33	6776-6788	hypothesized	_	
45-34	6789-6793	that	_	
45-35	6794-6797	the	_	
45-36	6798-6803	RSFCs	_	
45-37	6804-6811	between	_	
45-38	6812-6815	the	_	
45-39	6816-6819	NAc	_	
45-40	6820-6832	subdivisions	_	
45-41	6833-6836	and	_	
45-42	6837-6840	the	_	
45-43	6841-6851	prefrontal	_	
45-44	6852-6860	cortices	_	
45-45	6861-6865	were	_	
45-46	6866-6878	consistently	_	
45-47	6879-6886	altered	_	
45-48	6887-6892	among	_	
45-49	6893-6898	ATSAs	_	
45-50	6898-6899	.	_	

#Text=Meanwhile, considering the multi-aspect heterogeneity of the NAc, the regionally-dependent changes in RSFC of the NAc subdivisions may be revealed in ATSAs.
46-1	6900-6909	Meanwhile	_	
46-2	6909-6910	,	_	
46-3	6911-6922	considering	_	
46-4	6923-6926	the	_	
46-5	6927-6939	multi-aspect	_	
46-6	6940-6953	heterogeneity	_	
46-7	6954-6956	of	_	
46-8	6957-6960	the	_	
46-9	6961-6964	NAc	_	
46-10	6964-6965	,	_	
46-11	6966-6969	the	_	
46-12	6970-6990	regionally-dependent	_	
46-13	6991-6998	changes	_	
46-14	6999-7001	in	_	
46-15	7002-7006	RSFC	_	
46-16	7007-7009	of	_	
46-17	7010-7013	the	_	
46-18	7014-7017	NAc	_	
46-19	7018-7030	subdivisions	_	
46-20	7031-7034	may	_	
46-21	7035-7037	be	_	
46-22	7038-7046	revealed	_	
46-23	7047-7049	in	_	
46-24	7050-7055	ATSAs	_	
46-25	7055-7056	.	_	

#Text=Materials and methods
#Text=Subjects
#Text=Male ATSAs (n = 17) were recruited from the Wuhan Mental Health Centre affiliated with the Huazhong University of Science and Technology during the period from October 2012 to December 2012.
47-1	7057-7066	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[7]	
47-2	7067-7070	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[7]	
47-3	7071-7078	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[7]	
47-4	7079-7087	Subjects	_	
47-5	7088-7092	Male	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-6	7093-7098	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse[9]	
47-7	7099-7100	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-8	7100-7101	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-9	7102-7103	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-10	7104-7106	17	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-11	7106-7107	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-12	7108-7112	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-13	7113-7122	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-14	7123-7127	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-15	7128-7131	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-16	7132-7137	Wuhan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-17	7138-7144	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-18	7145-7151	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-19	7152-7158	Centre	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-20	7159-7169	affiliated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-21	7170-7174	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-22	7175-7178	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-23	7179-7187	Huazhong	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-24	7188-7198	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-25	7199-7201	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-26	7202-7209	Science	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-27	7210-7213	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-28	7214-7224	Technology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-29	7225-7231	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-30	7232-7235	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-31	7236-7242	period	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-32	7243-7247	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-33	7248-7255	October	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-34	7256-7260	2012	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-35	7261-7263	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-36	7264-7272	December	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-37	7273-7277	2012	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-38	7277-7278	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	

#Text=Healthy male controls (n = 22) were recruited from the local community and Huazhong University of Science and Technology by advertisements.
48-1	7279-7286	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[11]	
48-2	7287-7291	male	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[11]	
48-3	7292-7300	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[11]	
48-4	7301-7302	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-5	7302-7303	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-6	7304-7305	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-7	7306-7308	22	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-8	7308-7309	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-9	7310-7314	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-10	7315-7324	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-11	7325-7329	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-12	7330-7333	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-13	7334-7339	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-14	7340-7349	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-15	7350-7353	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-16	7354-7362	Huazhong	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-17	7363-7373	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-18	7374-7376	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-19	7377-7384	Science	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-20	7385-7388	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-21	7389-7399	Technology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-22	7400-7402	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-23	7403-7417	advertisements	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-24	7417-7418	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=The inclusion criteria for both groups were as follows: 18–40 years of age, male, at least 9 years of education, normal or corrected-to-normal hearing and vision, and no reported history of neurological problems, ophthalmic diseases, or severe head injuries.
49-1	7419-7422	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-2	7423-7432	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-3	7433-7441	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-4	7442-7445	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-5	7446-7450	both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-6	7451-7457	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-7	7458-7462	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-8	7463-7465	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-9	7466-7473	follows	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-10	7473-7474	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-11	7475-7477	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-12	7477-7478	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-13	7478-7480	40	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-14	7480-7481	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-15	7481-7486	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-16	7487-7489	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-17	7490-7493	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-18	7493-7494	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-19	7495-7499	male	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-20	7499-7500	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-21	7501-7503	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-22	7504-7509	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-23	7510-7511	9	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-24	7511-7512	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-25	7512-7517	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-26	7518-7520	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-27	7521-7530	education	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-28	7530-7531	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-29	7532-7538	normal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-30	7539-7541	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-31	7542-7561	corrected-to-normal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-32	7562-7569	hearing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-33	7570-7573	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-34	7574-7580	vision	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-35	7580-7581	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-36	7582-7585	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-37	7586-7588	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-38	7589-7597	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-39	7598-7605	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-40	7606-7608	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-41	7609-7621	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-42	7622-7630	problems	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-43	7630-7631	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-44	7632-7642	ophthalmic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-45	7643-7651	diseases	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-46	7651-7652	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-47	7653-7655	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-48	7656-7662	severe	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-49	7663-7667	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-50	7668-7676	injuries	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
49-51	7676-7677	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	

#Text=All enrolled ATSAs met the Diagnostic and Statistical Manual for Mental Disorders, 4th Edition (DSM-IV) criteria for drug dependence and were assessed using the Chinese version of the Addiction Severity Index (ASI-C).
50-1	7678-7681	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-2	7682-7690	enrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-3	7691-7696	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse[14]	
50-4	7697-7700	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-5	7701-7704	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-6	7705-7715	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-7	7716-7719	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-8	7720-7731	Statistical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-9	7732-7738	Manual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-10	7739-7742	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-11	7743-7749	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-12	7750-7759	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-13	7759-7760	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-14	7761-7764	4th	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-15	7765-7772	Edition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-16	7773-7774	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-17	7774-7780	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-18	7780-7781	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-19	7782-7790	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-20	7791-7794	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-21	7795-7799	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-22	7800-7810	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-23	7811-7814	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-24	7815-7819	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-25	7820-7828	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-26	7829-7834	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-27	7835-7838	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-28	7839-7846	Chinese	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-29	7847-7854	version	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-30	7855-7857	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-31	7858-7861	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-32	7862-7871	Addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-33	7872-7880	Severity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-34	7881-7886	Index	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-35	7887-7888	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-36	7888-7893	ASI-C	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-37	7893-7894	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
50-38	7894-7895	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Clinicians assessed each participant’s addiction severity on seven areas: medical, employment/support status, alcohol, drug, legal, family/social, and psychiatric by using a 0–9 Likert scale.
51-1	7896-7906	Clinicians	_	
51-2	7907-7915	assessed	_	
51-3	7916-7920	each	_	
51-4	7921-7932	participant	_	
51-5	7932-7933	’	_	
51-6	7933-7934	s	_	
51-7	7935-7944	addiction	_	
51-8	7945-7953	severity	_	
51-9	7954-7956	on	_	
51-10	7957-7962	seven	_	
51-11	7963-7968	areas	_	
51-12	7968-7969	:	_	
51-13	7970-7977	medical	_	
51-14	7977-7978	,	_	
51-15	7979-7989	employment	_	
51-16	7989-7990	/	_	
51-17	7990-7997	support	_	
51-18	7998-8004	status	_	
51-19	8004-8005	,	_	
51-20	8006-8013	alcohol	_	
51-21	8013-8014	,	_	
51-22	8015-8019	drug	_	
51-23	8019-8020	,	_	
51-24	8021-8026	legal	_	
51-25	8026-8027	,	_	
51-26	8028-8034	family	_	
51-27	8034-8035	/	_	
51-28	8035-8041	social	_	
51-29	8041-8042	,	_	
51-30	8043-8046	and	_	
51-31	8047-8058	psychiatric	_	
51-32	8059-8061	by	_	
51-33	8062-8067	using	_	
51-34	8068-8069	a	_	
51-35	8070-8071	0	_	
51-36	8071-8072	–	_	
51-37	8072-8073	9	_	
51-38	8074-8080	Likert	_	
51-39	8081-8086	scale	_	
51-40	8086-8087	.	_	

#Text=A higher score indicates a more serious problem.
52-1	8088-8089	A	_	
52-2	8090-8096	higher	_	
52-3	8097-8102	score	_	
52-4	8103-8112	indicates	_	
52-5	8113-8114	a	_	
52-6	8115-8119	more	_	
52-7	8120-8127	serious	_	
52-8	8128-8135	problem	_	
52-9	8135-8136	.	_	

#Text=The addiction severity of drugs was labeled as ASID.
53-1	8137-8140	The	_	
53-2	8141-8150	addiction	_	
53-3	8151-8159	severity	_	
53-4	8160-8162	of	_	
53-5	8163-8168	drugs	_	
53-6	8169-8172	was	_	
53-7	8173-8180	labeled	_	
53-8	8181-8183	as	_	
53-9	8184-8188	ASID	_	
53-10	8188-8189	.	_	

#Text=Furthermore, the enrolled ATSA participants all had used amphetamine-type stimulants for more than one year, and the accumulated dosage of the amphetamine-type stimulants they used was above 50 g.
54-1	8190-8201	Furthermore	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-2	8201-8202	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-3	8203-8206	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-4	8207-8215	enrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-5	8216-8220	ATSA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse[16]	
54-6	8221-8233	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-7	8234-8237	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-8	8238-8241	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-9	8242-8246	used	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-10	8247-8263	amphetamine-type	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-11	8264-8274	stimulants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-12	8275-8278	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-13	8279-8283	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-14	8284-8288	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-15	8289-8292	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-16	8293-8297	year	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-17	8297-8298	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-18	8299-8302	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-19	8303-8306	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-20	8307-8318	accumulated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-21	8319-8325	dosage	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-22	8326-8328	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-23	8329-8332	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-24	8333-8349	amphetamine-type	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-25	8350-8360	stimulants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-26	8361-8365	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-27	8366-8370	used	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-28	8371-8374	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-29	8375-8380	above	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-30	8381-8383	50	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-31	8383-8384	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-32	8384-8385	g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
54-33	8385-8386	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	

#Text=Based on self-reports of these abusers, among the 17 ATSAs, 8 participants used methamphetamine only and 9 participants used two or three amphetamine-type stimulants, such as methamphetamine, ecstasy or ketamine.
55-1	8387-8392	Based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-2	8393-8395	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-3	8396-8408	self-reports	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-4	8409-8411	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-5	8412-8417	these	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-6	8418-8425	abusers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-7	8425-8426	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-8	8427-8432	among	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-9	8433-8436	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-10	8437-8439	17	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-11	8440-8445	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse[18]	
55-12	8445-8446	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-13	8447-8448	8	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-14	8449-8461	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-15	8462-8466	used	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-16	8467-8482	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-17	8483-8487	only	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-18	8488-8491	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-19	8492-8493	9	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-20	8494-8506	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-21	8507-8511	used	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-22	8512-8515	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-23	8516-8518	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-24	8519-8524	three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-25	8525-8541	amphetamine-type	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-26	8542-8552	stimulants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-27	8552-8553	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-28	8554-8558	such	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-29	8559-8561	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-30	8562-8577	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-31	8577-8578	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-32	8579-8586	ecstasy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-33	8587-8589	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-34	8590-8598	ketamine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
55-35	8598-8599	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=None of the ATSAs and HCs had a history of abuse or dependence on other substances, with the exceptions of nicotine, caffeine, and alcohol.
56-1	8600-8604	None	_	
56-2	8605-8607	of	_	
56-3	8608-8611	the	_	
56-4	8612-8617	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse	
56-5	8618-8621	and	_	
56-6	8622-8625	HCs	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
56-7	8626-8629	had	_	
56-8	8630-8631	a	_	
56-9	8632-8639	history	_	
56-10	8640-8642	of	_	
56-11	8643-8648	abuse	_	
56-12	8649-8651	or	_	
56-13	8652-8662	dependence	_	
56-14	8663-8665	on	_	
56-15	8666-8671	other	_	
56-16	8672-8682	substances	_	
56-17	8682-8683	,	_	
56-18	8684-8688	with	_	
56-19	8689-8692	the	_	
56-20	8693-8703	exceptions	_	
56-21	8704-8706	of	_	
56-22	8707-8715	nicotine	_	
56-23	8715-8716	,	_	
56-24	8717-8725	caffeine	_	
56-25	8725-8726	,	_	
56-26	8727-8730	and	_	
56-27	8731-8738	alcohol	_	
56-28	8738-8739	.	_	

#Text=All of the ATSAs were inpatients, so they were in a state of withdrawal from any substance.
57-1	8740-8743	All	_	
57-2	8744-8746	of	_	
57-3	8747-8750	the	_	
57-4	8751-8756	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse	
57-5	8757-8761	were	_	
57-6	8762-8772	inpatients	_	
57-7	8772-8773	,	_	
57-8	8774-8776	so	_	
57-9	8777-8781	they	_	
57-10	8782-8786	were	_	
57-11	8787-8789	in	_	
57-12	8790-8791	a	_	
57-13	8792-8797	state	_	
57-14	8798-8800	of	_	
57-15	8801-8811	withdrawal	_	
57-16	8812-8816	from	_	
57-17	8817-8820	any	_	
57-18	8821-8830	substance	_	
57-19	8830-8831	.	_	

#Text=They didn’t take any medicine or other treatment during hospitalization.
58-1	8832-8836	They	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-2	8837-8841	didn	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-3	8841-8842	’	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-4	8842-8843	t	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-5	8844-8848	take	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-6	8849-8852	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-7	8853-8861	medicine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-8	8862-8864	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-9	8865-8870	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-10	8871-8880	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-11	8881-8887	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-12	8888-8903	hospitalization	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
58-13	8903-8904	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	

#Text=One ATSA and one HC subject were later excluded from the study because of excessive head motion during the fMRI scan.
59-1	8905-8908	One	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-2	8909-8913	ATSA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse[20]	
59-3	8914-8917	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-4	8918-8921	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-5	8922-8924	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]	
59-6	8925-8932	subject	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-7	8933-8937	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-8	8938-8943	later	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-9	8944-8952	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-10	8953-8957	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-11	8958-8961	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-12	8962-8967	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-13	8968-8975	because	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-14	8976-8978	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-15	8979-8988	excessive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-16	8989-8993	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-17	8994-9000	motion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-18	9001-9007	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-19	9008-9011	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-20	9012-9016	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[22]	
59-21	9017-9021	scan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
59-22	9021-9022	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	

#Text=This study was approved by the Ethics Committee of Wuhan Mental Health Centre.
60-1	9023-9027	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
60-2	9028-9033	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
60-3	9034-9037	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
60-4	9038-9046	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
60-5	9047-9049	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
60-6	9050-9053	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
60-7	9054-9060	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
60-8	9061-9070	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
60-9	9071-9073	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
60-10	9074-9079	Wuhan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
60-11	9080-9086	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
60-12	9087-9093	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
60-13	9094-9100	Centre	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
60-14	9100-9101	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	

#Text=All participants or families of ATSAs provided written informed consent before participation.
61-1	9102-9105	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-2	9106-9118	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-3	9119-9121	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-4	9122-9130	families	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-5	9131-9133	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-6	9134-9139	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]|http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse[24]	
61-7	9140-9148	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-8	9149-9156	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-9	9157-9165	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-10	9166-9173	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-11	9174-9180	before	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-12	9181-9194	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
61-13	9194-9195	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	

#Text=MRI data acquisition
#Text=Images were acquired with a 1.5 Tesla MRI scanner (Model: GE Signa HDxt) in Zhongshan Hospital, Wuhan City, Hubei Province, China.
62-1	9196-9199	MRI	_	
62-2	9200-9204	data	_	
62-3	9205-9216	acquisition	_	
62-4	9217-9223	Images	_	
62-5	9224-9228	were	_	
62-6	9229-9237	acquired	_	
62-7	9238-9242	with	_	
62-8	9243-9244	a	_	
62-9	9245-9248	1.5	_	
62-10	9249-9254	Tesla	_	
62-11	9255-9258	MRI	_	
62-12	9259-9266	scanner	_	
62-13	9267-9268	(	_	
62-14	9268-9273	Model	_	
62-15	9273-9274	:	_	
62-16	9275-9277	GE	_	
62-17	9278-9283	Signa	_	
62-18	9284-9288	HDxt	_	
62-19	9288-9289	)	_	
62-20	9290-9292	in	_	
62-21	9293-9302	Zhongshan	_	
62-22	9303-9311	Hospital	_	
62-23	9311-9312	,	_	
62-24	9313-9318	Wuhan	_	
62-25	9319-9323	City	_	
62-26	9323-9324	,	_	
62-27	9325-9330	Hubei	_	
62-28	9331-9339	Province	_	
62-29	9339-9340	,	_	
62-30	9341-9346	China	_	
62-31	9346-9347	.	_	

#Text=Whole-brain functional scans were collected using an echo-planar imaging (EPI) sequence (repetition time = 3000 ms; echo time = 40 ms; flip angle = 90°; matrix = 64 × 64; field of view = 220 × 220 mm2; number of slices = 33; slice thickness = 3 mm; slice gap = 1 mm).
63-1	9348-9359	Whole-brain	_	
63-2	9360-9370	functional	_	
63-3	9371-9376	scans	_	
63-4	9377-9381	were	_	
63-5	9382-9391	collected	_	
63-6	9392-9397	using	_	
63-7	9398-9400	an	_	
63-8	9401-9412	echo-planar	_	
63-9	9413-9420	imaging	_	
63-10	9421-9422	(	_	
63-11	9422-9425	EPI	_	
63-12	9425-9426	)	_	
63-13	9427-9435	sequence	_	
63-14	9436-9437	(	_	
63-15	9437-9447	repetition	_	
63-16	9448-9452	time	_	
63-17	9453-9454	=	_	
63-18	9455-9459	3000	_	
63-19	9459-9460	 	_	
63-20	9460-9462	ms	_	
63-21	9462-9463	;	_	
63-22	9464-9468	echo	_	
63-23	9469-9473	time	_	
63-24	9474-9475	=	_	
63-25	9476-9478	40	_	
63-26	9478-9479	 	_	
63-27	9479-9481	ms	_	
63-28	9481-9482	;	_	
63-29	9483-9487	flip	_	
63-30	9488-9493	angle	_	
63-31	9494-9495	=	_	
63-32	9496-9498	90	_	
63-33	9498-9499	°	_	
63-34	9499-9500	;	_	
63-35	9501-9507	matrix	_	
63-36	9508-9509	=	_	
63-37	9510-9512	64	_	
63-38	9513-9514	×	_	
63-39	9515-9517	64	_	
63-40	9517-9518	;	_	
63-41	9519-9524	field	_	
63-42	9525-9527	of	_	
63-43	9528-9532	view	_	
63-44	9533-9534	=	_	
63-45	9535-9538	220	_	
63-46	9539-9540	×	_	
63-47	9541-9544	220	_	
63-48	9545-9548	mm2	_	
63-49	9548-9549	;	_	
63-50	9550-9556	number	_	
63-51	9557-9559	of	_	
63-52	9560-9566	slices	_	
63-53	9567-9568	=	_	
63-54	9569-9571	33	_	
63-55	9571-9572	;	_	
63-56	9573-9578	slice	_	
63-57	9579-9588	thickness	_	
63-58	9589-9590	=	_	
63-59	9591-9592	3	_	
63-60	9592-9593	 	_	
63-61	9593-9595	mm	_	
63-62	9595-9596	;	_	
63-63	9597-9602	slice	_	
63-64	9603-9606	gap	_	
63-65	9607-9608	=	_	
63-66	9609-9610	1	_	
63-67	9610-9611	 	_	
63-68	9611-9613	mm	_	
63-69	9613-9614	)	_	
63-70	9614-9615	.	_	

#Text=Each functional run contained 180 volumes.
64-1	9616-9620	Each	_	
64-2	9621-9631	functional	_	
64-3	9632-9635	run	_	
64-4	9636-9645	contained	_	
64-5	9646-9649	180	_	
64-6	9650-9657	volumes	_	
64-7	9657-9658	.	_	

#Text=High-resolution T1-weighted images were acquired in a sagittal orientation employing a fast SPGR sequence (repetition/echo time = 9.176/2.956 ms; flip angle = 20°; slice thickness = 1.2 mm (no gap); number of slices = 128).
65-1	9659-9674	High-resolution	_	
65-2	9675-9677	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[25]	
65-3	9677-9678	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[25]	
65-4	9678-9686	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[25]	
65-5	9687-9693	images	_	
65-6	9694-9698	were	_	
65-7	9699-9707	acquired	_	
65-8	9708-9710	in	_	
65-9	9711-9712	a	_	
65-10	9713-9721	sagittal	_	
65-11	9722-9733	orientation	_	
65-12	9734-9743	employing	_	
65-13	9744-9745	a	_	
65-14	9746-9750	fast	_	
65-15	9751-9755	SPGR	_	
65-16	9756-9764	sequence	_	
65-17	9765-9766	(	_	
65-18	9766-9776	repetition	_	
65-19	9776-9777	/	_	
65-20	9777-9781	echo	_	
65-21	9782-9786	time	_	
65-22	9787-9788	=	_	
65-23	9789-9794	9.176	_	
65-24	9794-9795	/	_	
65-25	9795-9800	2.956	_	
65-26	9800-9801	 	_	
65-27	9801-9803	ms	_	
65-28	9803-9804	;	_	
65-29	9805-9809	flip	_	
65-30	9810-9815	angle	_	
65-31	9816-9817	=	_	
65-32	9818-9820	20	_	
65-33	9820-9821	°	_	
65-34	9821-9822	;	_	
65-35	9823-9828	slice	_	
65-36	9829-9838	thickness	_	
65-37	9839-9840	=	_	
65-38	9841-9844	1.2	_	
65-39	9844-9845	 	_	
65-40	9845-9847	mm	_	
65-41	9848-9849	(	_	
65-42	9849-9851	no	_	
65-43	9852-9855	gap	_	
65-44	9855-9856	)	_	
65-45	9856-9857	;	_	
65-46	9858-9864	number	_	
65-47	9865-9867	of	_	
65-48	9868-9874	slices	_	
65-49	9875-9876	=	_	
65-50	9877-9880	128	_	
65-51	9880-9881	)	_	
65-52	9881-9882	.	_	

#Text=Data preprocessing
#Text=Image preprocessing was performed using the Data Processing Assistant for Resting-State fMRI (DPARSF_v4.4, https://rfmri.org/DPARSF), the Statistical Parametric Mapping (SPM12) program (https://www.fil.ion.ucl.ac.uk/spm), and the Resting-State fMRI Data Analysis Toolkit (REST 1.8, https://www.restfmri.net).
66-1	9883-9887	Data	_	
66-2	9888-9901	preprocessing	_	
66-3	9902-9907	Image	_	
66-4	9908-9921	preprocessing	_	
66-5	9922-9925	was	_	
66-6	9926-9935	performed	_	
66-7	9936-9941	using	_	
66-8	9942-9945	the	_	
66-9	9946-9950	Data	_	
66-10	9951-9961	Processing	_	
66-11	9962-9971	Assistant	_	
66-12	9972-9975	for	_	
66-13	9976-9989	Resting-State	_	
66-14	9990-9994	fMRI	_	
66-15	9995-9996	(	_	
66-16	9996-10007	DPARSF_v4.4	_	
66-17	10007-10008	,	_	
66-18	10009-10014	https	_	
66-19	10014-10015	:	_	
66-20	10015-10016	/	_	
66-21	10016-10017	/	_	
66-22	10017-10026	rfmri.org	_	
66-23	10026-10027	/	_	
66-24	10027-10033	DPARSF	_	
66-25	10033-10034	)	_	
66-26	10034-10035	,	_	
66-27	10036-10039	the	_	
66-28	10040-10051	Statistical	_	
66-29	10052-10062	Parametric	_	
66-30	10063-10070	Mapping	_	
66-31	10071-10072	(	_	
66-32	10072-10077	SPM12	_	
66-33	10077-10078	)	_	
66-34	10079-10086	program	_	
66-35	10087-10088	(	_	
66-36	10088-10093	https	_	
66-37	10093-10094	:	_	
66-38	10094-10095	/	_	
66-39	10095-10096	/	_	
66-40	10096-10117	www.fil.ion.ucl.ac.uk	_	
66-41	10117-10118	/	_	
66-42	10118-10121	spm	_	
66-43	10121-10122	)	_	
66-44	10122-10123	,	_	
66-45	10124-10127	and	_	
66-46	10128-10131	the	_	
66-47	10132-10145	Resting-State	_	
66-48	10146-10150	fMRI	_	
66-49	10151-10155	Data	_	
66-50	10156-10164	Analysis	_	
66-51	10165-10172	Toolkit	_	
66-52	10173-10174	(	_	
66-53	10174-10178	REST	_	
66-54	10179-10182	1.8	_	
66-55	10182-10183	,	_	
66-56	10184-10189	https	_	
66-57	10189-10190	:	_	
66-58	10190-10191	/	_	
66-59	10191-10192	/	_	
66-60	10192-10208	www.restfmri.net	_	
66-61	10208-10209	)	_	
66-62	10209-10210	.	_	

#Text=Before preprocessing, we discarded the first 10 volumes to allow for signal stabilization.
67-1	10211-10217	Before	_	
67-2	10218-10231	preprocessing	_	
67-3	10231-10232	,	_	
67-4	10233-10235	we	_	
67-5	10236-10245	discarded	_	
67-6	10246-10249	the	_	
67-7	10250-10255	first	_	
67-8	10256-10258	10	_	
67-9	10259-10266	volumes	_	
67-10	10267-10269	to	_	
67-11	10270-10275	allow	_	
67-12	10276-10279	for	_	
67-13	10280-10286	signal	_	
67-14	10287-10300	stabilization	_	
67-15	10300-10301	.	_	

#Text=The remaining volumes were corrected for differences in slice acquisition times and then realigned to correct for small movements that occurred between scans.
68-1	10302-10305	The	_	
68-2	10306-10315	remaining	_	
68-3	10316-10323	volumes	_	
68-4	10324-10328	were	_	
68-5	10329-10338	corrected	_	
68-6	10339-10342	for	_	
68-7	10343-10354	differences	_	
68-8	10355-10357	in	_	
68-9	10358-10363	slice	_	
68-10	10364-10375	acquisition	_	
68-11	10376-10381	times	_	
68-12	10382-10385	and	_	
68-13	10386-10390	then	_	
68-14	10391-10400	realigned	_	
68-15	10401-10403	to	_	
68-16	10404-10411	correct	_	
68-17	10412-10415	for	_	
68-18	10416-10421	small	_	
68-19	10422-10431	movements	_	
68-20	10432-10436	that	_	
68-21	10437-10445	occurred	_	
68-22	10446-10453	between	_	
68-23	10454-10459	scans	_	
68-24	10459-10460	.	_	

#Text=Subjects with a maximum displacement of more than 3 mm (in the x, y, or z direction) or more than 3° of angular rotation about any axis for any of the 170 volumes were excluded from the study.
69-1	10461-10469	Subjects	_	
69-2	10470-10474	with	_	
69-3	10475-10476	a	_	
69-4	10477-10484	maximum	_	
69-5	10485-10497	displacement	_	
69-6	10498-10500	of	_	
69-7	10501-10505	more	_	
69-8	10506-10510	than	_	
69-9	10511-10512	3	_	
69-10	10512-10513	 	_	
69-11	10513-10515	mm	_	
69-12	10516-10517	(	_	
69-13	10517-10519	in	_	
69-14	10520-10523	the	_	
69-15	10524-10525	x	_	
69-16	10525-10526	,	_	
69-17	10527-10528	y	_	
69-18	10528-10529	,	_	
69-19	10530-10532	or	_	
69-20	10533-10534	z	_	
69-21	10535-10544	direction	_	
69-22	10544-10545	)	_	
69-23	10546-10548	or	_	
69-24	10549-10553	more	_	
69-25	10554-10558	than	_	
69-26	10559-10560	3	_	
69-27	10560-10561	°	_	
69-28	10562-10564	of	_	
69-29	10565-10572	angular	_	
69-30	10573-10581	rotation	_	
69-31	10582-10587	about	_	
69-32	10588-10591	any	_	
69-33	10592-10596	axis	_	
69-34	10597-10600	for	_	
69-35	10601-10604	any	_	
69-36	10605-10607	of	_	
69-37	10608-10611	the	_	
69-38	10612-10615	170	_	
69-39	10616-10623	volumes	_	
69-40	10624-10628	were	_	
69-41	10629-10637	excluded	_	
69-42	10638-10642	from	_	
69-43	10643-10646	the	_	
69-44	10647-10652	study	_	
69-45	10652-10653	.	_	

#Text=One ATSA and one HC were excluded from the analyses based on the recorded motion correction estimates.
70-1	10654-10657	One	_	
70-2	10658-10662	ATSA	_	
70-3	10663-10666	and	_	
70-4	10667-10670	one	_	
70-5	10671-10673	HC	_	
70-6	10674-10678	were	_	
70-7	10679-10687	excluded	_	
70-8	10688-10692	from	_	
70-9	10693-10696	the	_	
70-10	10697-10705	analyses	_	
70-11	10706-10711	based	_	
70-12	10712-10714	on	_	
70-13	10715-10718	the	_	
70-14	10719-10727	recorded	_	
70-15	10728-10734	motion	_	
70-16	10735-10745	correction	_	
70-17	10746-10755	estimates	_	
70-18	10755-10756	.	_	

#Text=The realigned EPI images were coregistered to individual T1-weighted structural images.
71-1	10757-10760	The	_	
71-2	10761-10770	realigned	_	
71-3	10771-10774	EPI	_	
71-4	10775-10781	images	_	
71-5	10782-10786	were	_	
71-6	10787-10799	coregistered	_	
71-7	10800-10802	to	_	
71-8	10803-10813	individual	_	
71-9	10814-10816	T1	_	
71-10	10816-10817	-	_	
71-11	10817-10825	weighted	_	
71-12	10826-10836	structural	_	
71-13	10837-10843	images	_	
71-14	10843-10844	.	_	

#Text=The locations of the NAc subdivisions in normalized T1 images for each subject can be seen in Additional file 1: Figure S1 and S2.
72-1	10845-10848	The	_	
72-2	10849-10858	locations	_	
72-3	10859-10861	of	_	
72-4	10862-10865	the	_	
72-5	10866-10869	NAc	_	
72-6	10870-10882	subdivisions	_	
72-7	10883-10885	in	_	
72-8	10886-10896	normalized	_	
72-9	10897-10899	T1	_	
72-10	10900-10906	images	_	
72-11	10907-10910	for	_	
72-12	10911-10915	each	_	
72-13	10916-10923	subject	_	
72-14	10924-10927	can	_	
72-15	10928-10930	be	_	
72-16	10931-10935	seen	_	
72-17	10936-10938	in	_	
72-18	10939-10949	Additional	_	
72-19	10950-10954	file	_	
72-20	10955-10956	1	_	
72-21	10956-10957	:	_	
72-22	10958-10964	Figure	_	
72-23	10965-10967	S1	_	
72-24	10968-10971	and	_	
72-25	10972-10974	S2	_	
72-26	10974-10975	.	_	

#Text=Then the transformed structural images were segmented into gray matter, white matter, and cerebrospinal fluid.
73-1	10976-10980	Then	_	
73-2	10981-10984	the	_	
73-3	10985-10996	transformed	_	
73-4	10997-11007	structural	_	
73-5	11008-11014	images	_	
73-6	11015-11019	were	_	
73-7	11020-11029	segmented	_	
73-8	11030-11034	into	_	
73-9	11035-11039	gray	_	
73-10	11040-11046	matter	_	
73-11	11046-11047	,	_	
73-12	11048-11053	white	_	
73-13	11054-11060	matter	_	
73-14	11060-11061	,	_	
73-15	11062-11065	and	_	
73-16	11066-11079	cerebrospinal	_	
73-17	11080-11085	fluid	_	
73-18	11085-11086	.	_	

#Text=Several sources of variance were removed from the realigned data by regression of nuisance variables, including 24 motion parameters (6 head motion parameters, 6 head motion parameters one time point before, and the 12 corresponding squared items), the signal averaged over the individual segmented cerebrospinal fluid and white matter (WM) regions, linear and quadratic trends.
74-1	11087-11094	Several	_	
74-2	11095-11102	sources	_	
74-3	11103-11105	of	_	
74-4	11106-11114	variance	_	
74-5	11115-11119	were	_	
74-6	11120-11127	removed	_	
74-7	11128-11132	from	_	
74-8	11133-11136	the	_	
74-9	11137-11146	realigned	_	
74-10	11147-11151	data	_	
74-11	11152-11154	by	_	
74-12	11155-11165	regression	_	
74-13	11166-11168	of	_	
74-14	11169-11177	nuisance	_	
74-15	11178-11187	variables	_	
74-16	11187-11188	,	_	
74-17	11189-11198	including	_	
74-18	11199-11201	24	_	
74-19	11202-11208	motion	_	
74-20	11209-11219	parameters	_	
74-21	11220-11221	(	_	
74-22	11221-11222	6	_	
74-23	11223-11227	head	_	
74-24	11228-11234	motion	_	
74-25	11235-11245	parameters	_	
74-26	11245-11246	,	_	
74-27	11247-11248	6	_	
74-28	11249-11253	head	_	
74-29	11254-11260	motion	_	
74-30	11261-11271	parameters	_	
74-31	11272-11275	one	_	
74-32	11276-11280	time	_	
74-33	11281-11286	point	_	
74-34	11287-11293	before	_	
74-35	11293-11294	,	_	
74-36	11295-11298	and	_	
74-37	11299-11302	the	_	
74-38	11303-11305	12	_	
74-39	11306-11319	corresponding	_	
74-40	11320-11327	squared	_	
74-41	11328-11333	items	_	
74-42	11333-11334	)	_	
74-43	11334-11335	,	_	
74-44	11336-11339	the	_	
74-45	11340-11346	signal	_	
74-46	11347-11355	averaged	_	
74-47	11356-11360	over	_	
74-48	11361-11364	the	_	
74-49	11365-11375	individual	_	
74-50	11376-11385	segmented	_	
74-51	11386-11399	cerebrospinal	_	
74-52	11400-11405	fluid	_	
74-53	11406-11409	and	_	
74-54	11410-11415	white	_	
74-55	11416-11422	matter	_	
74-56	11423-11424	(	_	
74-57	11424-11426	WM	_	
74-58	11426-11427	)	_	
74-59	11428-11435	regions	_	
74-60	11435-11436	,	_	
74-61	11437-11443	linear	_	
74-62	11444-11447	and	_	
74-63	11448-11457	quadratic	_	
74-64	11458-11464	trends	_	
74-65	11464-11465	.	_	

#Text=The resulting maps were then registered into MNI space with 2 × 2 × 2 mm3 cubic voxels using the transformation information acquired from T1 image unified segmentation.
75-1	11466-11469	The	_	
75-2	11470-11479	resulting	_	
75-3	11480-11484	maps	_	
75-4	11485-11489	were	_	
75-5	11490-11494	then	_	
75-6	11495-11505	registered	_	
75-7	11506-11510	into	_	
75-8	11511-11514	MNI	_	
75-9	11515-11520	space	_	
75-10	11521-11525	with	_	
75-11	11526-11527	2	_	
75-12	11528-11529	×	_	
75-13	11530-11531	2	_	
75-14	11532-11533	×	_	
75-15	11534-11535	2	_	
75-16	11536-11539	mm3	_	
75-17	11540-11545	cubic	_	
75-18	11546-11552	voxels	_	
75-19	11553-11558	using	_	
75-20	11559-11562	the	_	
75-21	11563-11577	transformation	_	
75-22	11578-11589	information	_	
75-23	11590-11598	acquired	_	
75-24	11599-11603	from	_	
75-25	11604-11606	T1	_	
75-26	11607-11612	image	_	
75-27	11613-11620	unified	_	
75-28	11621-11633	segmentation	_	
75-29	11633-11634	.	_	

#Text=A smoothing kernel of 4 mm was applied after registration.
76-1	11635-11636	A	_	
76-2	11637-11646	smoothing	_	
76-3	11647-11653	kernel	_	
76-4	11654-11656	of	_	
76-5	11657-11658	4	_	
76-6	11658-11659	 	_	
76-7	11659-11661	mm	_	
76-8	11662-11665	was	_	
76-9	11666-11673	applied	_	
76-10	11674-11679	after	_	
76-11	11680-11692	registration	_	
76-12	11692-11693	.	_	

#Text=Finally, temporal filtering (0.01–0.1 Hz) of the time series was performed.
77-1	11694-11701	Finally	_	
77-2	11701-11702	,	_	
77-3	11703-11711	temporal	_	
77-4	11712-11721	filtering	_	
77-5	11722-11723	(	_	
77-6	11723-11727	0.01	_	
77-7	11727-11728	–	_	
77-8	11728-11731	0.1	_	
77-9	11731-11732	 	_	
77-10	11732-11734	Hz	_	
77-11	11734-11735	)	_	
77-12	11736-11738	of	_	
77-13	11739-11742	the	_	
77-14	11743-11747	time	_	
77-15	11748-11754	series	_	
77-16	11755-11758	was	_	
77-17	11759-11768	performed	_	
77-18	11768-11769	.	_	

#Text=To characterize differences in in-scanner microhead motion, the mean frame-wise displacement (FD), which includes measures of voxel-wise differences in motion in its derivation, was used as a measure of the micro-head motion of each subject.
78-1	11770-11772	To	_	
78-2	11773-11785	characterize	_	
78-3	11786-11797	differences	_	
78-4	11798-11800	in	_	
78-5	11801-11811	in-scanner	_	
78-6	11812-11821	microhead	_	
78-7	11822-11828	motion	_	
78-8	11828-11829	,	_	
78-9	11830-11833	the	_	
78-10	11834-11838	mean	_	
78-11	11839-11849	frame-wise	_	
78-12	11850-11862	displacement	_	
78-13	11863-11864	(	_	
78-14	11864-11866	FD	_	
78-15	11866-11867	)	_	
78-16	11867-11868	,	_	
78-17	11869-11874	which	_	
78-18	11875-11883	includes	_	
78-19	11884-11892	measures	_	
78-20	11893-11895	of	_	
78-21	11896-11906	voxel-wise	_	
78-22	11907-11918	differences	_	
78-23	11919-11921	in	_	
78-24	11922-11928	motion	_	
78-25	11929-11931	in	_	
78-26	11932-11935	its	_	
78-27	11936-11946	derivation	_	
78-28	11946-11947	,	_	
78-29	11948-11951	was	_	
78-30	11952-11956	used	_	
78-31	11957-11959	as	_	
78-32	11960-11961	a	_	
78-33	11962-11969	measure	_	
78-34	11970-11972	of	_	
78-35	11973-11976	the	_	
78-36	11977-11987	micro-head	_	
78-37	11988-11994	motion	_	
78-38	11995-11997	of	_	
78-39	11998-12002	each	_	
78-40	12003-12010	subject	_	
78-41	12010-12011	.	_	

#Text=Definition of the regions of interest
#Text=The four subdivisions of nucleus accumbens (NAc) intersected by Xia et al.
79-1	12012-12022	Definition	_	
79-2	12023-12025	of	_	
79-3	12026-12029	the	_	
79-4	12030-12037	regions	_	
79-5	12038-12040	of	_	
79-6	12041-12049	interest	_	
79-7	12050-12053	The	_	
79-8	12054-12058	four	_	
79-9	12059-12071	subdivisions	_	
79-10	12072-12074	of	_	
79-11	12075-12082	nucleus	_	
79-12	12083-12092	accumbens	_	
79-13	12093-12094	(	_	
79-14	12094-12097	NAc	_	
79-15	12097-12098	)	_	
79-16	12099-12110	intersected	_	
79-17	12111-12113	by	_	
79-18	12114-12117	Xia	_	
79-19	12118-12120	et	_	
79-20	12121-12123	al	_	
79-21	12123-12124	.	_	

#Text=Using neuroanatomy and histochemistry, the differentiation of the NAc subregions has been extensively studied, yielding a widely-accepted dichotomic shell/core-like subdivisions that reflect dissociable roles respectively.
80-1	12126-12131	Using	_	
80-2	12132-12144	neuroanatomy	_	
80-3	12145-12148	and	_	
80-4	12149-12163	histochemistry	_	
80-5	12163-12164	,	_	
80-6	12165-12168	the	_	
80-7	12169-12184	differentiation	_	
80-8	12185-12187	of	_	
80-9	12188-12191	the	_	
80-10	12192-12195	NAc	_	
80-11	12196-12206	subregions	_	
80-12	12207-12210	has	_	
80-13	12211-12215	been	_	
80-14	12216-12227	extensively	_	
80-15	12228-12235	studied	_	
80-16	12235-12236	,	_	
80-17	12237-12245	yielding	_	
80-18	12246-12247	a	_	
80-19	12248-12263	widely-accepted	_	
80-20	12264-12274	dichotomic	_	
80-21	12275-12280	shell	_	
80-22	12280-12281	/	_	
80-23	12281-12290	core-like	_	
80-24	12291-12303	subdivisions	_	
80-25	12304-12308	that	_	
80-26	12309-12316	reflect	_	
80-27	12317-12328	dissociable	_	
80-28	12329-12334	roles	_	
80-29	12335-12347	respectively	_	
80-30	12347-12348	.	_	

#Text=Recently, to investigate the regional differentiation within the NAc, Xia et al. used three complementary parcellation schemes based on tractography, RSFC, and task-dependent co-activation and found that the 2-cluster solution with shell/core architecture provided the best description of the data.
81-1	12349-12357	Recently	_	
81-2	12357-12358	,	_	
81-3	12359-12361	to	_	
81-4	12362-12373	investigate	_	
81-5	12374-12377	the	_	
81-6	12378-12386	regional	_	
81-7	12387-12402	differentiation	_	
81-8	12403-12409	within	_	
81-9	12410-12413	the	_	
81-10	12414-12417	NAc	_	
81-11	12417-12418	,	_	
81-12	12419-12422	Xia	_	
81-13	12423-12425	et	_	
81-14	12426-12428	al	_	
81-15	12428-12429	.	_	
81-16	12430-12434	used	_	
81-17	12435-12440	three	_	
81-18	12441-12454	complementary	_	
81-19	12455-12467	parcellation	_	
81-20	12468-12475	schemes	_	
81-21	12476-12481	based	_	
81-22	12482-12484	on	_	
81-23	12485-12497	tractography	_	
81-24	12497-12498	,	_	
81-25	12499-12503	RSFC	_	
81-26	12503-12504	,	_	
81-27	12505-12508	and	_	
81-28	12509-12523	task-dependent	_	
81-29	12524-12537	co-activation	_	
81-30	12538-12541	and	_	
81-31	12542-12547	found	_	
81-32	12548-12552	that	_	
81-33	12553-12556	the	_	
81-34	12557-12558	2	_	
81-35	12558-12559	-	_	
81-36	12559-12566	cluster	_	
81-37	12567-12575	solution	_	
81-38	12576-12580	with	_	
81-39	12581-12586	shell	_	
81-40	12586-12587	/	_	
81-41	12587-12591	core	_	
81-42	12592-12604	architecture	_	
81-43	12605-12613	provided	_	
81-44	12614-12617	the	_	
81-45	12618-12622	best	_	
81-46	12623-12634	description	_	
81-47	12635-12637	of	_	
81-48	12638-12641	the	_	
81-49	12642-12646	data	_	
81-50	12646-12647	.	_	

#Text=The clusters generated in this solution across the three parcellation schemes were defined as the final parcels.
82-1	12648-12651	The	_	
82-2	12652-12660	clusters	_	
82-3	12661-12670	generated	_	
82-4	12671-12673	in	_	
82-5	12674-12678	this	_	
82-6	12679-12687	solution	_	
82-7	12688-12694	across	_	
82-8	12695-12698	the	_	
82-9	12699-12704	three	_	
82-10	12705-12717	parcellation	_	
82-11	12718-12725	schemes	_	
82-12	12726-12730	were	_	
82-13	12731-12738	defined	_	
82-14	12739-12741	as	_	
82-15	12742-12745	the	_	
82-16	12746-12751	final	_	
82-17	12752-12759	parcels	_	
82-18	12759-12760	.	_	

#Text=In our study, the subdivisions of the NAc derived from RSFC patterns of these parcels were chosen as the regions of interests for further functional connectivity analyses (Fig. 1).
83-1	12761-12763	In	_	
83-2	12764-12767	our	_	
83-3	12768-12773	study	_	
83-4	12773-12774	,	_	
83-5	12775-12778	the	_	
83-6	12779-12791	subdivisions	_	
83-7	12792-12794	of	_	
83-8	12795-12798	the	_	
83-9	12799-12802	NAc	_	
83-10	12803-12810	derived	_	
83-11	12811-12815	from	_	
83-12	12816-12820	RSFC	_	
83-13	12821-12829	patterns	_	
83-14	12830-12832	of	_	
83-15	12833-12838	these	_	
83-16	12839-12846	parcels	_	
83-17	12847-12851	were	_	
83-18	12852-12858	chosen	_	
83-19	12859-12861	as	_	
83-20	12862-12865	the	_	
83-21	12866-12873	regions	_	
83-22	12874-12876	of	_	
83-23	12877-12886	interests	_	
83-24	12887-12890	for	_	
83-25	12891-12898	further	_	
83-26	12899-12909	functional	_	
83-27	12910-12922	connectivity	_	
83-28	12923-12931	analyses	_	
83-29	12932-12933	(	_	
83-30	12933-12936	Fig	_	
83-31	12936-12937	.	_	
83-32	12937-12938	 	_	
83-33	12938-12939	1	_	
83-34	12939-12940	)	_	
83-35	12940-12941	.	_	

#Text=RSFC analyses
#Text=The seed-based RSFC of the four subdivisions of the NAc was analyzed.
84-1	12943-12947	RSFC	_	
84-2	12948-12956	analyses	_	
84-3	12957-12960	The	_	
84-4	12961-12971	seed-based	_	
84-5	12972-12976	RSFC	_	
84-6	12977-12979	of	_	
84-7	12980-12983	the	_	
84-8	12984-12988	four	_	
84-9	12989-13001	subdivisions	_	
84-10	13002-13004	of	_	
84-11	13005-13008	the	_	
84-12	13009-13012	NAc	_	
84-13	13013-13016	was	_	
84-14	13017-13025	analyzed	_	
84-15	13025-13026	.	_	

#Text=By averaging the time series of all of the voxels within the seed region, the mean time series of each seed region was acquired.
85-1	13027-13029	By	_	
85-2	13030-13039	averaging	_	
85-3	13040-13043	the	_	
85-4	13044-13048	time	_	
85-5	13049-13055	series	_	
85-6	13056-13058	of	_	
85-7	13059-13062	all	_	
85-8	13063-13065	of	_	
85-9	13066-13069	the	_	
85-10	13070-13076	voxels	_	
85-11	13077-13083	within	_	
85-12	13084-13087	the	_	
85-13	13088-13092	seed	_	
85-14	13093-13099	region	_	
85-15	13099-13100	,	_	
85-16	13101-13104	the	_	
85-17	13105-13109	mean	_	
85-18	13110-13114	time	_	
85-19	13115-13121	series	_	
85-20	13122-13124	of	_	
85-21	13125-13129	each	_	
85-22	13130-13134	seed	_	
85-23	13135-13141	region	_	
85-24	13142-13145	was	_	
85-25	13146-13154	acquired	_	
85-26	13154-13155	.	_	

#Text=Pearson’s correlation coefficients were computed between the mean time series of the seed region and time series of each voxel of the whole brain.
86-1	13156-13163	Pearson	_	
86-2	13163-13164	’	_	
86-3	13164-13165	s	_	
86-4	13166-13177	correlation	_	
86-5	13178-13190	coefficients	_	
86-6	13191-13195	were	_	
86-7	13196-13204	computed	_	
86-8	13205-13212	between	_	
86-9	13213-13216	the	_	
86-10	13217-13221	mean	_	
86-11	13222-13226	time	_	
86-12	13227-13233	series	_	
86-13	13234-13236	of	_	
86-14	13237-13240	the	_	
86-15	13241-13245	seed	_	
86-16	13246-13252	region	_	
86-17	13253-13256	and	_	
86-18	13257-13261	time	_	
86-19	13262-13268	series	_	
86-20	13269-13271	of	_	
86-21	13272-13276	each	_	
86-22	13277-13282	voxel	_	
86-23	13283-13285	of	_	
86-24	13286-13289	the	_	
86-25	13290-13295	whole	_	
86-26	13296-13301	brain	_	
86-27	13301-13302	.	_	

#Text=The correlation coefficients were converted into z-values using Fisher’s r-to-z transformation in order to improve their normality.
87-1	13303-13306	The	_	
87-2	13307-13318	correlation	_	
87-3	13319-13331	coefficients	_	
87-4	13332-13336	were	_	
87-5	13337-13346	converted	_	
87-6	13347-13351	into	_	
87-7	13352-13360	z-values	_	
87-8	13361-13366	using	_	
87-9	13367-13373	Fisher	_	
87-10	13373-13374	’	_	
87-11	13374-13375	s	_	
87-12	13376-13382	r-to-z	_	
87-13	13383-13397	transformation	_	
87-14	13398-13400	in	_	
87-15	13401-13406	order	_	
87-16	13407-13409	to	_	
87-17	13410-13417	improve	_	
87-18	13418-13423	their	_	
87-19	13424-13433	normality	_	
87-20	13433-13434	.	_	

#Text=The z-values were analyzed by one-sample t-tests to identify brain regions that exhibited significant positive or negative correlations with the seed region within each group (voxel-wise p < 0.001, cluster-wise FWE p < 0.05).
88-1	13435-13438	The	_	
88-2	13439-13447	z-values	_	
88-3	13448-13452	were	_	
88-4	13453-13461	analyzed	_	
88-5	13462-13464	by	_	
88-6	13465-13475	one-sample	_	
88-7	13476-13483	t-tests	_	
88-8	13484-13486	to	_	
88-9	13487-13495	identify	_	
88-10	13496-13501	brain	_	
88-11	13502-13509	regions	_	
88-12	13510-13514	that	_	
88-13	13515-13524	exhibited	_	
88-14	13525-13536	significant	_	
88-15	13537-13545	positive	_	
88-16	13546-13548	or	_	
88-17	13549-13557	negative	_	
88-18	13558-13570	correlations	_	
88-19	13571-13575	with	_	
88-20	13576-13579	the	_	
88-21	13580-13584	seed	_	
88-22	13585-13591	region	_	
88-23	13592-13598	within	_	
88-24	13599-13603	each	_	
88-25	13604-13609	group	_	
88-26	13610-13611	(	_	
88-27	13611-13621	voxel-wise	_	
88-28	13622-13623	p	_	
88-29	13624-13625	<	_	
88-30	13626-13631	0.001	_	
88-31	13631-13632	,	_	
88-32	13633-13645	cluster-wise	_	
88-33	13646-13649	FWE	_	
88-34	13650-13651	p	_	
88-35	13652-13653	<	_	
88-36	13654-13658	0.05	_	
88-37	13658-13659	)	_	
88-38	13659-13660	.	_	

#Text=Finally, the z-values were analyzed by two-sample t-tests to identify brain regions that exhibited significant differences in connectivity with the seed region between the ATSA group and HC group while accounting for the confounding effects of the education level, age and Jenkinson’s mean FD.
89-1	13661-13668	Finally	_	
89-2	13668-13669	,	_	
89-3	13670-13673	the	_	
89-4	13674-13682	z-values	_	
89-5	13683-13687	were	_	
89-6	13688-13696	analyzed	_	
89-7	13697-13699	by	_	
89-8	13700-13710	two-sample	_	
89-9	13711-13718	t-tests	_	
89-10	13719-13721	to	_	
89-11	13722-13730	identify	_	
89-12	13731-13736	brain	_	
89-13	13737-13744	regions	_	
89-14	13745-13749	that	_	
89-15	13750-13759	exhibited	_	
89-16	13760-13771	significant	_	
89-17	13772-13783	differences	_	
89-18	13784-13786	in	_	
89-19	13787-13799	connectivity	_	
89-20	13800-13804	with	_	
89-21	13805-13808	the	_	
89-22	13809-13813	seed	_	
89-23	13814-13820	region	_	
89-24	13821-13828	between	_	
89-25	13829-13832	the	_	
89-26	13833-13837	ATSA	_	
89-27	13838-13843	group	_	
89-28	13844-13847	and	_	
89-29	13848-13850	HC	_	
89-30	13851-13856	group	_	
89-31	13857-13862	while	_	
89-32	13863-13873	accounting	_	
89-33	13874-13877	for	_	
89-34	13878-13881	the	_	
89-35	13882-13893	confounding	_	
89-36	13894-13901	effects	_	
89-37	13902-13904	of	_	
89-38	13905-13908	the	_	
89-39	13909-13918	education	_	
89-40	13919-13924	level	_	
89-41	13924-13925	,	_	
89-42	13926-13929	age	_	
89-43	13930-13933	and	_	
89-44	13934-13943	Jenkinson	_	
89-45	13943-13944	’	_	
89-46	13944-13945	s	_	
89-47	13946-13950	mean	_	
89-48	13951-13953	FD	_	
89-49	13953-13954	.	_	

#Text=The statistical threshold of the two-sample t-test was set at voxel-wise p < 0.001 in conjunction with a cluster-wise FWE p < 0.0125 to correct for multiple comparisons [p < 0.0125 was selected to take in account the number of independent seed regions used (0.0125 = 0.05/4)].
90-1	13955-13958	The	_	
90-2	13959-13970	statistical	_	
90-3	13971-13980	threshold	_	
90-4	13981-13983	of	_	
90-5	13984-13987	the	_	
90-6	13988-13998	two-sample	_	
90-7	13999-14005	t-test	_	
90-8	14006-14009	was	_	
90-9	14010-14013	set	_	
90-10	14014-14016	at	_	
90-11	14017-14027	voxel-wise	_	
90-12	14028-14029	p	_	
90-13	14030-14031	<	_	
90-14	14032-14037	0.001	_	
90-15	14038-14040	in	_	
90-16	14041-14052	conjunction	_	
90-17	14053-14057	with	_	
90-18	14058-14059	a	_	
90-19	14060-14072	cluster-wise	_	
90-20	14073-14076	FWE	_	
90-21	14077-14078	p	_	
90-22	14079-14080	<	_	
90-23	14081-14087	0.0125	_	
90-24	14088-14090	to	_	
90-25	14091-14098	correct	_	
90-26	14099-14102	for	_	
90-27	14103-14111	multiple	_	
90-28	14112-14123	comparisons	_	
90-29	14124-14125	[	_	
90-30	14125-14126	p	_	
90-31	14127-14128	<	_	
90-32	14129-14135	0.0125	_	
90-33	14136-14139	was	_	
90-34	14140-14148	selected	_	
90-35	14149-14151	to	_	
90-36	14152-14156	take	_	
90-37	14157-14159	in	_	
90-38	14160-14167	account	_	
90-39	14168-14171	the	_	
90-40	14172-14178	number	_	
90-41	14179-14181	of	_	
90-42	14182-14193	independent	_	
90-43	14194-14198	seed	_	
90-44	14199-14206	regions	_	
90-45	14207-14211	used	_	
90-46	14212-14213	(	_	
90-47	14213-14219	0.0125	_	
90-48	14220-14221	=	_	
90-49	14222-14226	0.05	_	
90-50	14226-14227	/	_	
90-51	14227-14228	4	_	
90-52	14228-14229	)	_	
90-53	14229-14230	]	_	
90-54	14230-14231	.	_	

#Text=Results
#Text=Demographic data and head motion
#Text=Demographic data and subject head motion
#Text=\tHC\tATSA\tt/χ2\tp\t \tSample size\t21\t16\t\t\t \tAge (years)\t29.52 ± 2.54\t28.00 ± 4.24\t1.36\t0.18\t \tEducation\t\t\t21.45\t < 0.001\t \t Junior high school\t1\t9\t\t\t \t Senior high school\t0\t2\t\t\t \t College degree\t7\t5\t\t\t \t Bachelor degree\t13\t0\t\t\t \tMean FD\t0.06 ± 0.03\t0.05 ± 0.02\t1.49\t0.14\t \tASID\t\t7.13 ± 1.93\t\t\t \t
#Text=The characteristics of the subjects and head motion information can be seen in Table 1.
91-1	14232-14239	Results	_	
91-2	14240-14251	Demographic	_	
91-3	14252-14256	data	_	
91-4	14257-14260	and	_	
91-5	14261-14265	head	_	
91-6	14266-14272	motion	_	
91-7	14273-14284	Demographic	_	
91-8	14285-14289	data	_	
91-9	14290-14293	and	_	
91-10	14294-14301	subject	_	
91-11	14302-14306	head	_	
91-12	14307-14313	motion	_	
91-13	14315-14317	HC	_	
91-14	14318-14322	ATSA	_	
91-15	14323-14324	t	_	
91-16	14324-14325	/	_	
91-17	14325-14327	χ2	_	
91-18	14328-14329	p	_	
91-19	14332-14338	Sample	_	
91-20	14339-14343	size	_	
91-21	14344-14346	21	_	
91-22	14347-14349	16	_	
91-23	14354-14357	Age	_	
91-24	14358-14359	(	_	
91-25	14359-14364	years	_	
91-26	14364-14365	)	_	
91-27	14366-14371	29.52	_	
91-28	14372-14373	±	_	
91-29	14374-14378	2.54	_	
91-30	14379-14384	28.00	_	
91-31	14385-14386	±	_	
91-32	14387-14391	4.24	_	
91-33	14392-14396	1.36	_	
91-34	14397-14401	0.18	_	
91-35	14404-14413	Education	_	
91-36	14416-14421	21.45	_	
91-37	14423-14424	<	_	
91-38	14425-14430	0.001	_	
91-39	14433-14434	 	_	
91-40	14434-14440	Junior	_	
91-41	14441-14445	high	_	
91-42	14446-14452	school	_	
91-43	14453-14454	1	_	
91-44	14455-14456	9	_	
91-45	14461-14462	 	_	
91-46	14462-14468	Senior	_	
91-47	14469-14473	high	_	
91-48	14474-14480	school	_	
91-49	14481-14482	0	_	
91-50	14483-14484	2	_	
91-51	14489-14490	 	_	
91-52	14490-14497	College	_	
91-53	14498-14504	degree	_	
91-54	14505-14506	7	_	
91-55	14507-14508	5	_	
91-56	14513-14514	 	_	
91-57	14514-14522	Bachelor	_	
91-58	14523-14529	degree	_	
91-59	14530-14532	13	_	
91-60	14533-14534	0	_	
91-61	14539-14543	Mean	_	
91-62	14544-14546	FD	_	
91-63	14547-14551	0.06	_	
91-64	14552-14553	±	_	
91-65	14554-14558	0.03	_	
91-66	14559-14563	0.05	_	
91-67	14564-14565	±	_	
91-68	14566-14570	0.02	_	
91-69	14571-14575	1.49	_	
91-70	14576-14580	0.14	_	
91-71	14583-14587	ASID	_	
91-72	14589-14593	7.13	_	
91-73	14594-14595	±	_	
91-74	14596-14600	1.93	_	
91-75	14606-14609	The	_	
91-76	14610-14625	characteristics	_	
91-77	14626-14628	of	_	
91-78	14629-14632	the	_	
91-79	14633-14641	subjects	_	
91-80	14642-14645	and	_	
91-81	14646-14650	head	_	
91-82	14651-14657	motion	_	
91-83	14658-14669	information	_	
91-84	14670-14673	can	_	
91-85	14674-14676	be	_	
91-86	14677-14681	seen	_	
91-87	14682-14684	in	_	
91-88	14685-14690	Table	_	
91-89	14691-14692	1	_	
91-90	14692-14693	.	_	

#Text=The mean ages of the two groups were not significantly different (t = 1.36, p = 0.18).
92-1	14694-14697	The	_	
92-2	14698-14702	mean	_	
92-3	14703-14707	ages	_	
92-4	14708-14710	of	_	
92-5	14711-14714	the	_	
92-6	14715-14718	two	_	
92-7	14719-14725	groups	_	
92-8	14726-14730	were	_	
92-9	14731-14734	not	_	
92-10	14735-14748	significantly	_	
92-11	14749-14758	different	_	
92-12	14759-14760	(	_	
92-13	14760-14761	t	_	
92-14	14762-14763	=	_	
92-15	14764-14768	1.36	_	
92-16	14768-14769	,	_	
92-17	14770-14771	p	_	
92-18	14772-14773	=	_	
92-19	14774-14778	0.18	_	
92-20	14778-14779	)	_	
92-21	14779-14780	.	_	

#Text=The educational level of the ATSAs was significantly lower than that of the HC subjects (χ2 = 21.45, p < 0.001).
93-1	14781-14784	The	_	
93-2	14785-14796	educational	_	
93-3	14797-14802	level	_	
93-4	14803-14805	of	_	
93-5	14806-14809	the	_	
93-6	14810-14815	ATSAs	_	
93-7	14816-14819	was	_	
93-8	14820-14833	significantly	_	
93-9	14834-14839	lower	_	
93-10	14840-14844	than	_	
93-11	14845-14849	that	_	
93-12	14850-14852	of	_	
93-13	14853-14856	the	_	
93-14	14857-14859	HC	_	
93-15	14860-14868	subjects	_	
93-16	14869-14870	(	_	
93-17	14870-14872	χ2	_	
93-18	14873-14874	=	_	
93-19	14875-14880	21.45	_	
93-20	14880-14881	,	_	
93-21	14882-14883	p	_	
93-22	14884-14885	<	_	
93-23	14886-14891	0.001	_	
93-24	14891-14892	)	_	
93-25	14892-14893	.	_	

#Text=The educational level and age were included as covariates in the following analyses.
94-1	14894-14897	The	_	
94-2	14898-14909	educational	_	
94-3	14910-14915	level	_	
94-4	14916-14919	and	_	
94-5	14920-14923	age	_	
94-6	14924-14928	were	_	
94-7	14929-14937	included	_	
94-8	14938-14940	as	_	
94-9	14941-14951	covariates	_	
94-10	14952-14954	in	_	
94-11	14955-14958	the	_	
94-12	14959-14968	following	_	
94-13	14969-14977	analyses	_	
94-14	14977-14978	.	_	

#Text=The mean FDs of the ATSA group and HC group were not significantly different (t = 1.49, p = 0.14).
95-1	14979-14982	The	_	
95-2	14983-14987	mean	_	
95-3	14988-14991	FDs	_	
95-4	14992-14994	of	_	
95-5	14995-14998	the	_	
95-6	14999-15003	ATSA	_	
95-7	15004-15009	group	_	
95-8	15010-15013	and	_	
95-9	15014-15016	HC	_	
95-10	15017-15022	group	_	
95-11	15023-15027	were	_	
95-12	15028-15031	not	_	
95-13	15032-15045	significantly	_	
95-14	15046-15055	different	_	
95-15	15056-15057	(	_	
95-16	15057-15058	t	_	
95-17	15059-15060	=	_	
95-18	15061-15065	1.49	_	
95-19	15065-15066	,	_	
95-20	15067-15068	p	_	
95-21	15069-15070	=	_	
95-22	15071-15075	0.14	_	
95-23	15075-15076	)	_	
95-24	15076-15077	.	_	

#Text=Considering the influence of head motion on intrinsic functional connectivity, we also included it as a covariate in the following analyses.
96-1	15078-15089	Considering	_	
96-2	15090-15093	the	_	
96-3	15094-15103	influence	_	
96-4	15104-15106	of	_	
96-5	15107-15111	head	_	
96-6	15112-15118	motion	_	
96-7	15119-15121	on	_	
96-8	15122-15131	intrinsic	_	
96-9	15132-15142	functional	_	
96-10	15143-15155	connectivity	_	
96-11	15155-15156	,	_	
96-12	15157-15159	we	_	
96-13	15160-15164	also	_	
96-14	15165-15173	included	_	
96-15	15174-15176	it	_	
96-16	15177-15179	as	_	
96-17	15180-15181	a	_	
96-18	15182-15191	covariate	_	
96-19	15192-15194	in	_	
96-20	15195-15198	the	_	
96-21	15199-15208	following	_	
96-22	15209-15217	analyses	_	
96-23	15217-15218	.	_	

#Text=The mean ASID score of ATSAs was 7.13.
97-1	15219-15222	The	_	
97-2	15223-15227	mean	_	
97-3	15228-15232	ASID	_	
97-4	15233-15238	score	_	
97-5	15239-15241	of	_	
97-6	15242-15247	ATSAs	_	
97-7	15248-15251	was	_	
97-8	15252-15256	7.13	_	
97-9	15256-15257	.	_	

#Text=RSFC analyses
#Text=Regions showing significant differences in RSFCs with the left NAc core-like subdivision compared with the left NAc shell-like subdivision and significant changes in RSFCs with the right NAc core-like subdivision compared with the right NAc shell-like subdivision in the HC group.
98-1	15259-15263	RSFC	_	
98-2	15264-15272	analyses	_	
98-3	15273-15280	Regions	_	
98-4	15281-15288	showing	_	
98-5	15289-15300	significant	_	
98-6	15301-15312	differences	_	
98-7	15313-15315	in	_	
98-8	15316-15321	RSFCs	_	
98-9	15322-15326	with	_	
98-10	15327-15330	the	_	
98-11	15331-15335	left	_	
98-12	15336-15339	NAc	_	
98-13	15340-15349	core-like	_	
98-14	15350-15361	subdivision	_	
98-15	15362-15370	compared	_	
98-16	15371-15375	with	_	
98-17	15376-15379	the	_	
98-18	15380-15384	left	_	
98-19	15385-15388	NAc	_	
98-20	15389-15399	shell-like	_	
98-21	15400-15411	subdivision	_	
98-22	15412-15415	and	_	
98-23	15416-15427	significant	_	
98-24	15428-15435	changes	_	
98-25	15436-15438	in	_	
98-26	15439-15444	RSFCs	_	
98-27	15445-15449	with	_	
98-28	15450-15453	the	_	
98-29	15454-15459	right	_	
98-30	15460-15463	NAc	_	
98-31	15464-15473	core-like	_	
98-32	15474-15485	subdivision	_	
98-33	15486-15494	compared	_	
98-34	15495-15499	with	_	
98-35	15500-15503	the	_	
98-36	15504-15509	right	_	
98-37	15510-15513	NAc	_	
98-38	15514-15524	shell-like	_	
98-39	15525-15536	subdivision	_	
98-40	15537-15539	in	_	
98-41	15540-15543	the	_	
98-42	15544-15546	HC	_	
98-43	15547-15552	group	_	
98-44	15552-15553	.	_	

#Text=Warm colors represent the regions showing significant RSFCs with the NAc core-like subdivision compared with the NAc shell-like subdivision, and cool colors represent the regions showing significant RSFCs with the NAc shell-like subdivision compared with the NAc core-like subdivision.
99-1	15554-15558	Warm	_	
99-2	15559-15565	colors	_	
99-3	15566-15575	represent	_	
99-4	15576-15579	the	_	
99-5	15580-15587	regions	_	
99-6	15588-15595	showing	_	
99-7	15596-15607	significant	_	
99-8	15608-15613	RSFCs	_	
99-9	15614-15618	with	_	
99-10	15619-15622	the	_	
99-11	15623-15626	NAc	_	
99-12	15627-15636	core-like	_	
99-13	15637-15648	subdivision	_	
99-14	15649-15657	compared	_	
99-15	15658-15662	with	_	
99-16	15663-15666	the	_	
99-17	15667-15670	NAc	_	
99-18	15671-15681	shell-like	_	
99-19	15682-15693	subdivision	_	
99-20	15693-15694	,	_	
99-21	15695-15698	and	_	
99-22	15699-15703	cool	_	
99-23	15704-15710	colors	_	
99-24	15711-15720	represent	_	
99-25	15721-15724	the	_	
99-26	15725-15732	regions	_	
99-27	15733-15740	showing	_	
99-28	15741-15752	significant	_	
99-29	15753-15758	RSFCs	_	
99-30	15759-15763	with	_	
99-31	15764-15767	the	_	
99-32	15768-15771	NAc	_	
99-33	15772-15782	shell-like	_	
99-34	15783-15794	subdivision	_	
99-35	15795-15803	compared	_	
99-36	15804-15808	with	_	
99-37	15809-15812	the	_	
99-38	15813-15816	NAc	_	
99-39	15817-15826	core-like	_	
99-40	15827-15838	subdivision	_	
99-41	15838-15839	.	_	

#Text=The images were created using BrainNet Viewer (https://www.nitrc.org/projects/bnv/)
#Text=In order to validate the parcellation of the NAc subdivisions, we used paired-sample t-test to examine whether there were any regions showing significant differences in RSFCs with the NAc core-like subdivision compared with the NAc shell-like subdivision in the HC group.
100-1	15840-15843	The	_	
100-2	15844-15850	images	_	
100-3	15851-15855	were	_	
100-4	15856-15863	created	_	
100-5	15864-15869	using	_	
100-6	15870-15878	BrainNet	_	
100-7	15879-15885	Viewer	_	
100-8	15886-15887	(	_	
100-9	15887-15892	https	_	
100-10	15892-15893	:	_	
100-11	15893-15894	/	_	
100-12	15894-15895	/	_	
100-13	15895-15908	www.nitrc.org	_	
100-14	15908-15909	/	_	
100-15	15909-15917	projects	_	
100-16	15917-15918	/	_	
100-17	15918-15921	bnv	_	
100-18	15921-15922	/	_	
100-19	15922-15923	)	_	
100-20	15924-15926	In	_	
100-21	15927-15932	order	_	
100-22	15933-15935	to	_	
100-23	15936-15944	validate	_	
100-24	15945-15948	the	_	
100-25	15949-15961	parcellation	_	
100-26	15962-15964	of	_	
100-27	15965-15968	the	_	
100-28	15969-15972	NAc	_	
100-29	15973-15985	subdivisions	_	
100-30	15985-15986	,	_	
100-31	15987-15989	we	_	
100-32	15990-15994	used	_	
100-33	15995-16008	paired-sample	_	
100-34	16009-16015	t-test	_	
100-35	16016-16018	to	_	
100-36	16019-16026	examine	_	
100-37	16027-16034	whether	_	
100-38	16035-16040	there	_	
100-39	16041-16045	were	_	
100-40	16046-16049	any	_	
100-41	16050-16057	regions	_	
100-42	16058-16065	showing	_	
100-43	16066-16077	significant	_	
100-44	16078-16089	differences	_	
100-45	16090-16092	in	_	
100-46	16093-16098	RSFCs	_	
100-47	16099-16103	with	_	
100-48	16104-16107	the	_	
100-49	16108-16111	NAc	_	
100-50	16112-16121	core-like	_	
100-51	16122-16133	subdivision	_	
100-52	16134-16142	compared	_	
100-53	16143-16147	with	_	
100-54	16148-16151	the	_	
100-55	16152-16155	NAc	_	
100-56	16156-16166	shell-like	_	
100-57	16167-16178	subdivision	_	
100-58	16179-16181	in	_	
100-59	16182-16185	the	_	
100-60	16186-16188	HC	_	
100-61	16189-16194	group	_	
100-62	16194-16195	.	_	

#Text=We found that the positive RSFCs between the NAc core-like subdivision and the frontal gyrus, the cingulate gyrus and the inferior parietal lobule were significantly greater compared with the NAc shell-like subdivision and the positive RSFCs between the NAc core-like subdivision and the temporal gyrus, the parahippocampus gyrus, the insula, and the supplementary motor area were significantly smaller compared with the NAc shell-like subdivision in the HC group (cluster-level FWE p < 0.05; Fig. 2), which is consistent with the previous study.
101-1	16196-16198	We	_	
101-2	16199-16204	found	_	
101-3	16205-16209	that	_	
101-4	16210-16213	the	_	
101-5	16214-16222	positive	_	
101-6	16223-16228	RSFCs	_	
101-7	16229-16236	between	_	
101-8	16237-16240	the	_	
101-9	16241-16244	NAc	_	
101-10	16245-16254	core-like	_	
101-11	16255-16266	subdivision	_	
101-12	16267-16270	and	_	
101-13	16271-16274	the	_	
101-14	16275-16282	frontal	_	
101-15	16283-16288	gyrus	_	
101-16	16288-16289	,	_	
101-17	16290-16293	the	_	
101-18	16294-16303	cingulate	_	
101-19	16304-16309	gyrus	_	
101-20	16310-16313	and	_	
101-21	16314-16317	the	_	
101-22	16318-16326	inferior	_	
101-23	16327-16335	parietal	_	
101-24	16336-16342	lobule	_	
101-25	16343-16347	were	_	
101-26	16348-16361	significantly	_	
101-27	16362-16369	greater	_	
101-28	16370-16378	compared	_	
101-29	16379-16383	with	_	
101-30	16384-16387	the	_	
101-31	16388-16391	NAc	_	
101-32	16392-16402	shell-like	_	
101-33	16403-16414	subdivision	_	
101-34	16415-16418	and	_	
101-35	16419-16422	the	_	
101-36	16423-16431	positive	_	
101-37	16432-16437	RSFCs	_	
101-38	16438-16445	between	_	
101-39	16446-16449	the	_	
101-40	16450-16453	NAc	_	
101-41	16454-16463	core-like	_	
101-42	16464-16475	subdivision	_	
101-43	16476-16479	and	_	
101-44	16480-16483	the	_	
101-45	16484-16492	temporal	_	
101-46	16493-16498	gyrus	_	
101-47	16498-16499	,	_	
101-48	16500-16503	the	_	
101-49	16504-16519	parahippocampus	_	
101-50	16520-16525	gyrus	_	
101-51	16525-16526	,	_	
101-52	16527-16530	the	_	
101-53	16531-16537	insula	_	
101-54	16537-16538	,	_	
101-55	16539-16542	and	_	
101-56	16543-16546	the	_	
101-57	16547-16560	supplementary	_	
101-58	16561-16566	motor	_	
101-59	16567-16571	area	_	
101-60	16572-16576	were	_	
101-61	16577-16590	significantly	_	
101-62	16591-16598	smaller	_	
101-63	16599-16607	compared	_	
101-64	16608-16612	with	_	
101-65	16613-16616	the	_	
101-66	16617-16620	NAc	_	
101-67	16621-16631	shell-like	_	
101-68	16632-16643	subdivision	_	
101-69	16644-16646	in	_	
101-70	16647-16650	the	_	
101-71	16651-16653	HC	_	
101-72	16654-16659	group	_	
101-73	16660-16661	(	_	
101-74	16661-16674	cluster-level	_	
101-75	16675-16678	FWE	_	
101-76	16679-16680	p	_	
101-77	16681-16682	<	_	
101-78	16683-16687	0.05	_	
101-79	16687-16688	;	_	
101-80	16689-16692	Fig	_	
101-81	16692-16693	.	_	
101-82	16693-16694	 	_	
101-83	16694-16695	2	_	
101-84	16695-16696	)	_	
101-85	16696-16697	,	_	
101-86	16698-16703	which	_	
101-87	16704-16706	is	_	
101-88	16707-16717	consistent	_	
101-89	16718-16722	with	_	
101-90	16723-16726	the	_	
101-91	16727-16735	previous	_	
101-92	16736-16741	study	_	
101-93	16741-16742	.	_	

#Text=Spatial distributions of the RSFCs of the four seed regions within the HC group and the ATSA group.
102-1	16744-16751	Spatial	_	
102-2	16752-16765	distributions	_	
102-3	16766-16768	of	_	
102-4	16769-16772	the	_	
102-5	16773-16778	RSFCs	_	
102-6	16779-16781	of	_	
102-7	16782-16785	the	_	
102-8	16786-16790	four	_	
102-9	16791-16795	seed	_	
102-10	16796-16803	regions	_	
102-11	16804-16810	within	_	
102-12	16811-16814	the	_	
102-13	16815-16817	HC	_	
102-14	16818-16823	group	_	
102-15	16824-16827	and	_	
102-16	16828-16831	the	_	
102-17	16832-16836	ATSA	_	
102-18	16837-16842	group	_	
102-19	16842-16843	.	_	

#Text=The spatial distribution of RSFCs was projected onto a surface brain using BrainNet Viewer (https://www.nitrc.org/projects/bnv/)
#Text=Then, we separately used each subdivision of the NAc as a seed region to reveal the specific networks that were influenced by amphetamine-type stimulant abuse.
103-1	16844-16847	The	_	
103-2	16848-16855	spatial	_	
103-3	16856-16868	distribution	_	
103-4	16869-16871	of	_	
103-5	16872-16877	RSFCs	_	
103-6	16878-16881	was	_	
103-7	16882-16891	projected	_	
103-8	16892-16896	onto	_	
103-9	16897-16898	a	_	
103-10	16899-16906	surface	_	
103-11	16907-16912	brain	_	
103-12	16913-16918	using	_	
103-13	16919-16927	BrainNet	_	
103-14	16928-16934	Viewer	_	
103-15	16935-16936	(	_	
103-16	16936-16941	https	_	
103-17	16941-16942	:	_	
103-18	16942-16943	/	_	
103-19	16943-16944	/	_	
103-20	16944-16957	www.nitrc.org	_	
103-21	16957-16958	/	_	
103-22	16958-16966	projects	_	
103-23	16966-16967	/	_	
103-24	16967-16970	bnv	_	
103-25	16970-16971	/	_	
103-26	16971-16972	)	_	
103-27	16973-16977	Then	_	
103-28	16977-16978	,	_	
103-29	16979-16981	we	_	
103-30	16982-16992	separately	_	
103-31	16993-16997	used	_	
103-32	16998-17002	each	_	
103-33	17003-17014	subdivision	_	
103-34	17015-17017	of	_	
103-35	17018-17021	the	_	
103-36	17022-17025	NAc	_	
103-37	17026-17028	as	_	
103-38	17029-17030	a	_	
103-39	17031-17035	seed	_	
103-40	17036-17042	region	_	
103-41	17043-17045	to	_	
103-42	17046-17052	reveal	_	
103-43	17053-17056	the	_	
103-44	17057-17065	specific	_	
103-45	17066-17074	networks	_	
103-46	17075-17079	that	_	
103-47	17080-17084	were	_	
103-48	17085-17095	influenced	_	
103-49	17096-17098	by	_	
103-50	17099-17115	amphetamine-type	_	
103-51	17116-17125	stimulant	_	
103-52	17126-17131	abuse	_	
103-53	17131-17132	.	_	

#Text=In general, the spatial distribution of the RSFC of each seed region in the HC group was larger than that of the ATSA group (Fig. 3).
104-1	17133-17135	In	_	
104-2	17136-17143	general	_	
104-3	17143-17144	,	_	
104-4	17145-17148	the	_	
104-5	17149-17156	spatial	_	
104-6	17157-17169	distribution	_	
104-7	17170-17172	of	_	
104-8	17173-17176	the	_	
104-9	17177-17181	RSFC	_	
104-10	17182-17184	of	_	
104-11	17185-17189	each	_	
104-12	17190-17194	seed	_	
104-13	17195-17201	region	_	
104-14	17202-17204	in	_	
104-15	17205-17208	the	_	
104-16	17209-17211	HC	_	
104-17	17212-17217	group	_	
104-18	17218-17221	was	_	
104-19	17222-17228	larger	_	
104-20	17229-17233	than	_	
104-21	17234-17238	that	_	
104-22	17239-17241	of	_	
104-23	17242-17245	the	_	
104-24	17246-17250	ATSA	_	
104-25	17251-17256	group	_	
104-26	17257-17258	(	_	
104-27	17258-17261	Fig	_	
104-28	17261-17262	.	_	
104-29	17262-17263	 	_	
104-30	17263-17264	3	_	
104-31	17264-17265	)	_	
104-32	17265-17266	.	_	

#Text=The brain areas that held positive RSFCs with the four NAc subdivisions were concentrated mainly in the insular, frontal gyrus, anterior cingulate cortex, orbitofrontal cortex, hippocampus, and parahippocampal gyrus in both the HC and ATSA group (cluster-level FWE p < 0.05).
105-1	17267-17270	The	_	
105-2	17271-17276	brain	_	
105-3	17277-17282	areas	_	
105-4	17283-17287	that	_	
105-5	17288-17292	held	_	
105-6	17293-17301	positive	_	
105-7	17302-17307	RSFCs	_	
105-8	17308-17312	with	_	
105-9	17313-17316	the	_	
105-10	17317-17321	four	_	
105-11	17322-17325	NAc	_	
105-12	17326-17338	subdivisions	_	
105-13	17339-17343	were	_	
105-14	17344-17356	concentrated	_	
105-15	17357-17363	mainly	_	
105-16	17364-17366	in	_	
105-17	17367-17370	the	_	
105-18	17371-17378	insular	_	
105-19	17378-17379	,	_	
105-20	17380-17387	frontal	_	
105-21	17388-17393	gyrus	_	
105-22	17393-17394	,	_	
105-23	17395-17403	anterior	_	
105-24	17404-17413	cingulate	_	
105-25	17414-17420	cortex	_	
105-26	17420-17421	,	_	
105-27	17422-17435	orbitofrontal	_	
105-28	17436-17442	cortex	_	
105-29	17442-17443	,	_	
105-30	17444-17455	hippocampus	_	
105-31	17455-17456	,	_	
105-32	17457-17460	and	_	
105-33	17461-17476	parahippocampal	_	
105-34	17477-17482	gyrus	_	
105-35	17483-17485	in	_	
105-36	17486-17490	both	_	
105-37	17491-17494	the	_	
105-38	17495-17497	HC	_	
105-39	17498-17501	and	_	
105-40	17502-17506	ATSA	_	
105-41	17507-17512	group	_	
105-42	17513-17514	(	_	
105-43	17514-17527	cluster-level	_	
105-44	17528-17531	FWE	_	
105-45	17532-17533	p	_	
105-46	17534-17535	<	_	
105-47	17536-17540	0.05	_	
105-48	17540-17541	)	_	
105-49	17541-17542	.	_	

#Text=We also found negative RSFCs with all the NAc subdivisions in the precuneus, the superior parietal lobules and the inferior parietal lobules in the HC group (cluster-level FWE p < 0.05), while no significant negative RSFCs were found in the ATSA group.
106-1	17543-17545	We	_	
106-2	17546-17550	also	_	
106-3	17551-17556	found	_	
106-4	17557-17565	negative	_	
106-5	17566-17571	RSFCs	_	
106-6	17572-17576	with	_	
106-7	17577-17580	all	_	
106-8	17581-17584	the	_	
106-9	17585-17588	NAc	_	
106-10	17589-17601	subdivisions	_	
106-11	17602-17604	in	_	
106-12	17605-17608	the	_	
106-13	17609-17618	precuneus	_	
106-14	17618-17619	,	_	
106-15	17620-17623	the	_	
106-16	17624-17632	superior	_	
106-17	17633-17641	parietal	_	
106-18	17642-17649	lobules	_	
106-19	17650-17653	and	_	
106-20	17654-17657	the	_	
106-21	17658-17666	inferior	_	
106-22	17667-17675	parietal	_	
106-23	17676-17683	lobules	_	
106-24	17684-17686	in	_	
106-25	17687-17690	the	_	
106-26	17691-17693	HC	_	
106-27	17694-17699	group	_	
106-28	17700-17701	(	_	
106-29	17701-17714	cluster-level	_	
106-30	17715-17718	FWE	_	
106-31	17719-17720	p	_	
106-32	17721-17722	<	_	
106-33	17723-17727	0.05	_	
106-34	17727-17728	)	_	
106-35	17728-17729	,	_	
106-36	17730-17735	while	_	
106-37	17736-17738	no	_	
106-38	17739-17750	significant	_	
106-39	17751-17759	negative	_	
106-40	17760-17765	RSFCs	_	
106-41	17766-17770	were	_	
106-42	17771-17776	found	_	
106-43	17777-17779	in	_	
106-44	17780-17783	the	_	
106-45	17784-17788	ATSA	_	
106-46	17789-17794	group	_	
106-47	17794-17795	.	_	

#Text=The connectivity pattern of each NAc subdivision in the HC group is similar to that in Xia’s study by visual observations.
107-1	17796-17799	The	_	
107-2	17800-17812	connectivity	_	
107-3	17813-17820	pattern	_	
107-4	17821-17823	of	_	
107-5	17824-17828	each	_	
107-6	17829-17832	NAc	_	
107-7	17833-17844	subdivision	_	
107-8	17845-17847	in	_	
107-9	17848-17851	the	_	
107-10	17852-17854	HC	_	
107-11	17855-17860	group	_	
107-12	17861-17863	is	_	
107-13	17864-17871	similar	_	
107-14	17872-17874	to	_	
107-15	17875-17879	that	_	
107-16	17880-17882	in	_	
107-17	17883-17886	Xia	_	
107-18	17886-17887	’	_	
107-19	17887-17888	s	_	
107-20	17889-17894	study	_	
107-21	17895-17897	by	_	
107-22	17898-17904	visual	_	
107-23	17905-17917	observations	_	
107-24	17917-17918	.	_	

#Text=Group differences in functional connectivity between the ATSA group and the HC group
#Text=Seed region\tBrain region\tHemisphere\tBA\tMNI coordinates\tPeak T values\tCluster size\tCluster FWEp value\t \tHC > ATSA\t \t lNAc core\tOrbital part of superior frontal gyrus/orbital gyrus\tLeft\t11/47\t− 10 38 – 24\t5.27\t156\t0.001\t \t lNAc shell\tOrbital part of superior frontal gyrus/orbital gyrus\tLeft\t11/47\t− 8 44 – 20\t5.04\t127\t0.005\t \t rNAc core\tOrbital part of superior frontal gyrus/orbital gyrus\tLeft\t11/47\t− 10 44 – 22\t5.27\t145\t0.002\t \t rNAc shell\tOrbital part of superior frontal gyrus/orbital gyrus\tLeft\t11/47\t− 8 44 – 20\t5.21\t122\t0.007\t \tHC < ATSA\t \t lNAc core\tOpercular part of inferior frontal gyrus\tLeft\t44\t− 50 10 – 18\t4.86\t106\t0.014*\t \t lNAc shell\tOpercular part of inferior frontal gyrus\tLeft\t44\t− 42 8 – 20\t4.76\t100\t0.020*\t \t rNAc core\tOpercular part of inferior frontal gyrus\tLeft\t44\t− 46 4 – 18\t4.72\t91\t0.032*\t \t rNAc shell\tOpercular part of inferior frontal gyrus\tLeft\t44\t− 42 12 – 16\t4.84\t97\t0.023*\t \t
#Text=* These results can’t be corrected at the threshold of FWE p < 0.0125
#Text=Regions showing significant changes in RSFCs with the seed regions in the ATSA group compared with the HC group and group comparisons of the connectivity strength in these two groups.
108-1	17920-17925	Group	_	
108-2	17926-17937	differences	_	
108-3	17938-17940	in	_	
108-4	17941-17951	functional	_	
108-5	17952-17964	connectivity	_	
108-6	17965-17972	between	_	
108-7	17973-17976	the	_	
108-8	17977-17981	ATSA	_	
108-9	17982-17987	group	_	
108-10	17988-17991	and	_	
108-11	17992-17995	the	_	
108-12	17996-17998	HC	_	
108-13	17999-18004	group	_	
108-14	18005-18009	Seed	_	
108-15	18010-18016	region	_	
108-16	18017-18022	Brain	_	
108-17	18023-18029	region	_	
108-18	18030-18040	Hemisphere	_	
108-19	18041-18043	BA	_	
108-20	18044-18047	MNI	_	
108-21	18048-18059	coordinates	_	
108-22	18060-18064	Peak	_	
108-23	18065-18066	T	_	
108-24	18067-18073	values	_	
108-25	18074-18081	Cluster	_	
108-26	18082-18086	size	_	
108-27	18087-18094	Cluster	_	
108-28	18095-18099	FWEp	_	
108-29	18100-18105	value	_	
108-30	18108-18110	HC	_	
108-31	18111-18112	>	_	
108-32	18113-18117	ATSA	_	
108-33	18120-18121	 	_	
108-34	18121-18125	lNAc	_	
108-35	18126-18130	core	_	
108-36	18131-18138	Orbital	_	
108-37	18139-18143	part	_	
108-38	18144-18146	of	_	
108-39	18147-18155	superior	_	
108-40	18156-18163	frontal	_	
108-41	18164-18169	gyrus	_	
108-42	18169-18170	/	_	
108-43	18170-18177	orbital	_	
108-44	18178-18183	gyrus	_	
108-45	18184-18188	Left	_	
108-46	18189-18191	11	_	
108-47	18191-18192	/	_	
108-48	18192-18194	47	_	
108-49	18195-18196	−	_	
108-50	18197-18199	10	_	
108-51	18200-18202	38	_	
108-52	18203-18204	–	_	
108-53	18205-18207	24	_	
108-54	18208-18212	5.27	_	
108-55	18213-18216	156	_	
108-56	18217-18222	0.001	_	
108-57	18225-18226	 	_	
108-58	18226-18230	lNAc	_	
108-59	18231-18236	shell	_	
108-60	18237-18244	Orbital	_	
108-61	18245-18249	part	_	
108-62	18250-18252	of	_	
108-63	18253-18261	superior	_	
108-64	18262-18269	frontal	_	
108-65	18270-18275	gyrus	_	
108-66	18275-18276	/	_	
108-67	18276-18283	orbital	_	
108-68	18284-18289	gyrus	_	
108-69	18290-18294	Left	_	
108-70	18295-18297	11	_	
108-71	18297-18298	/	_	
108-72	18298-18300	47	_	
108-73	18301-18302	−	_	
108-74	18303-18304	8	_	
108-75	18305-18307	44	_	
108-76	18308-18309	–	_	
108-77	18309-18310	 	_	
108-78	18310-18312	20	_	
108-79	18313-18317	5.04	_	
108-80	18318-18321	127	_	
108-81	18322-18327	0.005	_	
108-82	18330-18331	 	_	
108-83	18331-18335	rNAc	_	
108-84	18336-18340	core	_	
108-85	18341-18348	Orbital	_	
108-86	18349-18353	part	_	
108-87	18354-18356	of	_	
108-88	18357-18365	superior	_	
108-89	18366-18373	frontal	_	
108-90	18374-18379	gyrus	_	
108-91	18379-18380	/	_	
108-92	18380-18387	orbital	_	
108-93	18388-18393	gyrus	_	
108-94	18394-18398	Left	_	
108-95	18399-18401	11	_	
108-96	18401-18402	/	_	
108-97	18402-18404	47	_	
108-98	18405-18406	−	_	
108-99	18407-18409	10	_	
108-100	18410-18412	44	_	
108-101	18413-18414	–	_	
108-102	18414-18415	 	_	
108-103	18415-18417	22	_	
108-104	18418-18422	5.27	_	
108-105	18423-18426	145	_	
108-106	18427-18432	0.002	_	
108-107	18435-18436	 	_	
108-108	18436-18440	rNAc	_	
108-109	18441-18446	shell	_	
108-110	18447-18454	Orbital	_	
108-111	18455-18459	part	_	
108-112	18460-18462	of	_	
108-113	18463-18471	superior	_	
108-114	18472-18479	frontal	_	
108-115	18480-18485	gyrus	_	
108-116	18485-18486	/	_	
108-117	18486-18493	orbital	_	
108-118	18494-18499	gyrus	_	
108-119	18500-18504	Left	_	
108-120	18505-18507	11	_	
108-121	18507-18508	/	_	
108-122	18508-18510	47	_	
108-123	18511-18512	−	_	
108-124	18513-18514	8	_	
108-125	18515-18517	44	_	
108-126	18518-18519	–	_	
108-127	18519-18520	 	_	
108-128	18520-18522	20	_	
108-129	18523-18527	5.21	_	
108-130	18528-18531	122	_	
108-131	18532-18537	0.007	_	
108-132	18540-18542	HC	_	
108-133	18543-18544	<	_	
108-134	18545-18549	ATSA	_	
108-135	18552-18553	 	_	
108-136	18553-18557	lNAc	_	
108-137	18558-18562	core	_	
108-138	18563-18572	Opercular	_	
108-139	18573-18577	part	_	
108-140	18578-18580	of	_	
108-141	18581-18589	inferior	_	
108-142	18590-18597	frontal	_	
108-143	18598-18603	gyrus	_	
108-144	18604-18608	Left	_	
108-145	18609-18611	44	_	
108-146	18612-18613	−	_	
108-147	18614-18616	50	_	
108-148	18617-18619	10	_	
108-149	18620-18621	–	_	
108-150	18621-18622	 	_	
108-151	18622-18624	18	_	
108-152	18625-18629	4.86	_	
108-153	18630-18633	106	_	
108-154	18634-18639	0.014	_	
108-155	18639-18640	*	_	
108-156	18643-18644	 	_	
108-157	18644-18648	lNAc	_	
108-158	18649-18654	shell	_	
108-159	18655-18664	Opercular	_	
108-160	18665-18669	part	_	
108-161	18670-18672	of	_	
108-162	18673-18681	inferior	_	
108-163	18682-18689	frontal	_	
108-164	18690-18695	gyrus	_	
108-165	18696-18700	Left	_	
108-166	18701-18703	44	_	
108-167	18704-18705	−	_	
108-168	18706-18708	42	_	
108-169	18709-18710	8	_	
108-170	18711-18712	–	_	
108-171	18712-18713	 	_	
108-172	18713-18715	20	_	
108-173	18716-18720	4.76	_	
108-174	18721-18724	100	_	
108-175	18725-18730	0.020	_	
108-176	18730-18731	*	_	
108-177	18734-18735	 	_	
108-178	18735-18739	rNAc	_	
108-179	18740-18744	core	_	
108-180	18745-18754	Opercular	_	
108-181	18755-18759	part	_	
108-182	18760-18762	of	_	
108-183	18763-18771	inferior	_	
108-184	18772-18779	frontal	_	
108-185	18780-18785	gyrus	_	
108-186	18786-18790	Left	_	
108-187	18791-18793	44	_	
108-188	18794-18795	−	_	
108-189	18796-18798	46	_	
108-190	18799-18800	4	_	
108-191	18801-18802	–	_	
108-192	18802-18803	 	_	
108-193	18803-18805	18	_	
108-194	18806-18810	4.72	_	
108-195	18811-18813	91	_	
108-196	18814-18819	0.032	_	
108-197	18819-18820	*	_	
108-198	18823-18824	 	_	
108-199	18824-18828	rNAc	_	
108-200	18829-18834	shell	_	
108-201	18835-18844	Opercular	_	
108-202	18845-18849	part	_	
108-203	18850-18852	of	_	
108-204	18853-18861	inferior	_	
108-205	18862-18869	frontal	_	
108-206	18870-18875	gyrus	_	
108-207	18876-18880	Left	_	
108-208	18881-18883	44	_	
108-209	18884-18885	−	_	
108-210	18886-18888	42	_	
108-211	18889-18891	12	_	
108-212	18892-18893	–	_	
108-213	18893-18894	 	_	
108-214	18894-18896	16	_	
108-215	18897-18901	4.84	_	
108-216	18902-18904	97	_	
108-217	18905-18910	0.023	_	
108-218	18910-18911	*	_	
108-219	18915-18916	*	_	
108-220	18916-18917	 	_	
108-221	18917-18922	These	_	
108-222	18923-18930	results	_	
108-223	18931-18934	can	_	
108-224	18934-18935	’	_	
108-225	18935-18936	t	_	
108-226	18937-18939	be	_	
108-227	18940-18949	corrected	_	
108-228	18950-18952	at	_	
108-229	18953-18956	the	_	
108-230	18957-18966	threshold	_	
108-231	18967-18969	of	_	
108-232	18970-18973	FWE	_	
108-233	18974-18975	p	_	
108-234	18976-18977	<	_	
108-235	18978-18984	0.0125	_	
108-236	18985-18992	Regions	_	
108-237	18993-19000	showing	_	
108-238	19001-19012	significant	_	
108-239	19013-19020	changes	_	
108-240	19021-19023	in	_	
108-241	19024-19029	RSFCs	_	
108-242	19030-19034	with	_	
108-243	19035-19038	the	_	
108-244	19039-19043	seed	_	
108-245	19044-19051	regions	_	
108-246	19052-19054	in	_	
108-247	19055-19058	the	_	
108-248	19059-19063	ATSA	_	
108-249	19064-19069	group	_	
108-250	19070-19078	compared	_	
108-251	19079-19083	with	_	
108-252	19084-19087	the	_	
108-253	19088-19090	HC	_	
108-254	19091-19096	group	_	
108-255	19097-19100	and	_	
108-256	19101-19106	group	_	
108-257	19107-19118	comparisons	_	
108-258	19119-19121	of	_	
108-259	19122-19125	the	_	
108-260	19126-19138	connectivity	_	
108-261	19139-19147	strength	_	
108-262	19148-19150	in	_	
108-263	19151-19156	these	_	
108-264	19157-19160	two	_	
108-265	19161-19167	groups	_	
108-266	19167-19168	.	_	

#Text=The images were created using BrainNet Viewer (https://www.nitrc.org/projects/bnv/).
109-1	19169-19172	The	_	
109-2	19173-19179	images	_	
109-3	19180-19184	were	_	
109-4	19185-19192	created	_	
109-5	19193-19198	using	_	
109-6	19199-19207	BrainNet	_	
109-7	19208-19214	Viewer	_	
109-8	19215-19216	(	_	
109-9	19216-19221	https	_	
109-10	19221-19222	:	_	
109-11	19222-19223	/	_	
109-12	19223-19224	/	_	
109-13	19224-19237	www.nitrc.org	_	
109-14	19237-19238	/	_	
109-15	19238-19246	projects	_	
109-16	19246-19247	/	_	
109-17	19247-19250	bnv	_	
109-18	19250-19251	/	_	
109-19	19251-19252	)	_	
109-20	19252-19253	.	_	

#Text=Error bars indicate standard errors of the mean
#Text=By comparing the RSFC patterns between the two groups, functional connectivity for all the NAc subdivisions showed significant group differences (Table 2, Fig. 4).
110-1	19254-19259	Error	_	
110-2	19260-19264	bars	_	
110-3	19265-19273	indicate	_	
110-4	19274-19282	standard	_	
110-5	19283-19289	errors	_	
110-6	19290-19292	of	_	
110-7	19293-19296	the	_	
110-8	19297-19301	mean	_	
110-9	19302-19304	By	_	
110-10	19305-19314	comparing	_	
110-11	19315-19318	the	_	
110-12	19319-19323	RSFC	_	
110-13	19324-19332	patterns	_	
110-14	19333-19340	between	_	
110-15	19341-19344	the	_	
110-16	19345-19348	two	_	
110-17	19349-19355	groups	_	
110-18	19355-19356	,	_	
110-19	19357-19367	functional	_	
110-20	19368-19380	connectivity	_	
110-21	19381-19384	for	_	
110-22	19385-19388	all	_	
110-23	19389-19392	the	_	
110-24	19393-19396	NAc	_	
110-25	19397-19409	subdivisions	_	
110-26	19410-19416	showed	_	
110-27	19417-19428	significant	_	
110-28	19429-19434	group	_	
110-29	19435-19446	differences	_	
110-30	19447-19448	(	_	
110-31	19448-19453	Table	_	
110-32	19454-19455	2	_	
110-33	19455-19456	,	_	
110-34	19457-19460	Fig	_	
110-35	19460-19461	.	_	
110-36	19461-19462	 	_	
110-37	19462-19463	4	_	
110-38	19463-19464	)	_	
110-39	19464-19465	.	_	

#Text=Specifically, in the ATSA group, all the four NAc subdivisions showed a decreased positive RSFC with the left orbital part of superior frontal gyrus (OFC) compared with the HC group (cluster-level FWE p < 0.0125).
111-1	19466-19478	Specifically	_	
111-2	19478-19479	,	_	
111-3	19480-19482	in	_	
111-4	19483-19486	the	_	
111-5	19487-19491	ATSA	_	
111-6	19492-19497	group	_	
111-7	19497-19498	,	_	
111-8	19499-19502	all	_	
111-9	19503-19506	the	_	
111-10	19507-19511	four	_	
111-11	19512-19515	NAc	_	
111-12	19516-19528	subdivisions	_	
111-13	19529-19535	showed	_	
111-14	19536-19537	a	_	
111-15	19538-19547	decreased	_	
111-16	19548-19556	positive	_	
111-17	19557-19561	RSFC	_	
111-18	19562-19566	with	_	
111-19	19567-19570	the	_	
111-20	19571-19575	left	_	
111-21	19576-19583	orbital	_	
111-22	19584-19588	part	_	
111-23	19589-19591	of	_	
111-24	19592-19600	superior	_	
111-25	19601-19608	frontal	_	
111-26	19609-19614	gyrus	_	
111-27	19615-19616	(	_	
111-28	19616-19619	OFC	_	
111-29	19619-19620	)	_	
111-30	19621-19629	compared	_	
111-31	19630-19634	with	_	
111-32	19635-19638	the	_	
111-33	19639-19641	HC	_	
111-34	19642-19647	group	_	
111-35	19648-19649	(	_	
111-36	19649-19662	cluster-level	_	
111-37	19663-19666	FWE	_	
111-38	19667-19668	p	_	
111-39	19669-19670	<	_	
111-40	19671-19677	0.0125	_	
111-41	19677-19678	)	_	
111-42	19678-19679	.	_	

#Text=In addition, we found that the RSFCs between all the NAc subdivisions and the left opercular part of inferior frontal gyrus (IFGoperc) were increased in the ATSA group (cluster-level FWE p < 0.05 but p > 0.0125).
112-1	19680-19682	In	_	
112-2	19683-19691	addition	_	
112-3	19691-19692	,	_	
112-4	19693-19695	we	_	
112-5	19696-19701	found	_	
112-6	19702-19706	that	_	
112-7	19707-19710	the	_	
112-8	19711-19716	RSFCs	_	
112-9	19717-19724	between	_	
112-10	19725-19728	all	_	
112-11	19729-19732	the	_	
112-12	19733-19736	NAc	_	
112-13	19737-19749	subdivisions	_	
112-14	19750-19753	and	_	
112-15	19754-19757	the	_	
112-16	19758-19762	left	_	
112-17	19763-19772	opercular	_	
112-18	19773-19777	part	_	
112-19	19778-19780	of	_	
112-20	19781-19789	inferior	_	
112-21	19790-19797	frontal	_	
112-22	19798-19803	gyrus	_	
112-23	19804-19805	(	_	
112-24	19805-19813	IFGoperc	_	
112-25	19813-19814	)	_	
112-26	19815-19819	were	_	
112-27	19820-19829	increased	_	
112-28	19830-19832	in	_	
112-29	19833-19836	the	_	
112-30	19837-19841	ATSA	_	
112-31	19842-19847	group	_	
112-32	19848-19849	(	_	
112-33	19849-19862	cluster-level	_	
112-34	19863-19866	FWE	_	
112-35	19867-19868	p	_	
112-36	19869-19870	<	_	
112-37	19871-19875	0.05	_	
112-38	19876-19879	but	_	
112-39	19880-19881	p	_	
112-40	19882-19883	>	_	
112-41	19884-19890	0.0125	_	
112-42	19890-19891	)	_	
112-43	19891-19892	.	_	

#Text=We didn’t find any regionally-dependent changes in the RSFC of the NAc subdivisions.
113-1	19893-19895	We	_	
113-2	19896-19900	didn	_	
113-3	19900-19901	’	_	
113-4	19901-19902	t	_	
113-5	19903-19907	find	_	
113-6	19908-19911	any	_	
113-7	19912-19932	regionally-dependent	_	
113-8	19933-19940	changes	_	
113-9	19941-19943	in	_	
113-10	19944-19947	the	_	
113-11	19948-19952	RSFC	_	
113-12	19953-19955	of	_	
113-13	19956-19959	the	_	
113-14	19960-19963	NAc	_	
113-15	19964-19976	subdivisions	_	
113-16	19976-19977	.	_	

#Text=In addition, we also used masks to restrict our analyses of group comparisons in the voxels in which connections of the seed region were significant within the HC group or within the ATSA group.
114-1	19978-19980	In	_	
114-2	19981-19989	addition	_	
114-3	19989-19990	,	_	
114-4	19991-19993	we	_	
114-5	19994-19998	also	_	
114-6	19999-20003	used	_	
114-7	20004-20009	masks	_	
114-8	20010-20012	to	_	
114-9	20013-20021	restrict	_	
114-10	20022-20025	our	_	
114-11	20026-20034	analyses	_	
114-12	20035-20037	of	_	
114-13	20038-20043	group	_	
114-14	20044-20055	comparisons	_	
114-15	20056-20058	in	_	
114-16	20059-20062	the	_	
114-17	20063-20069	voxels	_	
114-18	20070-20072	in	_	
114-19	20073-20078	which	_	
114-20	20079-20090	connections	_	
114-21	20091-20093	of	_	
114-22	20094-20097	the	_	
114-23	20098-20102	seed	_	
114-24	20103-20109	region	_	
114-25	20110-20114	were	_	
114-26	20115-20126	significant	_	
114-27	20127-20133	within	_	
114-28	20134-20137	the	_	
114-29	20138-20140	HC	_	
114-30	20141-20146	group	_	
114-31	20147-20149	or	_	
114-32	20150-20156	within	_	
114-33	20157-20160	the	_	
114-34	20161-20165	ATSA	_	
114-35	20166-20171	group	_	
114-36	20171-20172	.	_	

#Text=We found that the results were the same except for the RSFCs between the right NAc subdivisions and the left IFGoperc.
115-1	20173-20175	We	_	
115-2	20176-20181	found	_	
115-3	20182-20186	that	_	
115-4	20187-20190	the	_	
115-5	20191-20198	results	_	
115-6	20199-20203	were	_	
115-7	20204-20207	the	_	
115-8	20208-20212	same	_	
115-9	20213-20219	except	_	
115-10	20220-20223	for	_	
115-11	20224-20227	the	_	
115-12	20228-20233	RSFCs	_	
115-13	20234-20241	between	_	
115-14	20242-20245	the	_	
115-15	20246-20251	right	_	
115-16	20252-20255	NAc	_	
115-17	20256-20268	subdivisions	_	
115-18	20269-20272	and	_	
115-19	20273-20276	the	_	
115-20	20277-20281	left	_	
115-21	20282-20290	IFGoperc	_	
115-22	20290-20291	.	_	

#Text=That is, the increased RSFCs between the right NAc subdivisions and the left IFGoperc disappeared when applying the abovementioned mask.
116-1	20292-20296	That	_	
116-2	20297-20299	is	_	
116-3	20299-20300	,	_	
116-4	20301-20304	the	_	
116-5	20305-20314	increased	_	
116-6	20315-20320	RSFCs	_	
116-7	20321-20328	between	_	
116-8	20329-20332	the	_	
116-9	20333-20338	right	_	
116-10	20339-20342	NAc	_	
116-11	20343-20355	subdivisions	_	
116-12	20356-20359	and	_	
116-13	20360-20363	the	_	
116-14	20364-20368	left	_	
116-15	20369-20377	IFGoperc	_	
116-16	20378-20389	disappeared	_	
116-17	20390-20394	when	_	
116-18	20395-20403	applying	_	
116-19	20404-20407	the	_	
116-20	20408-20422	abovementioned	_	
116-21	20423-20427	mask	_	
116-22	20427-20428	.	_	

#Text=Correlations between addiction severity (measured by ASID) and the disrupted RSFCs of NAc subdivisions with the left OFC in the ATSA group
#Text=We further calculated the links between addiction severity (measured by ASID) and the strength of the abovementioned abnormal connectivity in the ATSA group.
117-1	20431-20443	Correlations	_	
117-2	20444-20451	between	_	
117-3	20452-20461	addiction	_	
117-4	20462-20470	severity	_	
117-5	20471-20472	(	_	
117-6	20472-20480	measured	_	
117-7	20481-20483	by	_	
117-8	20484-20488	ASID	_	
117-9	20488-20489	)	_	
117-10	20490-20493	and	_	
117-11	20494-20497	the	_	
117-12	20498-20507	disrupted	_	
117-13	20508-20513	RSFCs	_	
117-14	20514-20516	of	_	
117-15	20517-20520	NAc	_	
117-16	20521-20533	subdivisions	_	
117-17	20534-20538	with	_	
117-18	20539-20542	the	_	
117-19	20543-20547	left	_	
117-20	20548-20551	OFC	_	
117-21	20552-20554	in	_	
117-22	20555-20558	the	_	
117-23	20559-20563	ATSA	_	
117-24	20564-20569	group	_	
117-25	20570-20572	We	_	
117-26	20573-20580	further	_	
117-27	20581-20591	calculated	_	
117-28	20592-20595	the	_	
117-29	20596-20601	links	_	
117-30	20602-20609	between	_	
117-31	20610-20619	addiction	_	
117-32	20620-20628	severity	_	
117-33	20629-20630	(	_	
117-34	20630-20638	measured	_	
117-35	20639-20641	by	_	
117-36	20642-20646	ASID	_	
117-37	20646-20647	)	_	
117-38	20648-20651	and	_	
117-39	20652-20655	the	_	
117-40	20656-20664	strength	_	
117-41	20665-20667	of	_	
117-42	20668-20671	the	_	
117-43	20672-20686	abovementioned	_	
117-44	20687-20695	abnormal	_	
117-45	20696-20708	connectivity	_	
117-46	20709-20711	in	_	
117-47	20712-20715	the	_	
117-48	20716-20720	ATSA	_	
117-49	20721-20726	group	_	
117-50	20726-20727	.	_	

#Text=Results showed that the RSFCs between all the NAc subdivisions and the left OFC were negatively correlated with the ASID score in ATSAs (Fig. 5).
118-1	20728-20735	Results	_	
118-2	20736-20742	showed	_	
118-3	20743-20747	that	_	
118-4	20748-20751	the	_	
118-5	20752-20757	RSFCs	_	
118-6	20758-20765	between	_	
118-7	20766-20769	all	_	
118-8	20770-20773	the	_	
118-9	20774-20777	NAc	_	
118-10	20778-20790	subdivisions	_	
118-11	20791-20794	and	_	
118-12	20795-20798	the	_	
118-13	20799-20803	left	_	
118-14	20804-20807	OFC	_	
118-15	20808-20812	were	_	
118-16	20813-20823	negatively	_	
118-17	20824-20834	correlated	_	
118-18	20835-20839	with	_	
118-19	20840-20843	the	_	
118-20	20844-20848	ASID	_	
118-21	20849-20854	score	_	
118-22	20855-20857	in	_	
118-23	20858-20863	ATSAs	_	
118-24	20864-20865	(	_	
118-25	20865-20868	Fig	_	
118-26	20868-20869	.	_	
118-27	20869-20870	 	_	
118-28	20870-20871	5	_	
118-29	20871-20872	)	_	
118-30	20872-20873	.	_	

#Text=The correlation coefficients were significant for the NAc core-like subdivisions (left: r = − 0.50, p = 0.048; right: r = − 0.54, p = 0.031) and marginally significant for the NAc shell-like subdivisions (left: r = − 0.44, p = 0.089; right: r = − 0.46, p = 0.075).
119-1	20874-20877	The	_	
119-2	20878-20889	correlation	_	
119-3	20890-20902	coefficients	_	
119-4	20903-20907	were	_	
119-5	20908-20919	significant	_	
119-6	20920-20923	for	_	
119-7	20924-20927	the	_	
119-8	20928-20931	NAc	_	
119-9	20932-20941	core-like	_	
119-10	20942-20954	subdivisions	_	
119-11	20955-20956	(	_	
119-12	20956-20960	left	_	
119-13	20960-20961	:	_	
119-14	20962-20963	r	_	
119-15	20964-20965	=	_	
119-16	20966-20967	−	_	
119-17	20968-20972	0.50	_	
119-18	20972-20973	,	_	
119-19	20974-20975	p	_	
119-20	20976-20977	=	_	
119-21	20978-20983	0.048	_	
119-22	20983-20984	;	_	
119-23	20985-20990	right	_	
119-24	20990-20991	:	_	
119-25	20992-20993	r	_	
119-26	20994-20995	=	_	
119-27	20996-20997	−	_	
119-28	20998-21002	0.54	_	
119-29	21002-21003	,	_	
119-30	21004-21005	p	_	
119-31	21006-21007	=	_	
119-32	21008-21013	0.031	_	
119-33	21013-21014	)	_	
119-34	21015-21018	and	_	
119-35	21019-21029	marginally	_	
119-36	21030-21041	significant	_	
119-37	21042-21045	for	_	
119-38	21046-21049	the	_	
119-39	21050-21053	NAc	_	
119-40	21054-21064	shell-like	_	
119-41	21065-21077	subdivisions	_	
119-42	21078-21079	(	_	
119-43	21079-21083	left	_	
119-44	21083-21084	:	_	
119-45	21085-21086	r	_	
119-46	21087-21088	=	_	
119-47	21089-21090	−	_	
119-48	21091-21095	0.44	_	
119-49	21095-21096	,	_	
119-50	21097-21098	p	_	
119-51	21099-21100	=	_	
119-52	21101-21106	0.089	_	
119-53	21106-21107	;	_	
119-54	21108-21113	right	_	
119-55	21113-21114	:	_	
119-56	21115-21116	r	_	
119-57	21117-21118	=	_	
119-58	21119-21120	−	_	
119-59	21121-21125	0.46	_	
119-60	21125-21126	,	_	
119-61	21127-21128	p	_	
119-62	21129-21130	=	_	
119-63	21131-21136	0.075	_	
119-64	21136-21137	)	_	
119-65	21137-21138	.	_	

#Text=Given the commonalities of the NAc subdivisions in group-comparison results, we speculated whether the observed differences are due to general connectivity differences, not attributable to any specific subdivisions of the NAc.
120-1	21140-21145	Given	_	
120-2	21146-21149	the	_	
120-3	21150-21163	commonalities	_	
120-4	21164-21166	of	_	
120-5	21167-21170	the	_	
120-6	21171-21174	NAc	_	
120-7	21175-21187	subdivisions	_	
120-8	21188-21190	in	_	
120-9	21191-21207	group-comparison	_	
120-10	21208-21215	results	_	
120-11	21215-21216	,	_	
120-12	21217-21219	we	_	
120-13	21220-21230	speculated	_	
120-14	21231-21238	whether	_	
120-15	21239-21242	the	_	
120-16	21243-21251	observed	_	
120-17	21252-21263	differences	_	
120-18	21264-21267	are	_	
120-19	21268-21271	due	_	
120-20	21272-21274	to	_	
120-21	21275-21282	general	_	
120-22	21283-21295	connectivity	_	
120-23	21296-21307	differences	_	
120-24	21307-21308	,	_	
120-25	21309-21312	not	_	
120-26	21313-21325	attributable	_	
120-27	21326-21328	to	_	
120-28	21329-21332	any	_	
120-29	21333-21341	specific	_	
120-30	21342-21354	subdivisions	_	
120-31	21355-21357	of	_	
120-32	21358-21361	the	_	
120-33	21362-21365	NAc	_	
120-34	21365-21366	.	_	

#Text=In order to test this possibility, we combined the NAc core-like and shell-like subdivisions in the same hemisphere as a seed region and conducted the RSFC analyses again.
121-1	21367-21369	In	_	
121-2	21370-21375	order	_	
121-3	21376-21378	to	_	
121-4	21379-21383	test	_	
121-5	21384-21388	this	_	
121-6	21389-21400	possibility	_	
121-7	21400-21401	,	_	
121-8	21402-21404	we	_	
121-9	21405-21413	combined	_	
121-10	21414-21417	the	_	
121-11	21418-21421	NAc	_	
121-12	21422-21431	core-like	_	
121-13	21432-21435	and	_	
121-14	21436-21446	shell-like	_	
121-15	21447-21459	subdivisions	_	
121-16	21460-21462	in	_	
121-17	21463-21466	the	_	
121-18	21467-21471	same	_	
121-19	21472-21482	hemisphere	_	
121-20	21483-21485	as	_	
121-21	21486-21487	a	_	
121-22	21488-21492	seed	_	
121-23	21493-21499	region	_	
121-24	21500-21503	and	_	
121-25	21504-21513	conducted	_	
121-26	21514-21517	the	_	
121-27	21518-21522	RSFC	_	
121-28	21523-21531	analyses	_	
121-29	21532-21537	again	_	
121-30	21537-21538	.	_	

#Text=Results showed that no regions showed significant group differences in the connectivity of the left NAc.
122-1	21539-21546	Results	_	
122-2	21547-21553	showed	_	
122-3	21554-21558	that	_	
122-4	21559-21561	no	_	
122-5	21562-21569	regions	_	
122-6	21570-21576	showed	_	
122-7	21577-21588	significant	_	
122-8	21589-21594	group	_	
122-9	21595-21606	differences	_	
122-10	21607-21609	in	_	
122-11	21610-21613	the	_	
122-12	21614-21626	connectivity	_	
122-13	21627-21629	of	_	
122-14	21630-21633	the	_	
122-15	21634-21638	left	_	
122-16	21639-21642	NAc	_	
122-17	21642-21643	.	_	

#Text=Only the left OFC (peak MNI coordinate: − 10, 46, − 24; cluster size: 89) showed significant group difference in the connectivity of the right NAc.
123-1	21644-21648	Only	_	
123-2	21649-21652	the	_	
123-3	21653-21657	left	_	
123-4	21658-21661	OFC	_	
123-5	21662-21663	(	_	
123-6	21663-21667	peak	_	
123-7	21668-21671	MNI	_	
123-8	21672-21682	coordinate	_	
123-9	21682-21683	:	_	
123-10	21684-21685	−	_	
123-11	21686-21688	10	_	
123-12	21688-21689	,	_	
123-13	21690-21692	46	_	
123-14	21692-21693	,	_	
123-15	21694-21695	−	_	
123-16	21696-21698	24	_	
123-17	21698-21699	;	_	
123-18	21700-21707	cluster	_	
123-19	21708-21712	size	_	
123-20	21712-21713	:	_	
123-21	21714-21716	89	_	
123-22	21716-21717	)	_	
123-23	21718-21724	showed	_	
123-24	21725-21736	significant	_	
123-25	21737-21742	group	_	
123-26	21743-21753	difference	_	
123-27	21754-21756	in	_	
123-28	21757-21760	the	_	
123-29	21761-21773	connectivity	_	
123-30	21774-21776	of	_	
123-31	21777-21780	the	_	
123-32	21781-21786	right	_	
123-33	21787-21790	NAc	_	
123-34	21790-21791	.	_	

#Text=Discussion
#Text=In the current study, we demonstrated that the RSFC of the NAc subdivisions was disrupted in ATSAs.
124-1	21792-21802	Discussion	_	
124-2	21803-21805	In	_	
124-3	21806-21809	the	_	
124-4	21810-21817	current	_	
124-5	21818-21823	study	_	
124-6	21823-21824	,	_	
124-7	21825-21827	we	_	
124-8	21828-21840	demonstrated	_	
124-9	21841-21845	that	_	
124-10	21846-21849	the	_	
124-11	21850-21854	RSFC	_	
124-12	21855-21857	of	_	
124-13	21858-21861	the	_	
124-14	21862-21865	NAc	_	
124-15	21866-21878	subdivisions	_	
124-16	21879-21882	was	_	
124-17	21883-21892	disrupted	_	
124-18	21893-21895	in	_	
124-19	21896-21901	ATSAs	_	
124-20	21901-21902	.	_	

#Text=Seed-based RSFC analyses revealed that the ATSA group showed altered RSFCs related to all the NAc subdivisions involved regions in the left OFC and the left IFGoperc.
125-1	21903-21913	Seed-based	_	
125-2	21914-21918	RSFC	_	
125-3	21919-21927	analyses	_	
125-4	21928-21936	revealed	_	
125-5	21937-21941	that	_	
125-6	21942-21945	the	_	
125-7	21946-21950	ATSA	_	
125-8	21951-21956	group	_	
125-9	21957-21963	showed	_	
125-10	21964-21971	altered	_	
125-11	21972-21977	RSFCs	_	
125-12	21978-21985	related	_	
125-13	21986-21988	to	_	
125-14	21989-21992	all	_	
125-15	21993-21996	the	_	
125-16	21997-22000	NAc	_	
125-17	22001-22013	subdivisions	_	
125-18	22014-22022	involved	_	
125-19	22023-22030	regions	_	
125-20	22031-22033	in	_	
125-21	22034-22037	the	_	
125-22	22038-22042	left	_	
125-23	22043-22046	OFC	_	
125-24	22047-22050	and	_	
125-25	22051-22054	the	_	
125-26	22055-22059	left	_	
125-27	22060-22068	IFGoperc	_	
125-28	22068-22069	.	_	

#Text=Besides, the RSFCs between the NAc subdivisions and the left OFC were negatively correlated with the addiction severity in ATSAs.
126-1	22070-22077	Besides	_	
126-2	22077-22078	,	_	
126-3	22079-22082	the	_	
126-4	22083-22088	RSFCs	_	
126-5	22089-22096	between	_	
126-6	22097-22100	the	_	
126-7	22101-22104	NAc	_	
126-8	22105-22117	subdivisions	_	
126-9	22118-22121	and	_	
126-10	22122-22125	the	_	
126-11	22126-22130	left	_	
126-12	22131-22134	OFC	_	
126-13	22135-22139	were	_	
126-14	22140-22150	negatively	_	
126-15	22151-22161	correlated	_	
126-16	22162-22166	with	_	
126-17	22167-22170	the	_	
126-18	22171-22180	addiction	_	
126-19	22181-22189	severity	_	
126-20	22190-22192	in	_	
126-21	22193-22198	ATSAs	_	
126-22	22198-22199	.	_	

#Text=NAc is a central brain region of reward processing.
127-1	22200-22203	NAc	_	
127-2	22204-22206	is	_	
127-3	22207-22208	a	_	
127-4	22209-22216	central	_	
127-5	22217-22222	brain	_	
127-6	22223-22229	region	_	
127-7	22230-22232	of	_	
127-8	22233-22239	reward	_	
127-9	22240-22250	processing	_	
127-10	22250-22251	.	_	

#Text=It is well-accepted that most addictive drugs exert their initial reinforcing effects by inducing large dopamine rapidly in the NAc.
128-1	22252-22254	It	_	
128-2	22255-22257	is	_	
128-3	22258-22271	well-accepted	_	
128-4	22272-22276	that	_	
128-5	22277-22281	most	_	
128-6	22282-22291	addictive	_	
128-7	22292-22297	drugs	_	
128-8	22298-22303	exert	_	
128-9	22304-22309	their	_	
128-10	22310-22317	initial	_	
128-11	22318-22329	reinforcing	_	
128-12	22330-22337	effects	_	
128-13	22338-22340	by	_	
128-14	22341-22349	inducing	_	
128-15	22350-22355	large	_	
128-16	22356-22364	dopamine	_	
128-17	22365-22372	rapidly	_	
128-18	22373-22375	in	_	
128-19	22376-22379	the	_	
128-20	22380-22383	NAc	_	
128-21	22383-22384	.	_	

#Text=This effect can render the drugs as highly salient, drive people’s strong motivations and stimulate compulsive drug-seeking behaviors.
129-1	22385-22389	This	_	
129-2	22390-22396	effect	_	
129-3	22397-22400	can	_	
129-4	22401-22407	render	_	
129-5	22408-22411	the	_	
129-6	22412-22417	drugs	_	
129-7	22418-22420	as	_	
129-8	22421-22427	highly	_	
129-9	22428-22435	salient	_	
129-10	22435-22436	,	_	
129-11	22437-22442	drive	_	
129-12	22443-22449	people	_	
129-13	22449-22450	’	_	
129-14	22450-22451	s	_	
129-15	22452-22458	strong	_	
129-16	22459-22470	motivations	_	
129-17	22471-22474	and	_	
129-18	22475-22484	stimulate	_	
129-19	22485-22495	compulsive	_	
129-20	22496-22508	drug-seeking	_	
129-21	22509-22518	behaviors	_	
129-22	22518-22519	.	_	

#Text=The OFC is a major brain region of cognitive impulse control.
130-1	22520-22523	The	_	
130-2	22524-22527	OFC	_	
130-3	22528-22530	is	_	
130-4	22531-22532	a	_	
130-5	22533-22538	major	_	
130-6	22539-22544	brain	_	
130-7	22545-22551	region	_	
130-8	22552-22554	of	_	
130-9	22555-22564	cognitive	_	
130-10	22565-22572	impulse	_	
130-11	22573-22580	control	_	
130-12	22580-22581	.	_	

#Text=Previous study found that subjects with OFC lesions are more impulsive overall compared both to normal controls and to those with non-OFC brain damage.
131-1	22582-22590	Previous	_	
131-2	22591-22596	study	_	
131-3	22597-22602	found	_	
131-4	22603-22607	that	_	
131-5	22608-22616	subjects	_	
131-6	22617-22621	with	_	
131-7	22622-22625	OFC	_	
131-8	22626-22633	lesions	_	
131-9	22634-22637	are	_	
131-10	22638-22642	more	_	
131-11	22643-22652	impulsive	_	
131-12	22653-22660	overall	_	
131-13	22661-22669	compared	_	
131-14	22670-22674	both	_	
131-15	22675-22677	to	_	
131-16	22678-22684	normal	_	
131-17	22685-22693	controls	_	
131-18	22694-22697	and	_	
131-19	22698-22700	to	_	
131-20	22701-22706	those	_	
131-21	22707-22711	with	_	
131-22	22712-22719	non-OFC	_	
131-23	22720-22725	brain	_	
131-24	22726-22732	damage	_	
131-25	22732-22733	.	_	

#Text=By using transcranial direct current stimulation applied over OFC, researchers found participants had improved ability to inhibit inappropriate responses.
132-1	22734-22736	By	_	
132-2	22737-22742	using	_	
132-3	22743-22755	transcranial	_	
132-4	22756-22762	direct	_	
132-5	22763-22770	current	_	
132-6	22771-22782	stimulation	_	
132-7	22783-22790	applied	_	
132-8	22791-22795	over	_	
132-9	22796-22799	OFC	_	
132-10	22799-22800	,	_	
132-11	22801-22812	researchers	_	
132-12	22813-22818	found	_	
132-13	22819-22831	participants	_	
132-14	22832-22835	had	_	
132-15	22836-22844	improved	_	
132-16	22845-22852	ability	_	
132-17	22853-22855	to	_	
132-18	22856-22863	inhibit	_	
132-19	22864-22877	inappropriate	_	
132-20	22878-22887	responses	_	
132-21	22887-22888	.	_	

#Text=It is speculated that the elevated response in NAc combined with a disturbed cognitive control function in prefrontal cortex might lead to compulsive addictive behavior when facing rewarding cues.
133-1	22889-22891	It	_	
133-2	22892-22894	is	_	
133-3	22895-22905	speculated	_	
133-4	22906-22910	that	_	
133-5	22911-22914	the	_	
133-6	22915-22923	elevated	_	
133-7	22924-22932	response	_	
133-8	22933-22935	in	_	
133-9	22936-22939	NAc	_	
133-10	22940-22948	combined	_	
133-11	22949-22953	with	_	
133-12	22954-22955	a	_	
133-13	22956-22965	disturbed	_	
133-14	22966-22975	cognitive	_	
133-15	22976-22983	control	_	
133-16	22984-22992	function	_	
133-17	22993-22995	in	_	
133-18	22996-23006	prefrontal	_	
133-19	23007-23013	cortex	_	
133-20	23014-23019	might	_	
133-21	23020-23024	lead	_	
133-22	23025-23027	to	_	
133-23	23028-23038	compulsive	_	
133-24	23039-23048	addictive	_	
133-25	23049-23057	behavior	_	
133-26	23058-23062	when	_	
133-27	23063-23069	facing	_	
133-28	23070-23079	rewarding	_	
133-29	23080-23084	cues	_	
133-30	23084-23085	.	_	

#Text=Consistent with this speculation, reduced connectivity strength between the NAc and the OFC has been found in internet gaming disorder.
134-1	23086-23096	Consistent	_	
134-2	23097-23101	with	_	
134-3	23102-23106	this	_	
134-4	23107-23118	speculation	_	
134-5	23118-23119	,	_	
134-6	23120-23127	reduced	_	
134-7	23128-23140	connectivity	_	
134-8	23141-23149	strength	_	
134-9	23150-23157	between	_	
134-10	23158-23161	the	_	
134-11	23162-23165	NAc	_	
134-12	23166-23169	and	_	
134-13	23170-23173	the	_	
134-14	23174-23177	OFC	_	
134-15	23178-23181	has	_	
134-16	23182-23186	been	_	
134-17	23187-23192	found	_	
134-18	23193-23195	in	_	
134-19	23196-23204	internet	_	
134-20	23205-23211	gaming	_	
134-21	23212-23220	disorder	_	
134-22	23220-23221	.	_	

#Text=This suggests that abnormal interactions between the rewarding process and cognitive control could be associated with addictions.
135-1	23222-23226	This	_	
135-2	23227-23235	suggests	_	
135-3	23236-23240	that	_	
135-4	23241-23249	abnormal	_	
135-5	23250-23262	interactions	_	
135-6	23263-23270	between	_	
135-7	23271-23274	the	_	
135-8	23275-23284	rewarding	_	
135-9	23285-23292	process	_	
135-10	23293-23296	and	_	
135-11	23297-23306	cognitive	_	
135-12	23307-23314	control	_	
135-13	23315-23320	could	_	
135-14	23321-23323	be	_	
135-15	23324-23334	associated	_	
135-16	23335-23339	with	_	
135-17	23340-23350	addictions	_	
135-18	23350-23351	.	_	

#Text=Our study showed that ATSAs had significantly reduced RSFC with the NAc subdivisions over the left OFC, supporting the disrupted connectivity between the NAc and prefrontal cortices involved in the mechanism of ATSAs.
136-1	23352-23355	Our	_	
136-2	23356-23361	study	_	
136-3	23362-23368	showed	_	
136-4	23369-23373	that	_	
136-5	23374-23379	ATSAs	_	
136-6	23380-23383	had	_	
136-7	23384-23397	significantly	_	
136-8	23398-23405	reduced	_	
136-9	23406-23410	RSFC	_	
136-10	23411-23415	with	_	
136-11	23416-23419	the	_	
136-12	23420-23423	NAc	_	
136-13	23424-23436	subdivisions	_	
136-14	23437-23441	over	_	
136-15	23442-23445	the	_	
136-16	23446-23450	left	_	
136-17	23451-23454	OFC	_	
136-18	23454-23455	,	_	
136-19	23456-23466	supporting	_	
136-20	23467-23470	the	_	
136-21	23471-23480	disrupted	_	
136-22	23481-23493	connectivity	_	
136-23	23494-23501	between	_	
136-24	23502-23505	the	_	
136-25	23506-23509	NAc	_	
136-26	23510-23513	and	_	
136-27	23514-23524	prefrontal	_	
136-28	23525-23533	cortices	_	
136-29	23534-23542	involved	_	
136-30	23543-23545	in	_	
136-31	23546-23549	the	_	
136-32	23550-23559	mechanism	_	
136-33	23560-23562	of	_	
136-34	23563-23568	ATSAs	_	
136-35	23568-23569	.	_	

#Text=In addition, we found that the RSFCs between the NAc subdivisions and the left OFC were negatively correlated with the addiction severity in ATSAs.
137-1	23570-23572	In	_	
137-2	23573-23581	addition	_	
137-3	23581-23582	,	_	
137-4	23583-23585	we	_	
137-5	23586-23591	found	_	
137-6	23592-23596	that	_	
137-7	23597-23600	the	_	
137-8	23601-23606	RSFCs	_	
137-9	23607-23614	between	_	
137-10	23615-23618	the	_	
137-11	23619-23622	NAc	_	
137-12	23623-23635	subdivisions	_	
137-13	23636-23639	and	_	
137-14	23640-23643	the	_	
137-15	23644-23648	left	_	
137-16	23649-23652	OFC	_	
137-17	23653-23657	were	_	
137-18	23658-23668	negatively	_	
137-19	23669-23679	correlated	_	
137-20	23680-23684	with	_	
137-21	23685-23688	the	_	
137-22	23689-23698	addiction	_	
137-23	23699-23707	severity	_	
137-24	23708-23710	in	_	
137-25	23711-23716	ATSAs	_	
137-26	23716-23717	.	_	

#Text=This showed that the more severe the ATSAs’ symptoms, the weaker the connectivity between the NAc subdivisions and the left OFC, which provided further evidence that the connectivity between the NAc and prefrontal cortices plays an important role in the pathophysiological basis of ATSAs.
138-1	23718-23722	This	_	
138-2	23723-23729	showed	_	
138-3	23730-23734	that	_	
138-4	23735-23738	the	_	
138-5	23739-23743	more	_	
138-6	23744-23750	severe	_	
138-7	23751-23754	the	_	
138-8	23755-23760	ATSAs	_	
138-9	23760-23761	’	_	
138-10	23762-23770	symptoms	_	
138-11	23770-23771	,	_	
138-12	23772-23775	the	_	
138-13	23776-23782	weaker	_	
138-14	23783-23786	the	_	
138-15	23787-23799	connectivity	_	
138-16	23800-23807	between	_	
138-17	23808-23811	the	_	
138-18	23812-23815	NAc	_	
138-19	23816-23828	subdivisions	_	
138-20	23829-23832	and	_	
138-21	23833-23836	the	_	
138-22	23837-23841	left	_	
138-23	23842-23845	OFC	_	
138-24	23845-23846	,	_	
138-25	23847-23852	which	_	
138-26	23853-23861	provided	_	
138-27	23862-23869	further	_	
138-28	23870-23878	evidence	_	
138-29	23879-23883	that	_	
138-30	23884-23887	the	_	
138-31	23888-23900	connectivity	_	
138-32	23901-23908	between	_	
138-33	23909-23912	the	_	
138-34	23913-23916	NAc	_	
138-35	23917-23920	and	_	
138-36	23921-23931	prefrontal	_	
138-37	23932-23940	cortices	_	
138-38	23941-23946	plays	_	
138-39	23947-23949	an	_	
138-40	23950-23959	important	_	
138-41	23960-23964	role	_	
138-42	23965-23967	in	_	
138-43	23968-23971	the	_	
138-44	23972-23990	pathophysiological	_	
138-45	23991-23996	basis	_	
138-46	23997-23999	of	_	
138-47	24000-24005	ATSAs	_	
138-48	24005-24006	.	_	

#Text=We also found increased positive RSFCs between all the NAc subdivisions and the left IFGoperc when using FWE corrected p < 0.05 for multiple corrections.
139-1	24007-24009	We	_	
139-2	24010-24014	also	_	
139-3	24015-24020	found	_	
139-4	24021-24030	increased	_	
139-5	24031-24039	positive	_	
139-6	24040-24045	RSFCs	_	
139-7	24046-24053	between	_	
139-8	24054-24057	all	_	
139-9	24058-24061	the	_	
139-10	24062-24065	NAc	_	
139-11	24066-24078	subdivisions	_	
139-12	24079-24082	and	_	
139-13	24083-24086	the	_	
139-14	24087-24091	left	_	
139-15	24092-24100	IFGoperc	_	
139-16	24101-24105	when	_	
139-17	24106-24111	using	_	
139-18	24112-24115	FWE	_	
139-19	24116-24125	corrected	_	
139-20	24126-24127	p	_	
139-21	24128-24129	<	_	
139-22	24130-24134	0.05	_	
139-23	24135-24138	for	_	
139-24	24139-24147	multiple	_	
139-25	24148-24159	corrections	_	
139-26	24159-24160	.	_	

#Text=Many studies have addressed the role of the IFG in response inhibition.
140-1	24161-24165	Many	_	
140-2	24166-24173	studies	_	
140-3	24174-24178	have	_	
140-4	24179-24188	addressed	_	
140-5	24189-24192	the	_	
140-6	24193-24197	role	_	
140-7	24198-24200	of	_	
140-8	24201-24204	the	_	
140-9	24205-24208	IFG	_	
140-10	24209-24211	in	_	
140-11	24212-24220	response	_	
140-12	24221-24231	inhibition	_	
140-13	24231-24232	.	_	

#Text=Lesion studies in human and nonhuman primates have linked the IFG with the ability to inhibit inappropriate motor responses and functional neuroimaging studies also have implicated the IFG in response inhibition.
141-1	24233-24239	Lesion	_	
141-2	24240-24247	studies	_	
141-3	24248-24250	in	_	
141-4	24251-24256	human	_	
141-5	24257-24260	and	_	
141-6	24261-24269	nonhuman	_	
141-7	24270-24278	primates	_	
141-8	24279-24283	have	_	
141-9	24284-24290	linked	_	
141-10	24291-24294	the	_	
141-11	24295-24298	IFG	_	
141-12	24299-24303	with	_	
141-13	24304-24307	the	_	
141-14	24308-24315	ability	_	
141-15	24316-24318	to	_	
141-16	24319-24326	inhibit	_	
141-17	24327-24340	inappropriate	_	
141-18	24341-24346	motor	_	
141-19	24347-24356	responses	_	
141-20	24357-24360	and	_	
141-21	24361-24371	functional	_	
141-22	24372-24384	neuroimaging	_	
141-23	24385-24392	studies	_	
141-24	24393-24397	also	_	
141-25	24398-24402	have	_	
141-26	24403-24413	implicated	_	
141-27	24414-24417	the	_	
141-28	24418-24421	IFG	_	
141-29	24422-24424	in	_	
141-30	24425-24433	response	_	
141-31	24434-24444	inhibition	_	
141-32	24444-24445	.	_	

#Text=In substance-dependent individuals, a previous study has found the association between years of cocaine use and go-nogo task-related brain activation.
142-1	24446-24448	In	_	
142-2	24449-24468	substance-dependent	_	
142-3	24469-24480	individuals	_	
142-4	24480-24481	,	_	
142-5	24482-24483	a	_	
142-6	24484-24492	previous	_	
142-7	24493-24498	study	_	
142-8	24499-24502	has	_	
142-9	24503-24508	found	_	
142-10	24509-24512	the	_	
142-11	24513-24524	association	_	
142-12	24525-24532	between	_	
142-13	24533-24538	years	_	
142-14	24539-24541	of	_	
142-15	24542-24549	cocaine	_	
142-16	24550-24553	use	_	
142-17	24554-24557	and	_	
142-18	24558-24565	go-nogo	_	
142-19	24566-24578	task-related	_	
142-20	24579-24584	brain	_	
142-21	24585-24595	activation	_	
142-22	24595-24596	.	_	

#Text=Specifically, greater activation in ventral striatum when facing cocaine cues and greater activation in the IFGoperc when facing response inhibition cues were found in subjects with more years of cocaine use.
143-1	24597-24609	Specifically	_	
143-2	24609-24610	,	_	
143-3	24611-24618	greater	_	
143-4	24619-24629	activation	_	
143-5	24630-24632	in	_	
143-6	24633-24640	ventral	_	
143-7	24641-24649	striatum	_	
143-8	24650-24654	when	_	
143-9	24655-24661	facing	_	
143-10	24662-24669	cocaine	_	
143-11	24670-24674	cues	_	
143-12	24675-24678	and	_	
143-13	24679-24686	greater	_	
143-14	24687-24697	activation	_	
143-15	24698-24700	in	_	
143-16	24701-24704	the	_	
143-17	24705-24713	IFGoperc	_	
143-18	24714-24718	when	_	
143-19	24719-24725	facing	_	
143-20	24726-24734	response	_	
143-21	24735-24745	inhibition	_	
143-22	24746-24750	cues	_	
143-23	24751-24755	were	_	
143-24	24756-24761	found	_	
143-25	24762-24764	in	_	
143-26	24765-24773	subjects	_	
143-27	24774-24778	with	_	
143-28	24779-24783	more	_	
143-29	24784-24789	years	_	
143-30	24790-24792	of	_	
143-31	24793-24800	cocaine	_	
143-32	24801-24804	use	_	
143-33	24804-24805	.	_	

#Text=In our study, there were no significant RSFCs between the NAc subdivisions and the left IFGoperc in the HC group while ATSAs had increased positive RSFCs between the left NAc subdivisions and the left IFGoperc.
144-1	24806-24808	In	_	
144-2	24809-24812	our	_	
144-3	24813-24818	study	_	
144-4	24818-24819	,	_	
144-5	24820-24825	there	_	
144-6	24826-24830	were	_	
144-7	24831-24833	no	_	
144-8	24834-24845	significant	_	
144-9	24846-24851	RSFCs	_	
144-10	24852-24859	between	_	
144-11	24860-24863	the	_	
144-12	24864-24867	NAc	_	
144-13	24868-24880	subdivisions	_	
144-14	24881-24884	and	_	
144-15	24885-24888	the	_	
144-16	24889-24893	left	_	
144-17	24894-24902	IFGoperc	_	
144-18	24903-24905	in	_	
144-19	24906-24909	the	_	
144-20	24910-24912	HC	_	
144-21	24913-24918	group	_	
144-22	24919-24924	while	_	
144-23	24925-24930	ATSAs	_	
144-24	24931-24934	had	_	
144-25	24935-24944	increased	_	
144-26	24945-24953	positive	_	
144-27	24954-24959	RSFCs	_	
144-28	24960-24967	between	_	
144-29	24968-24971	the	_	
144-30	24972-24976	left	_	
144-31	24977-24980	NAc	_	
144-32	24981-24993	subdivisions	_	
144-33	24994-24997	and	_	
144-34	24998-25001	the	_	
144-35	25002-25006	left	_	
144-36	25007-25015	IFGoperc	_	
144-37	25015-25016	.	_	

#Text=It should be noted that all the ATSAs recruited in the current study were inpatients and receiving detoxification during scanning.
145-1	25017-25019	It	_	
145-2	25020-25026	should	_	
145-3	25027-25029	be	_	
145-4	25030-25035	noted	_	
145-5	25036-25040	that	_	
145-6	25041-25044	all	_	
145-7	25045-25048	the	_	
145-8	25049-25054	ATSAs	_	
145-9	25055-25064	recruited	_	
145-10	25065-25067	in	_	
145-11	25068-25071	the	_	
145-12	25072-25079	current	_	
145-13	25080-25085	study	_	
145-14	25086-25090	were	_	
145-15	25091-25101	inpatients	_	
145-16	25102-25105	and	_	
145-17	25106-25115	receiving	_	
145-18	25116-25130	detoxification	_	
145-19	25131-25137	during	_	
145-20	25138-25146	scanning	_	
145-21	25146-25147	.	_	

#Text=We speculated that these patients needed to constantly struggle with their addiction motivation during hospitalization.
146-1	25148-25150	We	_	
146-2	25151-25161	speculated	_	
146-3	25162-25166	that	_	
146-4	25167-25172	these	_	
146-5	25173-25181	patients	_	
146-6	25182-25188	needed	_	
146-7	25189-25191	to	_	
146-8	25192-25202	constantly	_	
146-9	25203-25211	struggle	_	
146-10	25212-25216	with	_	
146-11	25217-25222	their	_	
146-12	25223-25232	addiction	_	
146-13	25233-25243	motivation	_	
146-14	25244-25250	during	_	
146-15	25251-25266	hospitalization	_	
146-16	25266-25267	.	_	

#Text=Thus, the increased RSFCs between the NAc subdivisions and the left IFGoperc in our study may suggest that ATSAs need to use effortful control resources to resist impulsive addictive drug-seeking behavior when they received detoxification.
147-1	25268-25272	Thus	_	
147-2	25272-25273	,	_	
147-3	25274-25277	the	_	
147-4	25278-25287	increased	_	
147-5	25288-25293	RSFCs	_	
147-6	25294-25301	between	_	
147-7	25302-25305	the	_	
147-8	25306-25309	NAc	_	
147-9	25310-25322	subdivisions	_	
147-10	25323-25326	and	_	
147-11	25327-25330	the	_	
147-12	25331-25335	left	_	
147-13	25336-25344	IFGoperc	_	
147-14	25345-25347	in	_	
147-15	25348-25351	our	_	
147-16	25352-25357	study	_	
147-17	25358-25361	may	_	
147-18	25362-25369	suggest	_	
147-19	25370-25374	that	_	
147-20	25375-25380	ATSAs	_	
147-21	25381-25385	need	_	
147-22	25386-25388	to	_	
147-23	25389-25392	use	_	
147-24	25393-25402	effortful	_	
147-25	25403-25410	control	_	
147-26	25411-25420	resources	_	
147-27	25421-25423	to	_	
147-28	25424-25430	resist	_	
147-29	25431-25440	impulsive	_	
147-30	25441-25450	addictive	_	
147-31	25451-25463	drug-seeking	_	
147-32	25464-25472	behavior	_	
147-33	25473-25477	when	_	
147-34	25478-25482	they	_	
147-35	25483-25491	received	_	
147-36	25492-25506	detoxification	_	
147-37	25506-25507	.	_	

#Text=However, the finding of increased positive RSFCs between the NAc subdivisions and the left IFGoperc in ATSAs did not pass the strict threshold for multiple corrections (i.e., FWE corrected p < 0.0125), whether this connectivity is disrupted and how this connectivity plays a role should be further investigated in the future.
148-1	25508-25515	However	_	
148-2	25515-25516	,	_	
148-3	25517-25520	the	_	
148-4	25521-25528	finding	_	
148-5	25529-25531	of	_	
148-6	25532-25541	increased	_	
148-7	25542-25550	positive	_	
148-8	25551-25556	RSFCs	_	
148-9	25557-25564	between	_	
148-10	25565-25568	the	_	
148-11	25569-25572	NAc	_	
148-12	25573-25585	subdivisions	_	
148-13	25586-25589	and	_	
148-14	25590-25593	the	_	
148-15	25594-25598	left	_	
148-16	25599-25607	IFGoperc	_	
148-17	25608-25610	in	_	
148-18	25611-25616	ATSAs	_	
148-19	25617-25620	did	_	
148-20	25621-25624	not	_	
148-21	25625-25629	pass	_	
148-22	25630-25633	the	_	
148-23	25634-25640	strict	_	
148-24	25641-25650	threshold	_	
148-25	25651-25654	for	_	
148-26	25655-25663	multiple	_	
148-27	25664-25675	corrections	_	
148-28	25676-25677	(	_	
148-29	25677-25680	i.e	_	
148-30	25680-25681	.	_	
148-31	25681-25682	,	_	
148-32	25683-25686	FWE	_	
148-33	25687-25696	corrected	_	
148-34	25697-25698	p	_	
148-35	25699-25700	<	_	
148-36	25701-25707	0.0125	_	
148-37	25707-25708	)	_	
148-38	25708-25709	,	_	
148-39	25710-25717	whether	_	
148-40	25718-25722	this	_	
148-41	25723-25735	connectivity	_	
148-42	25736-25738	is	_	
148-43	25739-25748	disrupted	_	
148-44	25749-25752	and	_	
148-45	25753-25756	how	_	
148-46	25757-25761	this	_	
148-47	25762-25774	connectivity	_	
148-48	25775-25780	plays	_	
148-49	25781-25782	a	_	
148-50	25783-25787	role	_	
148-51	25788-25794	should	_	
148-52	25795-25797	be	_	
148-53	25798-25805	further	_	
148-54	25806-25818	investigated	_	
148-55	25819-25821	in	_	
148-56	25822-25825	the	_	
148-57	25826-25832	future	_	
148-58	25832-25833	.	_	

#Text=Our study has several limitations that should be noted.
149-1	25834-25837	Our	_	
149-2	25838-25843	study	_	
149-3	25844-25847	has	_	
149-4	25848-25855	several	_	
149-5	25856-25867	limitations	_	
149-6	25868-25872	that	_	
149-7	25873-25879	should	_	
149-8	25880-25882	be	_	
149-9	25883-25888	noted	_	
149-10	25888-25889	.	_	

#Text=First, we only included males in the study, so the interpretation of the findings should be restricted to males.
150-1	25890-25895	First	_	
150-2	25895-25896	,	_	
150-3	25897-25899	we	_	
150-4	25900-25904	only	_	
150-5	25905-25913	included	_	
150-6	25914-25919	males	_	
150-7	25920-25922	in	_	
150-8	25923-25926	the	_	
150-9	25927-25932	study	_	
150-10	25932-25933	,	_	
150-11	25934-25936	so	_	
150-12	25937-25940	the	_	
150-13	25941-25955	interpretation	_	
150-14	25956-25958	of	_	
150-15	25959-25962	the	_	
150-16	25963-25971	findings	_	
150-17	25972-25978	should	_	
150-18	25979-25981	be	_	
150-19	25982-25992	restricted	_	
150-20	25993-25995	to	_	
150-21	25996-26001	males	_	
150-22	26001-26002	.	_	

#Text=Secondly, the current findings should be replicated in future using images with higher spatial resolution.
151-1	26003-26011	Secondly	_	
151-2	26011-26012	,	_	
151-3	26013-26016	the	_	
151-4	26017-26024	current	_	
151-5	26025-26033	findings	_	
151-6	26034-26040	should	_	
151-7	26041-26043	be	_	
151-8	26044-26054	replicated	_	
151-9	26055-26057	in	_	
151-10	26058-26064	future	_	
151-11	26065-26070	using	_	
151-12	26071-26077	images	_	
151-13	26078-26082	with	_	
151-14	26083-26089	higher	_	
151-15	26090-26097	spatial	_	
151-16	26098-26108	resolution	_	
151-17	26108-26109	.	_	

#Text=Thirdly, our sample size is small, future replications of this investigation are needed to verify these findings.
152-1	26110-26117	Thirdly	_	
152-2	26117-26118	,	_	
152-3	26119-26122	our	_	
152-4	26123-26129	sample	_	
152-5	26130-26134	size	_	
152-6	26135-26137	is	_	
152-7	26138-26143	small	_	
152-8	26143-26144	,	_	
152-9	26145-26151	future	_	
152-10	26152-26164	replications	_	
152-11	26165-26167	of	_	
152-12	26168-26172	this	_	
152-13	26173-26186	investigation	_	
152-14	26187-26190	are	_	
152-15	26191-26197	needed	_	
152-16	26198-26200	to	_	
152-17	26201-26207	verify	_	
152-18	26208-26213	these	_	
152-19	26214-26222	findings	_	
152-20	26222-26223	.	_	

#Text=Fourthly, three ATSA participants included in our study had a history of abuse or dependence on alcohol.
153-1	26224-26232	Fourthly	_	
153-2	26232-26233	,	_	
153-3	26234-26239	three	_	
153-4	26240-26244	ATSA	_	
153-5	26245-26257	participants	_	
153-6	26258-26266	included	_	
153-7	26267-26269	in	_	
153-8	26270-26273	our	_	
153-9	26274-26279	study	_	
153-10	26280-26283	had	_	
153-11	26284-26285	a	_	
153-12	26286-26293	history	_	
153-13	26294-26296	of	_	
153-14	26297-26302	abuse	_	
153-15	26303-26305	or	_	
153-16	26306-26316	dependence	_	
153-17	26317-26319	on	_	
153-18	26320-26327	alcohol	_	
153-19	26327-26328	.	_	

#Text=Previous studies found that alcohol use was associated with weaker prefronto-striatal functional connectivity.
154-1	26329-26337	Previous	_	
154-2	26338-26345	studies	_	
154-3	26346-26351	found	_	
154-4	26352-26356	that	_	
154-5	26357-26364	alcohol	_	
154-6	26365-26368	use	_	
154-7	26369-26372	was	_	
154-8	26373-26383	associated	_	
154-9	26384-26388	with	_	
154-10	26389-26395	weaker	_	
154-11	26396-26414	prefronto-striatal	_	
154-12	26415-26425	functional	_	
154-13	26426-26438	connectivity	_	
154-14	26438-26439	.	_	

#Text=Abstinent alcohol-dependent adults also exhibited lower prefronto-striatal functional connectivity.
155-1	26440-26449	Abstinent	_	
155-2	26450-26467	alcohol-dependent	_	
155-3	26468-26474	adults	_	
155-4	26475-26479	also	_	
155-5	26480-26489	exhibited	_	
155-6	26490-26495	lower	_	
155-7	26496-26514	prefronto-striatal	_	
155-8	26515-26525	functional	_	
155-9	26526-26538	connectivity	_	
155-10	26538-26539	.	_	

#Text=Thus, the abnormal resting-state brain function observed in the ATSAs may be confounded by alcohol intake.
156-1	26540-26544	Thus	_	
156-2	26544-26545	,	_	
156-3	26546-26549	the	_	
156-4	26550-26558	abnormal	_	
156-5	26559-26572	resting-state	_	
156-6	26573-26578	brain	_	
156-7	26579-26587	function	_	
156-8	26588-26596	observed	_	
156-9	26597-26599	in	_	
156-10	26600-26603	the	_	
156-11	26604-26609	ATSAs	_	
156-12	26610-26613	may	_	
156-13	26614-26616	be	_	
156-14	26617-26627	confounded	_	
156-15	26628-26630	by	_	
156-16	26631-26638	alcohol	_	
156-17	26639-26645	intake	_	
156-18	26645-26646	.	_	

#Text=ATSAs with history of abuse on alcohol may further reduce the RSFC between the NAc subdivisions and prefrontal cortex.
157-1	26647-26652	ATSAs	_	
157-2	26653-26657	with	_	
157-3	26658-26665	history	_	
157-4	26666-26668	of	_	
157-5	26669-26674	abuse	_	
157-6	26675-26677	on	_	
157-7	26678-26685	alcohol	_	
157-8	26686-26689	may	_	
157-9	26690-26697	further	_	
157-10	26698-26704	reduce	_	
157-11	26705-26708	the	_	
157-12	26709-26713	RSFC	_	
157-13	26714-26721	between	_	
157-14	26722-26725	the	_	
157-15	26726-26729	NAc	_	
157-16	26730-26742	subdivisions	_	
157-17	26743-26746	and	_	
157-18	26747-26757	prefrontal	_	
157-19	26758-26764	cortex	_	
157-20	26764-26765	.	_	

#Text=Future studies with alcohol-naïve participants may distinguish the effects of alcohol on resting-state brain function from the effects of amphetamine-type stimulants per se.
158-1	26766-26772	Future	_	
158-2	26773-26780	studies	_	
158-3	26781-26785	with	_	
158-4	26786-26799	alcohol-naïve	_	
158-5	26800-26812	participants	_	
158-6	26813-26816	may	_	
158-7	26817-26828	distinguish	_	
158-8	26829-26832	the	_	
158-9	26833-26840	effects	_	
158-10	26841-26843	of	_	
158-11	26844-26851	alcohol	_	
158-12	26852-26854	on	_	
158-13	26855-26868	resting-state	_	
158-14	26869-26874	brain	_	
158-15	26875-26883	function	_	
158-16	26884-26888	from	_	
158-17	26889-26892	the	_	
158-18	26893-26900	effects	_	
158-19	26901-26903	of	_	
158-20	26904-26920	amphetamine-type	_	
158-21	26921-26931	stimulants	_	
158-22	26932-26935	per	_	
158-23	26936-26938	se	_	
158-24	26938-26939	.	_	

#Text=Lastly, we interpreted the results of RSFC based on the evidence of literature reviews.
159-1	26940-26946	Lastly	_	
159-2	26946-26947	,	_	
159-3	26948-26950	we	_	
159-4	26951-26962	interpreted	_	
159-5	26963-26966	the	_	
159-6	26967-26974	results	_	
159-7	26975-26977	of	_	
159-8	26978-26982	RSFC	_	
159-9	26983-26988	based	_	
159-10	26989-26991	on	_	
159-11	26992-26995	the	_	
159-12	26996-27004	evidence	_	
159-13	27005-27007	of	_	
159-14	27008-27018	literature	_	
159-15	27019-27026	reviews	_	
159-16	27026-27027	.	_	

#Text=Thus, the specific functions of RSFC in the NAc subdivisions were not proven in our study.
160-1	27028-27032	Thus	_	
160-2	27032-27033	,	_	
160-3	27034-27037	the	_	
160-4	27038-27046	specific	_	
160-5	27047-27056	functions	_	
160-6	27057-27059	of	_	
160-7	27060-27064	RSFC	_	
160-8	27065-27067	in	_	
160-9	27068-27071	the	_	
160-10	27072-27075	NAc	_	
160-11	27076-27088	subdivisions	_	
160-12	27089-27093	were	_	
160-13	27094-27097	not	_	
160-14	27098-27104	proven	_	
160-15	27105-27107	in	_	
160-16	27108-27111	our	_	
160-17	27112-27117	study	_	
160-18	27117-27118	.	_	

#Text=To assess the functions of these altered connectivities in ATSAs, well-designed studies are necessary in the future.
161-1	27119-27121	To	_	
161-2	27122-27128	assess	_	
161-3	27129-27132	the	_	
161-4	27133-27142	functions	_	
161-5	27143-27145	of	_	
161-6	27146-27151	these	_	
161-7	27152-27159	altered	_	
161-8	27160-27174	connectivities	_	
161-9	27175-27177	in	_	
161-10	27178-27183	ATSAs	_	
161-11	27183-27184	,	_	
161-12	27185-27198	well-designed	_	
161-13	27199-27206	studies	_	
161-14	27207-27210	are	_	
161-15	27211-27220	necessary	_	
161-16	27221-27223	in	_	
161-17	27224-27227	the	_	
161-18	27228-27234	future	_	
161-19	27234-27235	.	_	

#Text=For example, by combining fMRI with brain stimulation techniques such as transcranial magnetic stimulation on prefrontal cortex, we can observe the specific behavior changes in ATSAs and provide additional evidence for the role of the prefrontal-striatal circuit in ATSAs by moderating function of the prefrontal cortex involved in the prefrontal-striatal circuit.
162-1	27236-27239	For	_	
162-2	27240-27247	example	_	
162-3	27247-27248	,	_	
162-4	27249-27251	by	_	
162-5	27252-27261	combining	_	
162-6	27262-27266	fMRI	_	
162-7	27267-27271	with	_	
162-8	27272-27277	brain	_	
162-9	27278-27289	stimulation	_	
162-10	27290-27300	techniques	_	
162-11	27301-27305	such	_	
162-12	27306-27308	as	_	
162-13	27309-27321	transcranial	_	
162-14	27322-27330	magnetic	_	
162-15	27331-27342	stimulation	_	
162-16	27343-27345	on	_	
162-17	27346-27356	prefrontal	_	
162-18	27357-27363	cortex	_	
162-19	27363-27364	,	_	
162-20	27365-27367	we	_	
162-21	27368-27371	can	_	
162-22	27372-27379	observe	_	
162-23	27380-27383	the	_	
162-24	27384-27392	specific	_	
162-25	27393-27401	behavior	_	
162-26	27402-27409	changes	_	
162-27	27410-27412	in	_	
162-28	27413-27418	ATSAs	_	
162-29	27419-27422	and	_	
162-30	27423-27430	provide	_	
162-31	27431-27441	additional	_	
162-32	27442-27450	evidence	_	
162-33	27451-27454	for	_	
162-34	27455-27458	the	_	
162-35	27459-27463	role	_	
162-36	27464-27466	of	_	
162-37	27467-27470	the	_	
162-38	27471-27490	prefrontal-striatal	_	
162-39	27491-27498	circuit	_	
162-40	27499-27501	in	_	
162-41	27502-27507	ATSAs	_	
162-42	27508-27510	by	_	
162-43	27511-27521	moderating	_	
162-44	27522-27530	function	_	
162-45	27531-27533	of	_	
162-46	27534-27537	the	_	
162-47	27538-27548	prefrontal	_	
162-48	27549-27555	cortex	_	
162-49	27556-27564	involved	_	
162-50	27565-27567	in	_	
162-51	27568-27571	the	_	
162-52	27572-27591	prefrontal-striatal	_	
162-53	27592-27599	circuit	_	
162-54	27599-27600	.	_	

#Text=In addition, longitudinal studies across acute and remission periods might provide new insight into the characteristics of these alterations and determine whether these changes are trait or state markers in ATSAs.
163-1	27601-27603	In	_	
163-2	27604-27612	addition	_	
163-3	27612-27613	,	_	
163-4	27614-27626	longitudinal	_	
163-5	27627-27634	studies	_	
163-6	27635-27641	across	_	
163-7	27642-27647	acute	_	
163-8	27648-27651	and	_	
163-9	27652-27661	remission	_	
163-10	27662-27669	periods	_	
163-11	27670-27675	might	_	
163-12	27676-27683	provide	_	
163-13	27684-27687	new	_	
163-14	27688-27695	insight	_	
163-15	27696-27700	into	_	
163-16	27701-27704	the	_	
163-17	27705-27720	characteristics	_	
163-18	27721-27723	of	_	
163-19	27724-27729	these	_	
163-20	27730-27741	alterations	_	
163-21	27742-27745	and	_	
163-22	27746-27755	determine	_	
163-23	27756-27763	whether	_	
163-24	27764-27769	these	_	
163-25	27770-27777	changes	_	
163-26	27778-27781	are	_	
163-27	27782-27787	trait	_	
163-28	27788-27790	or	_	
163-29	27791-27796	state	_	
163-30	27797-27804	markers	_	
163-31	27805-27807	in	_	
163-32	27808-27813	ATSAs	_	
163-33	27813-27814	.	_	

#Text=Conclusion
#Text=In summary, our result demonstrated that the NAc subdivisions, the center of reward processing, had altered RSFCs to prefrontal cortices among subjects with ATSA.
164-1	27815-27825	Conclusion	_	
164-2	27826-27828	In	_	
164-3	27829-27836	summary	_	
164-4	27836-27837	,	_	
164-5	27838-27841	our	_	
164-6	27842-27848	result	_	
164-7	27849-27861	demonstrated	_	
164-8	27862-27866	that	_	
164-9	27867-27870	the	_	
164-10	27871-27874	NAc	_	
164-11	27875-27887	subdivisions	_	
164-12	27887-27888	,	_	
164-13	27889-27892	the	_	
164-14	27893-27899	center	_	
164-15	27900-27902	of	_	
164-16	27903-27909	reward	_	
164-17	27910-27920	processing	_	
164-18	27920-27921	,	_	
164-19	27922-27925	had	_	
164-20	27926-27933	altered	_	
164-21	27934-27939	RSFCs	_	
164-22	27940-27942	to	_	
164-23	27943-27953	prefrontal	_	
164-24	27954-27962	cortices	_	
164-25	27963-27968	among	_	
164-26	27969-27977	subjects	_	
164-27	27978-27982	with	_	
164-28	27983-27987	ATSA	_	
164-29	27987-27988	.	_	

#Text=These results provide evidence that there are common RSFC patterns of the NAc subdivisions in ATSAs.
165-1	27989-27994	These	_	
165-2	27995-28002	results	_	
165-3	28003-28010	provide	_	
165-4	28011-28019	evidence	_	
165-5	28020-28024	that	_	
165-6	28025-28030	there	_	
165-7	28031-28034	are	_	
165-8	28035-28041	common	_	
165-9	28042-28046	RSFC	_	
165-10	28047-28055	patterns	_	
165-11	28056-28058	of	_	
165-12	28059-28062	the	_	
165-13	28063-28066	NAc	_	
165-14	28067-28079	subdivisions	_	
165-15	28080-28082	in	_	
165-16	28083-28088	ATSAs	_	
165-17	28088-28089	.	_	

#Text=The common abnormality indicated by disrupted functional connectivity between the NAc subdivisions and the left OFC suggests abnormal interaction between the rewarding process and cognitive control in ATSAs.
166-1	28090-28093	The	_	
166-2	28094-28100	common	_	
166-3	28101-28112	abnormality	_	
166-4	28113-28122	indicated	_	
166-5	28123-28125	by	_	
166-6	28126-28135	disrupted	_	
166-7	28136-28146	functional	_	
166-8	28147-28159	connectivity	_	
166-9	28160-28167	between	_	
166-10	28168-28171	the	_	
166-11	28172-28175	NAc	_	
166-12	28176-28188	subdivisions	_	
166-13	28189-28192	and	_	
166-14	28193-28196	the	_	
166-15	28197-28201	left	_	
166-16	28202-28205	OFC	_	
166-17	28206-28214	suggests	_	
166-18	28215-28223	abnormal	_	
166-19	28224-28235	interaction	_	
166-20	28236-28243	between	_	
166-21	28244-28247	the	_	
166-22	28248-28257	rewarding	_	
166-23	28258-28265	process	_	
166-24	28266-28269	and	_	
166-25	28270-28279	cognitive	_	
166-26	28280-28287	control	_	
166-27	28288-28290	in	_	
166-28	28291-28296	ATSAs	_	
166-29	28296-28297	.	_	

#Text=The abnormality of the RSFCs between the NAc subdivisions and the left IFGoperc may indicate that ATSAs need to use effortful control resources to self-regulate impulsive addictive behavior.
167-1	28298-28301	The	_	
167-2	28302-28313	abnormality	_	
167-3	28314-28316	of	_	
167-4	28317-28320	the	_	
167-5	28321-28326	RSFCs	_	
167-6	28327-28334	between	_	
167-7	28335-28338	the	_	
167-8	28339-28342	NAc	_	
167-9	28343-28355	subdivisions	_	
167-10	28356-28359	and	_	
167-11	28360-28363	the	_	
167-12	28364-28368	left	_	
167-13	28369-28377	IFGoperc	_	
167-14	28378-28381	may	_	
167-15	28382-28390	indicate	_	
167-16	28391-28395	that	_	
167-17	28396-28401	ATSAs	_	
167-18	28402-28406	need	_	
167-19	28407-28409	to	_	
167-20	28410-28413	use	_	
167-21	28414-28423	effortful	_	
167-22	28424-28431	control	_	
167-23	28432-28441	resources	_	
167-24	28442-28444	to	_	
167-25	28445-28458	self-regulate	_	
167-26	28459-28468	impulsive	_	
167-27	28469-28478	addictive	_	
167-28	28479-28487	behavior	_	
167-29	28487-28488	.	_	

#Text=Our results shed insight on the neurobiological mechanisms of ATSA and suggest potential novel therapeutic targets for treatment and intervention of ATSAs.
168-1	28489-28492	Our	_	
168-2	28493-28500	results	_	
168-3	28501-28505	shed	_	
168-4	28506-28513	insight	_	
168-5	28514-28516	on	_	
168-6	28517-28520	the	_	
168-7	28521-28536	neurobiological	_	
168-8	28537-28547	mechanisms	_	
168-9	28548-28550	of	_	
168-10	28551-28555	ATSA	_	
168-11	28556-28559	and	_	
168-12	28560-28567	suggest	_	
168-13	28568-28577	potential	_	
168-14	28578-28583	novel	_	
168-15	28584-28595	therapeutic	_	
168-16	28596-28603	targets	_	
168-17	28604-28607	for	_	
168-18	28608-28617	treatment	_	
168-19	28618-28621	and	_	
168-20	28622-28634	intervention	_	
168-21	28635-28637	of	_	
168-22	28638-28643	ATSAs	_	
168-23	28643-28644	.	_	

#Text=Supplementary information
#Text=Abbreviations
#Text=NAc
#Text=nucleus accumbens
#Text=ATSAs
#Text=amphetamine-type stimulant abusers
#Text=fMRI
#Text=functional magnetic resonance imaging
#Text=RSFC
#Text=resting-state functional connectivity
#Text=HCs
#Text=healthy controls
#Text=DSM-IV
#Text=Diagnostic and Statistical Manual for Mental Disorders, 4th Edition
#Text=ASI-C
#Text=Chinese version of the Addiction Severity Index
#Text=EPI
#Text=echo-planar imaging
#Text=WM
#Text=white matter
#Text=FD
#Text=frame-wise displacement
#Text=OFC
#Text=orbital part of superior frontal gyrus
#Text=IFGoperc
#Text=opercular part of inferior frontal gyrus
#Text=Publisher's Note
#Text=Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
169-1	28645-28658	Supplementary	_	
169-2	28659-28670	information	_	
169-3	28671-28684	Abbreviations	_	
169-4	28685-28688	NAc	_	
169-5	28689-28696	nucleus	_	
169-6	28697-28706	accumbens	_	
169-7	28707-28712	ATSAs	_	
169-8	28713-28729	amphetamine-type	_	
169-9	28730-28739	stimulant	_	
169-10	28740-28747	abusers	_	
169-11	28748-28752	fMRI	_	
169-12	28753-28763	functional	_	
169-13	28764-28772	magnetic	_	
169-14	28773-28782	resonance	_	
169-15	28783-28790	imaging	_	
169-16	28791-28795	RSFC	_	
169-17	28796-28809	resting-state	_	
169-18	28810-28820	functional	_	
169-19	28821-28833	connectivity	_	
169-20	28834-28837	HCs	_	
169-21	28838-28845	healthy	_	
169-22	28846-28854	controls	_	
169-23	28855-28861	DSM-IV	_	
169-24	28862-28872	Diagnostic	_	
169-25	28873-28876	and	_	
169-26	28877-28888	Statistical	_	
169-27	28889-28895	Manual	_	
169-28	28896-28899	for	_	
169-29	28900-28906	Mental	_	
169-30	28907-28916	Disorders	_	
169-31	28916-28917	,	_	
169-32	28918-28921	4th	_	
169-33	28922-28929	Edition	_	
169-34	28930-28935	ASI-C	_	
169-35	28936-28943	Chinese	_	
169-36	28944-28951	version	_	
169-37	28952-28954	of	_	
169-38	28955-28958	the	_	
169-39	28959-28968	Addiction	_	
169-40	28969-28977	Severity	_	
169-41	28978-28983	Index	_	
169-42	28984-28987	EPI	_	
169-43	28988-28999	echo-planar	_	
169-44	29000-29007	imaging	_	
169-45	29008-29010	WM	_	
169-46	29011-29016	white	_	
169-47	29017-29023	matter	_	
169-48	29024-29026	FD	_	
169-49	29027-29037	frame-wise	_	
169-50	29038-29050	displacement	_	
169-51	29051-29054	OFC	_	
169-52	29055-29062	orbital	_	
169-53	29063-29067	part	_	
169-54	29068-29070	of	_	
169-55	29071-29079	superior	_	
169-56	29080-29087	frontal	_	
169-57	29088-29093	gyrus	_	
169-58	29094-29102	IFGoperc	_	
169-59	29103-29112	opercular	_	
169-60	29113-29117	part	_	
169-61	29118-29120	of	_	
169-62	29121-29129	inferior	_	
169-63	29130-29137	frontal	_	
169-64	29138-29143	gyrus	_	
169-65	29144-29155	Publisher's	_	
169-66	29156-29160	Note	_	
169-67	29161-29169	Springer	_	
169-68	29170-29176	Nature	_	
169-69	29177-29184	remains	_	
169-70	29185-29192	neutral	_	
169-71	29193-29197	with	_	
169-72	29198-29204	regard	_	
169-73	29205-29207	to	_	
169-74	29208-29222	jurisdictional	_	
169-75	29223-29229	claims	_	
169-76	29230-29232	in	_	
169-77	29233-29242	published	_	
169-78	29243-29247	maps	_	
169-79	29248-29251	and	_	
169-80	29252-29265	institutional	_	
169-81	29266-29278	affiliations	_	
169-82	29278-29279	.	_	

#Text=Supplementary information
#Text=Supplementary information accompanies this paper at 10.1186/s12868-019-0548-y.
170-1	29280-29293	Supplementary	_	
170-2	29294-29305	information	_	
170-3	29306-29319	Supplementary	_	
170-4	29320-29331	information	_	
170-5	29332-29343	accompanies	_	
170-6	29344-29348	this	_	
170-7	29349-29354	paper	_	
170-8	29355-29357	at	_	
170-9	29358-29365	10.1186	_	
170-10	29365-29366	/	_	
170-11	29366-29372	s12868	_	
170-12	29372-29373	-	_	
170-13	29373-29376	019	_	
170-14	29376-29377	-	_	
170-15	29377-29381	0548	_	
170-16	29381-29382	-	_	
170-17	29382-29383	y	_	
170-18	29383-29384	.	_	

#Text=Authors’ contributions
#Text=YW, XNL and YZ provided the theoretical framework and intellectual content guidance.
171-1	29385-29392	Authors	_	
171-2	29392-29393	’	_	
171-3	29394-29407	contributions	_	
171-4	29408-29410	YW	_	
171-5	29410-29411	,	_	
171-6	29412-29415	XNL	_	
171-7	29416-29419	and	_	
171-8	29420-29422	YZ	_	
171-9	29423-29431	provided	_	
171-10	29432-29435	the	_	
171-11	29436-29447	theoretical	_	
171-12	29448-29457	framework	_	
171-13	29458-29461	and	_	
171-14	29462-29474	intellectual	_	
171-15	29475-29482	content	_	
171-16	29483-29491	guidance	_	
171-17	29491-29492	.	_	

#Text=KJY and CXF collected all data.
172-1	29493-29496	KJY	_	
172-2	29497-29500	and	_	
172-3	29501-29504	CXF	_	
172-4	29505-29514	collected	_	
172-5	29515-29518	all	_	
172-6	29519-29523	data	_	
172-7	29523-29524	.	_	

#Text=YW performed the data analysis and wrote the first draft.
173-1	29525-29527	YW	_	
173-2	29528-29537	performed	_	
173-3	29538-29541	the	_	
173-4	29542-29546	data	_	
173-5	29547-29555	analysis	_	
173-6	29556-29559	and	_	
173-7	29560-29565	wrote	_	
173-8	29566-29569	the	_	
173-9	29570-29575	first	_	
173-10	29576-29581	draft	_	
173-11	29581-29582	.	_	

#Text=YW and YZ were responsible for the interpretation of the results.
174-1	29583-29585	YW	_	
174-2	29586-29589	and	_	
174-3	29590-29592	YZ	_	
174-4	29593-29597	were	_	
174-5	29598-29609	responsible	_	
174-6	29610-29613	for	_	
174-7	29614-29617	the	_	
174-8	29618-29632	interpretation	_	
174-9	29633-29635	of	_	
174-10	29636-29639	the	_	
174-11	29640-29647	results	_	
174-12	29647-29648	.	_	

#Text=All the authors critically reviewed the content of the manuscript.
175-1	29649-29652	All	_	
175-2	29653-29656	the	_	
175-3	29657-29664	authors	_	
175-4	29665-29675	critically	_	
175-5	29676-29684	reviewed	_	
175-6	29685-29688	the	_	
175-7	29689-29696	content	_	
175-8	29697-29699	of	_	
175-9	29700-29703	the	_	
175-10	29704-29714	manuscript	_	
175-11	29714-29715	.	_	

#Text=All authors read and approved the final manuscript.
176-1	29716-29719	All	_	
176-2	29720-29727	authors	_	
176-3	29728-29732	read	_	
176-4	29733-29736	and	_	
176-5	29737-29745	approved	_	
176-6	29746-29749	the	_	
176-7	29750-29755	final	_	
176-8	29756-29766	manuscript	_	
176-9	29766-29767	.	_	

#Text=Funding
#Text=This research was supported by the National Key Technology R&D Program in the 12th Five-Year Plan of China (2012BAI01B07).
177-1	29768-29775	Funding	_	
177-2	29776-29780	This	_	
177-3	29781-29789	research	_	
177-4	29790-29793	was	_	
177-5	29794-29803	supported	_	
177-6	29804-29806	by	_	
177-7	29807-29810	the	_	
177-8	29811-29819	National	_	
177-9	29820-29823	Key	_	
177-10	29824-29834	Technology	_	
177-11	29835-29836	R	_	
177-12	29836-29837	&	_	
177-13	29837-29838	D	_	
177-14	29839-29846	Program	_	
177-15	29847-29849	in	_	
177-16	29850-29853	the	_	
177-17	29854-29858	12th	_	
177-18	29859-29868	Five-Year	_	
177-19	29869-29873	Plan	_	
177-20	29874-29876	of	_	
177-21	29877-29882	China	_	
177-22	29883-29884	(	_	
177-23	29884-29896	2012BAI01B07	_	
177-24	29896-29897	)	_	
177-25	29897-29898	.	_	

#Text=Availability of data and materials
#Text=The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
178-1	29899-29911	Availability	_	
178-2	29912-29914	of	_	
178-3	29915-29919	data	_	
178-4	29920-29923	and	_	
178-5	29924-29933	materials	_	
178-6	29934-29937	The	_	
178-7	29938-29946	datasets	_	
178-8	29947-29951	used	_	
178-9	29952-29955	and	_	
178-10	29955-29956	/	_	
178-11	29956-29958	or	_	
178-12	29959-29967	analyzed	_	
178-13	29968-29974	during	_	
178-14	29975-29978	the	_	
178-15	29979-29986	current	_	
178-16	29987-29992	study	_	
178-17	29993-29996	are	_	
178-18	29997-30006	available	_	
178-19	30007-30011	from	_	
178-20	30012-30015	the	_	
178-21	30016-30029	corresponding	_	
178-22	30030-30036	author	_	
178-23	30037-30039	on	_	
178-24	30040-30050	reasonable	_	
178-25	30051-30058	request	_	
178-26	30058-30059	.	_	

#Text=Ethics approval and consent to participate
#Text=This study was approved by the Ethics Committee of Wuhan Mental Health Centre.
179-1	30060-30066	Ethics	_	
179-2	30067-30075	approval	_	
179-3	30076-30079	and	_	
179-4	30080-30087	consent	_	
179-5	30088-30090	to	_	
179-6	30091-30102	participate	_	
179-7	30103-30107	This	_	
179-8	30108-30113	study	_	
179-9	30114-30117	was	_	
179-10	30118-30126	approved	_	
179-11	30127-30129	by	_	
179-12	30130-30133	the	_	
179-13	30134-30140	Ethics	_	
179-14	30141-30150	Committee	_	
179-15	30151-30153	of	_	
179-16	30154-30159	Wuhan	_	
179-17	30160-30166	Mental	_	
179-18	30167-30173	Health	_	
179-19	30174-30180	Centre	_	
179-20	30180-30181	.	_	

#Text=All participants or families of ATSAs provided informed consent before participation.
180-1	30182-30185	All	_	
180-2	30186-30198	participants	_	
180-3	30199-30201	or	_	
180-4	30202-30210	families	_	
180-5	30211-30213	of	_	
180-6	30214-30219	ATSAs	_	
180-7	30220-30228	provided	_	
180-8	30229-30237	informed	_	
180-9	30238-30245	consent	_	
180-10	30246-30252	before	_	
180-11	30253-30266	participation	_	
180-12	30266-30267	.	_	

#Text=Consent for publication
#Text=Not applicable.
181-1	30268-30275	Consent	_	
181-2	30276-30279	for	_	
181-3	30280-30291	publication	_	
181-4	30292-30295	Not	_	
181-5	30296-30306	applicable	_	
181-6	30306-30307	.	_	

#Text=Competing interests
#Text=The authors declare that they have no competing interests.
182-1	30308-30317	Competing	_	
182-2	30318-30327	interests	_	
182-3	30328-30331	The	_	
182-4	30332-30339	authors	_	
182-5	30340-30347	declare	_	
182-6	30348-30352	that	_	
182-7	30353-30357	they	_	
182-8	30358-30362	have	_	
182-9	30363-30365	no	_	
182-10	30366-30375	competing	_	
182-11	30376-30385	interests	_	
182-12	30385-30386	.	_	

#Text=References
#Text=Drug addiction: the neurobiology of behaviour gone awry
#Text=The new pattern of drug abuse in China
#Text=The neural basis of addiction: a pathology of motivation and choice
#Text=Drug addiction: the neurobiology of disrupted self-control
#Text=Splitting the difference: How does the brain code reward episodes?
183-1	30387-30397	References	_	
183-2	30398-30402	Drug	_	
183-3	30403-30412	addiction	_	
183-4	30412-30413	:	_	
183-5	30414-30417	the	_	
183-6	30418-30430	neurobiology	_	
183-7	30431-30433	of	_	
183-8	30434-30443	behaviour	_	
183-9	30444-30448	gone	_	
183-10	30449-30453	awry	_	
183-11	30454-30457	The	_	
183-12	30458-30461	new	_	
183-13	30462-30469	pattern	_	
183-14	30470-30472	of	_	
183-15	30473-30477	drug	_	
183-16	30478-30483	abuse	_	
183-17	30484-30486	in	_	
183-18	30487-30492	China	_	
183-19	30493-30496	The	_	
183-20	30497-30503	neural	_	
183-21	30504-30509	basis	_	
183-22	30510-30512	of	_	
183-23	30513-30522	addiction	_	
183-24	30522-30523	:	_	
183-25	30524-30525	a	_	
183-26	30526-30535	pathology	_	
183-27	30536-30538	of	_	
183-28	30539-30549	motivation	_	
183-29	30550-30553	and	_	
183-30	30554-30560	choice	_	
183-31	30561-30565	Drug	_	
183-32	30566-30575	addiction	_	
183-33	30575-30576	:	_	
183-34	30577-30580	the	_	
183-35	30581-30593	neurobiology	_	
183-36	30594-30596	of	_	
183-37	30597-30606	disrupted	_	
183-38	30607-30619	self-control	_	
183-39	30620-30629	Splitting	_	
183-40	30630-30633	the	_	
183-41	30634-30644	difference	_	
183-42	30644-30645	:	_	
183-43	30646-30649	How	_	
183-44	30650-30654	does	_	
183-45	30655-30658	the	_	
183-46	30659-30664	brain	_	
183-47	30665-30669	code	_	
183-48	30670-30676	reward	_	
183-49	30677-30685	episodes	_	
183-50	30685-30686	?	_	

#Text=Brain dopamine and reward
#Text=The nucleus accumbens: an interface between cognition, emotion, and action
#Text=Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging
#Text=Addiction related alteration in resting-state brain connectivity
#Text=Regional homogeneity changes in heroin-dependent individuals: resting-state functional MR imaging study
#Text=Combining spatial and temporal information to explore resting-state networks changes in abstinent heroin-dependent individuals
#Text=Alterations in brain connectivity in three sub-regions of the anterior cingulate cortex in heroin-dependent individuals: evidence from resting state fMRI
#Text=Association of nicotine addiction and nicotine's actions with separate cingulate cortex functional circuits
#Text=CYP2A6 genetic variation alters striatal-cingulate circuits, network hubs, and executive processing in smokers
#Text=Insula’s functional connectivity with ventromedial prefrontal cortex mediates the impact of trait alexithymia on state tobacco craving
#Text=Resting state functional connectivity in addiction: lessons learned and a road ahead
#Text=Mesocorticolimbic circuits are impaired in chronic cocaine users as demonstrated by resting-state functional connectivity
#Text=Impaired functional connectivity within and between frontostriatal circuits and its association with compulsive drug use and trait impulsivity in cocaine addiction
#Text=Right prefrontal and ventral striatum interactions underlying impulsive choice and impulsive responding
#Text=Methylphenidate reduces functional connectivity of nucleus accumbens in brain reward circuit
#Text=Initial evidence that OPRM1 genotype moderates ventral and dorsal striatum functional connectivity during alcohol cues
#Text=Neural correlates of substance abuse: reduced functional connectivity between areas underlying reward and cognitive control
#Text=The nucleus accumbens: a comprehensive review
#Text=Multimodal connectivity-based parcellation reveals a shell-core dichotomy of the human nucleus accumbens
#Text=Reliability and validity of Chinese version of the Addiction Severity Index among drug users in the community
#Text=The fifth edition of the Addiction Severity Index
#Text=DPARSF: a MATLAB toolbox for “pipeline” data analysis of resting-state fMRI
#Text=REST: a toolkit for resting-state functional magnetic resonance imaging data processing
#Text=Unified segmentation
#Text=Standardizing the intrinsic brain: towards robust measurement of inter-individual variation in 1000 functional connectomes
#Text=Improved optimization for the robust and accurate linear registration and motion correction of brain images
#Text=The influence of head motion on intrinsic functional connectivity MRI
#Text=Is there a common molecular pathway for addiction?
184-1	30687-30692	Brain	_	
184-2	30693-30701	dopamine	_	
184-3	30702-30705	and	_	
184-4	30706-30712	reward	_	
184-5	30713-30716	The	_	
184-6	30717-30724	nucleus	_	
184-7	30725-30734	accumbens	_	
184-8	30734-30735	:	_	
184-9	30736-30738	an	_	
184-10	30739-30748	interface	_	
184-11	30749-30756	between	_	
184-12	30757-30766	cognition	_	
184-13	30766-30767	,	_	
184-14	30768-30775	emotion	_	
184-15	30775-30776	,	_	
184-16	30777-30780	and	_	
184-17	30781-30787	action	_	
184-18	30788-30799	Spontaneous	_	
184-19	30800-30812	fluctuations	_	
184-20	30813-30815	in	_	
184-21	30816-30821	brain	_	
184-22	30822-30830	activity	_	
184-23	30831-30839	observed	_	
184-24	30840-30844	with	_	
184-25	30845-30855	functional	_	
184-26	30856-30864	magnetic	_	
184-27	30865-30874	resonance	_	
184-28	30875-30882	imaging	_	
184-29	30883-30892	Addiction	_	
184-30	30893-30900	related	_	
184-31	30901-30911	alteration	_	
184-32	30912-30914	in	_	
184-33	30915-30928	resting-state	_	
184-34	30929-30934	brain	_	
184-35	30935-30947	connectivity	_	
184-36	30948-30956	Regional	_	
184-37	30957-30968	homogeneity	_	
184-38	30969-30976	changes	_	
184-39	30977-30979	in	_	
184-40	30980-30996	heroin-dependent	_	
184-41	30997-31008	individuals	_	
184-42	31008-31009	:	_	
184-43	31010-31023	resting-state	_	
184-44	31024-31034	functional	_	
184-45	31035-31037	MR	_	
184-46	31038-31045	imaging	_	
184-47	31046-31051	study	_	
184-48	31052-31061	Combining	_	
184-49	31062-31069	spatial	_	
184-50	31070-31073	and	_	
184-51	31074-31082	temporal	_	
184-52	31083-31094	information	_	
184-53	31095-31097	to	_	
184-54	31098-31105	explore	_	
184-55	31106-31119	resting-state	_	
184-56	31120-31128	networks	_	
184-57	31129-31136	changes	_	
184-58	31137-31139	in	_	
184-59	31140-31149	abstinent	_	
184-60	31150-31166	heroin-dependent	_	
184-61	31167-31178	individuals	_	
184-62	31179-31190	Alterations	_	
184-63	31191-31193	in	_	
184-64	31194-31199	brain	_	
184-65	31200-31212	connectivity	_	
184-66	31213-31215	in	_	
184-67	31216-31221	three	_	
184-68	31222-31233	sub-regions	_	
184-69	31234-31236	of	_	
184-70	31237-31240	the	_	
184-71	31241-31249	anterior	_	
184-72	31250-31259	cingulate	_	
184-73	31260-31266	cortex	_	
184-74	31267-31269	in	_	
184-75	31270-31286	heroin-dependent	_	
184-76	31287-31298	individuals	_	
184-77	31298-31299	:	_	
184-78	31300-31308	evidence	_	
184-79	31309-31313	from	_	
184-80	31314-31321	resting	_	
184-81	31322-31327	state	_	
184-82	31328-31332	fMRI	_	
184-83	31333-31344	Association	_	
184-84	31345-31347	of	_	
184-85	31348-31356	nicotine	_	
184-86	31357-31366	addiction	_	
184-87	31367-31370	and	_	
184-88	31371-31381	nicotine's	_	
184-89	31382-31389	actions	_	
184-90	31390-31394	with	_	
184-91	31395-31403	separate	_	
184-92	31404-31413	cingulate	_	
184-93	31414-31420	cortex	_	
184-94	31421-31431	functional	_	
184-95	31432-31440	circuits	_	
184-96	31441-31447	CYP2A6	_	
184-97	31448-31455	genetic	_	
184-98	31456-31465	variation	_	
184-99	31466-31472	alters	_	
184-100	31473-31491	striatal-cingulate	_	
184-101	31492-31500	circuits	_	
184-102	31500-31501	,	_	
184-103	31502-31509	network	_	
184-104	31510-31514	hubs	_	
184-105	31514-31515	,	_	
184-106	31516-31519	and	_	
184-107	31520-31529	executive	_	
184-108	31530-31540	processing	_	
184-109	31541-31543	in	_	
184-110	31544-31551	smokers	_	
184-111	31552-31558	Insula	_	
184-112	31558-31559	’	_	
184-113	31559-31560	s	_	
184-114	31561-31571	functional	_	
184-115	31572-31584	connectivity	_	
184-116	31585-31589	with	_	
184-117	31590-31602	ventromedial	_	
184-118	31603-31613	prefrontal	_	
184-119	31614-31620	cortex	_	
184-120	31621-31629	mediates	_	
184-121	31630-31633	the	_	
184-122	31634-31640	impact	_	
184-123	31641-31643	of	_	
184-124	31644-31649	trait	_	
184-125	31650-31661	alexithymia	_	
184-126	31662-31664	on	_	
184-127	31665-31670	state	_	
184-128	31671-31678	tobacco	_	
184-129	31679-31686	craving	_	
184-130	31687-31694	Resting	_	
184-131	31695-31700	state	_	
184-132	31701-31711	functional	_	
184-133	31712-31724	connectivity	_	
184-134	31725-31727	in	_	
184-135	31728-31737	addiction	_	
184-136	31737-31738	:	_	
184-137	31739-31746	lessons	_	
184-138	31747-31754	learned	_	
184-139	31755-31758	and	_	
184-140	31759-31760	a	_	
184-141	31761-31765	road	_	
184-142	31766-31771	ahead	_	
184-143	31772-31789	Mesocorticolimbic	_	
184-144	31790-31798	circuits	_	
184-145	31799-31802	are	_	
184-146	31803-31811	impaired	_	
184-147	31812-31814	in	_	
184-148	31815-31822	chronic	_	
184-149	31823-31830	cocaine	_	
184-150	31831-31836	users	_	
184-151	31837-31839	as	_	
184-152	31840-31852	demonstrated	_	
184-153	31853-31855	by	_	
184-154	31856-31869	resting-state	_	
184-155	31870-31880	functional	_	
184-156	31881-31893	connectivity	_	
184-157	31894-31902	Impaired	_	
184-158	31903-31913	functional	_	
184-159	31914-31926	connectivity	_	
184-160	31927-31933	within	_	
184-161	31934-31937	and	_	
184-162	31938-31945	between	_	
184-163	31946-31960	frontostriatal	_	
184-164	31961-31969	circuits	_	
184-165	31970-31973	and	_	
184-166	31974-31977	its	_	
184-167	31978-31989	association	_	
184-168	31990-31994	with	_	
184-169	31995-32005	compulsive	_	
184-170	32006-32010	drug	_	
184-171	32011-32014	use	_	
184-172	32015-32018	and	_	
184-173	32019-32024	trait	_	
184-174	32025-32036	impulsivity	_	
184-175	32037-32039	in	_	
184-176	32040-32047	cocaine	_	
184-177	32048-32057	addiction	_	
184-178	32058-32063	Right	_	
184-179	32064-32074	prefrontal	_	
184-180	32075-32078	and	_	
184-181	32079-32086	ventral	_	
184-182	32087-32095	striatum	_	
184-183	32096-32108	interactions	_	
184-184	32109-32119	underlying	_	
184-185	32120-32129	impulsive	_	
184-186	32130-32136	choice	_	
184-187	32137-32140	and	_	
184-188	32141-32150	impulsive	_	
184-189	32151-32161	responding	_	
184-190	32162-32177	Methylphenidate	_	
184-191	32178-32185	reduces	_	
184-192	32186-32196	functional	_	
184-193	32197-32209	connectivity	_	
184-194	32210-32212	of	_	
184-195	32213-32220	nucleus	_	
184-196	32221-32230	accumbens	_	
184-197	32231-32233	in	_	
184-198	32234-32239	brain	_	
184-199	32240-32246	reward	_	
184-200	32247-32254	circuit	_	
184-201	32255-32262	Initial	_	
184-202	32263-32271	evidence	_	
184-203	32272-32276	that	_	
184-204	32277-32282	OPRM1	_	
184-205	32283-32291	genotype	_	
184-206	32292-32301	moderates	_	
184-207	32302-32309	ventral	_	
184-208	32310-32313	and	_	
184-209	32314-32320	dorsal	_	
184-210	32321-32329	striatum	_	
184-211	32330-32340	functional	_	
184-212	32341-32353	connectivity	_	
184-213	32354-32360	during	_	
184-214	32361-32368	alcohol	_	
184-215	32369-32373	cues	_	
184-216	32374-32380	Neural	_	
184-217	32381-32391	correlates	_	
184-218	32392-32394	of	_	
184-219	32395-32404	substance	_	
184-220	32405-32410	abuse	_	
184-221	32410-32411	:	_	
184-222	32412-32419	reduced	_	
184-223	32420-32430	functional	_	
184-224	32431-32443	connectivity	_	
184-225	32444-32451	between	_	
184-226	32452-32457	areas	_	
184-227	32458-32468	underlying	_	
184-228	32469-32475	reward	_	
184-229	32476-32479	and	_	
184-230	32480-32489	cognitive	_	
184-231	32490-32497	control	_	
184-232	32498-32501	The	_	
184-233	32502-32509	nucleus	_	
184-234	32510-32519	accumbens	_	
184-235	32519-32520	:	_	
184-236	32521-32522	a	_	
184-237	32523-32536	comprehensive	_	
184-238	32537-32543	review	_	
184-239	32544-32554	Multimodal	_	
184-240	32555-32573	connectivity-based	_	
184-241	32574-32586	parcellation	_	
184-242	32587-32594	reveals	_	
184-243	32595-32596	a	_	
184-244	32597-32607	shell-core	_	
184-245	32608-32617	dichotomy	_	
184-246	32618-32620	of	_	
184-247	32621-32624	the	_	
184-248	32625-32630	human	_	
184-249	32631-32638	nucleus	_	
184-250	32639-32648	accumbens	_	
184-251	32649-32660	Reliability	_	
184-252	32661-32664	and	_	
184-253	32665-32673	validity	_	
184-254	32674-32676	of	_	
184-255	32677-32684	Chinese	_	
184-256	32685-32692	version	_	
184-257	32693-32695	of	_	
184-258	32696-32699	the	_	
184-259	32700-32709	Addiction	_	
184-260	32710-32718	Severity	_	
184-261	32719-32724	Index	_	
184-262	32725-32730	among	_	
184-263	32731-32735	drug	_	
184-264	32736-32741	users	_	
184-265	32742-32744	in	_	
184-266	32745-32748	the	_	
184-267	32749-32758	community	_	
184-268	32759-32762	The	_	
184-269	32763-32768	fifth	_	
184-270	32769-32776	edition	_	
184-271	32777-32779	of	_	
184-272	32780-32783	the	_	
184-273	32784-32793	Addiction	_	
184-274	32794-32802	Severity	_	
184-275	32803-32808	Index	_	
184-276	32809-32815	DPARSF	_	
184-277	32815-32816	:	_	
184-278	32817-32818	a	_	
184-279	32819-32825	MATLAB	_	
184-280	32826-32833	toolbox	_	
184-281	32834-32837	for	_	
184-282	32838-32839	“	_	
184-283	32839-32847	pipeline	_	
184-284	32847-32848	”	_	
184-285	32849-32853	data	_	
184-286	32854-32862	analysis	_	
184-287	32863-32865	of	_	
184-288	32866-32879	resting-state	_	
184-289	32880-32884	fMRI	_	
184-290	32885-32889	REST	_	
184-291	32889-32890	:	_	
184-292	32891-32892	a	_	
184-293	32893-32900	toolkit	_	
184-294	32901-32904	for	_	
184-295	32905-32918	resting-state	_	
184-296	32919-32929	functional	_	
184-297	32930-32938	magnetic	_	
184-298	32939-32948	resonance	_	
184-299	32949-32956	imaging	_	
184-300	32957-32961	data	_	
184-301	32962-32972	processing	_	
184-302	32973-32980	Unified	_	
184-303	32981-32993	segmentation	_	
184-304	32994-33007	Standardizing	_	
184-305	33008-33011	the	_	
184-306	33012-33021	intrinsic	_	
184-307	33022-33027	brain	_	
184-308	33027-33028	:	_	
184-309	33029-33036	towards	_	
184-310	33037-33043	robust	_	
184-311	33044-33055	measurement	_	
184-312	33056-33058	of	_	
184-313	33059-33075	inter-individual	_	
184-314	33076-33085	variation	_	
184-315	33086-33088	in	_	
184-316	33089-33093	1000	_	
184-317	33094-33104	functional	_	
184-318	33105-33116	connectomes	_	
184-319	33117-33125	Improved	_	
184-320	33126-33138	optimization	_	
184-321	33139-33142	for	_	
184-322	33143-33146	the	_	
184-323	33147-33153	robust	_	
184-324	33154-33157	and	_	
184-325	33158-33166	accurate	_	
184-326	33167-33173	linear	_	
184-327	33174-33186	registration	_	
184-328	33187-33190	and	_	
184-329	33191-33197	motion	_	
184-330	33198-33208	correction	_	
184-331	33209-33211	of	_	
184-332	33212-33217	brain	_	
184-333	33218-33224	images	_	
184-334	33225-33228	The	_	
184-335	33229-33238	influence	_	
184-336	33239-33241	of	_	
184-337	33242-33246	head	_	
184-338	33247-33253	motion	_	
184-339	33254-33256	on	_	
184-340	33257-33266	intrinsic	_	
184-341	33267-33277	functional	_	
184-342	33278-33290	connectivity	_	
184-343	33291-33294	MRI	_	
184-344	33295-33297	Is	_	
184-345	33298-33303	there	_	
184-346	33304-33305	a	_	
184-347	33306-33312	common	_	
184-348	33313-33322	molecular	_	
184-349	33323-33330	pathway	_	
184-350	33331-33334	for	_	
184-351	33335-33344	addiction	_	
184-352	33344-33345	?	_	

#Text=Dopamine in drug abuse and addiction: results of imaging studies and treatment implications
#Text=Impulsivity and risk-taking behavior in focal frontal lobe lesions
#Text=Enhancing decision-making and cognitive impulse control with transcranial direct current stimulation (tDCS) applied over the orbitofrontal cortex (OFC): a randomized and sham-controlled exploratory study
#Text=What goes up, can come down: novel brain stimulation paradigms may attenuate craving and craving-related neural circuitry in substance dependent individuals
#Text=Frontostriatal circuits, resting state functional connectivity and cognitive control in internet gaming disorder
#Text=Cortical activity during manual response inhibition guided by color and orientation cues
#Text=Involvement of the inferior frontal junction in cognitive control: Meta-analyses of switching and Stroop studies
#Text=Imaging response inhibition in a stop-signal task: neural correlates independent of signal monitoring and post-response processing
#Text=Left inferior frontal gyrus is critical for response inhibition
#Text=Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans
#Text=Immature frontal lobe contributions to cognitive control in children: evidence from fMRI
#Text=Mapping interference resolution across task domains: a shared control process in left inferior frontal gyrus
#Text=The relationship between years of cocaine use and brain activation to cocaine and response inhibition cues
#Text=Fronto-striatal functional connectivity during response inhibition in alcohol dependence
#Text=Prefrontal response and frontostriatal functional connectivity to monetary reward in abstinent alcohol-dependent young adults
#Text=Alterations in brain structure and functional connectivity in alcohol dependent patients and possible association with impulsivity
#Text=Limbic and cortical information processing in the nucleus accumbens
185-1	33346-33354	Dopamine	_	
185-2	33355-33357	in	_	
185-3	33358-33362	drug	_	
185-4	33363-33368	abuse	_	
185-5	33369-33372	and	_	
185-6	33373-33382	addiction	_	
185-7	33382-33383	:	_	
185-8	33384-33391	results	_	
185-9	33392-33394	of	_	
185-10	33395-33402	imaging	_	
185-11	33403-33410	studies	_	
185-12	33411-33414	and	_	
185-13	33415-33424	treatment	_	
185-14	33425-33437	implications	_	
185-15	33438-33449	Impulsivity	_	
185-16	33450-33453	and	_	
185-17	33454-33465	risk-taking	_	
185-18	33466-33474	behavior	_	
185-19	33475-33477	in	_	
185-20	33478-33483	focal	_	
185-21	33484-33491	frontal	_	
185-22	33492-33496	lobe	_	
185-23	33497-33504	lesions	_	
185-24	33505-33514	Enhancing	_	
185-25	33515-33530	decision-making	_	
185-26	33531-33534	and	_	
185-27	33535-33544	cognitive	_	
185-28	33545-33552	impulse	_	
185-29	33553-33560	control	_	
185-30	33561-33565	with	_	
185-31	33566-33578	transcranial	_	
185-32	33579-33585	direct	_	
185-33	33586-33593	current	_	
185-34	33594-33605	stimulation	_	
185-35	33606-33607	(	_	
185-36	33607-33611	tDCS	_	
185-37	33611-33612	)	_	
185-38	33613-33620	applied	_	
185-39	33621-33625	over	_	
185-40	33626-33629	the	_	
185-41	33630-33643	orbitofrontal	_	
185-42	33644-33650	cortex	_	
185-43	33651-33652	(	_	
185-44	33652-33655	OFC	_	
185-45	33655-33656	)	_	
185-46	33656-33657	:	_	
185-47	33658-33659	a	_	
185-48	33660-33670	randomized	_	
185-49	33671-33674	and	_	
185-50	33675-33690	sham-controlled	_	
185-51	33691-33702	exploratory	_	
185-52	33703-33708	study	_	
185-53	33709-33713	What	_	
185-54	33714-33718	goes	_	
185-55	33719-33721	up	_	
185-56	33721-33722	,	_	
185-57	33723-33726	can	_	
185-58	33727-33731	come	_	
185-59	33732-33736	down	_	
185-60	33736-33737	:	_	
185-61	33738-33743	novel	_	
185-62	33744-33749	brain	_	
185-63	33750-33761	stimulation	_	
185-64	33762-33771	paradigms	_	
185-65	33772-33775	may	_	
185-66	33776-33785	attenuate	_	
185-67	33786-33793	craving	_	
185-68	33794-33797	and	_	
185-69	33798-33813	craving-related	_	
185-70	33814-33820	neural	_	
185-71	33821-33830	circuitry	_	
185-72	33831-33833	in	_	
185-73	33834-33843	substance	_	
185-74	33844-33853	dependent	_	
185-75	33854-33865	individuals	_	
185-76	33866-33880	Frontostriatal	_	
185-77	33881-33889	circuits	_	
185-78	33889-33890	,	_	
185-79	33891-33898	resting	_	
185-80	33899-33904	state	_	
185-81	33905-33915	functional	_	
185-82	33916-33928	connectivity	_	
185-83	33929-33932	and	_	
185-84	33933-33942	cognitive	_	
185-85	33943-33950	control	_	
185-86	33951-33953	in	_	
185-87	33954-33962	internet	_	
185-88	33963-33969	gaming	_	
185-89	33970-33978	disorder	_	
185-90	33979-33987	Cortical	_	
185-91	33988-33996	activity	_	
185-92	33997-34003	during	_	
185-93	34004-34010	manual	_	
185-94	34011-34019	response	_	
185-95	34020-34030	inhibition	_	
185-96	34031-34037	guided	_	
185-97	34038-34040	by	_	
185-98	34041-34046	color	_	
185-99	34047-34050	and	_	
185-100	34051-34062	orientation	_	
185-101	34063-34067	cues	_	
185-102	34068-34079	Involvement	_	
185-103	34080-34082	of	_	
185-104	34083-34086	the	_	
185-105	34087-34095	inferior	_	
185-106	34096-34103	frontal	_	
185-107	34104-34112	junction	_	
185-108	34113-34115	in	_	
185-109	34116-34125	cognitive	_	
185-110	34126-34133	control	_	
185-111	34133-34134	:	_	
185-112	34135-34148	Meta-analyses	_	
185-113	34149-34151	of	_	
185-114	34152-34161	switching	_	
185-115	34162-34165	and	_	
185-116	34166-34172	Stroop	_	
185-117	34173-34180	studies	_	
185-118	34181-34188	Imaging	_	
185-119	34189-34197	response	_	
185-120	34198-34208	inhibition	_	
185-121	34209-34211	in	_	
185-122	34212-34213	a	_	
185-123	34214-34225	stop-signal	_	
185-124	34226-34230	task	_	
185-125	34230-34231	:	_	
185-126	34232-34238	neural	_	
185-127	34239-34249	correlates	_	
185-128	34250-34261	independent	_	
185-129	34262-34264	of	_	
185-130	34265-34271	signal	_	
185-131	34272-34282	monitoring	_	
185-132	34283-34286	and	_	
185-133	34287-34300	post-response	_	
185-134	34301-34311	processing	_	
185-135	34312-34316	Left	_	
185-136	34317-34325	inferior	_	
185-137	34326-34333	frontal	_	
185-138	34334-34339	gyrus	_	
185-139	34340-34342	is	_	
185-140	34343-34351	critical	_	
185-141	34352-34355	for	_	
185-142	34356-34364	response	_	
185-143	34365-34375	inhibition	_	
185-144	34376-34387	Stop-signal	_	
185-145	34388-34398	inhibition	_	
185-146	34399-34408	disrupted	_	
185-147	34409-34411	by	_	
185-148	34412-34418	damage	_	
185-149	34419-34421	to	_	
185-150	34422-34427	right	_	
185-151	34428-34436	inferior	_	
185-152	34437-34444	frontal	_	
185-153	34445-34450	gyrus	_	
185-154	34451-34453	in	_	
185-155	34454-34460	humans	_	
185-156	34461-34469	Immature	_	
185-157	34470-34477	frontal	_	
185-158	34478-34482	lobe	_	
185-159	34483-34496	contributions	_	
185-160	34497-34499	to	_	
185-161	34500-34509	cognitive	_	
185-162	34510-34517	control	_	
185-163	34518-34520	in	_	
185-164	34521-34529	children	_	
185-165	34529-34530	:	_	
185-166	34531-34539	evidence	_	
185-167	34540-34544	from	_	
185-168	34545-34549	fMRI	_	
185-169	34550-34557	Mapping	_	
185-170	34558-34570	interference	_	
185-171	34571-34581	resolution	_	
185-172	34582-34588	across	_	
185-173	34589-34593	task	_	
185-174	34594-34601	domains	_	
185-175	34601-34602	:	_	
185-176	34603-34604	a	_	
185-177	34605-34611	shared	_	
185-178	34612-34619	control	_	
185-179	34620-34627	process	_	
185-180	34628-34630	in	_	
185-181	34631-34635	left	_	
185-182	34636-34644	inferior	_	
185-183	34645-34652	frontal	_	
185-184	34653-34658	gyrus	_	
185-185	34659-34662	The	_	
185-186	34663-34675	relationship	_	
185-187	34676-34683	between	_	
185-188	34684-34689	years	_	
185-189	34690-34692	of	_	
185-190	34693-34700	cocaine	_	
185-191	34701-34704	use	_	
185-192	34705-34708	and	_	
185-193	34709-34714	brain	_	
185-194	34715-34725	activation	_	
185-195	34726-34728	to	_	
185-196	34729-34736	cocaine	_	
185-197	34737-34740	and	_	
185-198	34741-34749	response	_	
185-199	34750-34760	inhibition	_	
185-200	34761-34765	cues	_	
185-201	34766-34781	Fronto-striatal	_	
185-202	34782-34792	functional	_	
185-203	34793-34805	connectivity	_	
185-204	34806-34812	during	_	
185-205	34813-34821	response	_	
185-206	34822-34832	inhibition	_	
185-207	34833-34835	in	_	
185-208	34836-34843	alcohol	_	
185-209	34844-34854	dependence	_	
185-210	34855-34865	Prefrontal	_	
185-211	34866-34874	response	_	
185-212	34875-34878	and	_	
185-213	34879-34893	frontostriatal	_	
185-214	34894-34904	functional	_	
185-215	34905-34917	connectivity	_	
185-216	34918-34920	to	_	
185-217	34921-34929	monetary	_	
185-218	34930-34936	reward	_	
185-219	34937-34939	in	_	
185-220	34940-34949	abstinent	_	
185-221	34950-34967	alcohol-dependent	_	
185-222	34968-34973	young	_	
185-223	34974-34980	adults	_	
185-224	34981-34992	Alterations	_	
185-225	34993-34995	in	_	
185-226	34996-35001	brain	_	
185-227	35002-35011	structure	_	
185-228	35012-35015	and	_	
185-229	35016-35026	functional	_	
185-230	35027-35039	connectivity	_	
185-231	35040-35042	in	_	
185-232	35043-35050	alcohol	_	
185-233	35051-35060	dependent	_	
185-234	35061-35069	patients	_	
185-235	35070-35073	and	_	
185-236	35074-35082	possible	_	
185-237	35083-35094	association	_	
185-238	35095-35099	with	_	
185-239	35100-35111	impulsivity	_	
185-240	35112-35118	Limbic	_	
185-241	35119-35122	and	_	
185-242	35123-35131	cortical	_	
185-243	35132-35143	information	_	
185-244	35144-35154	processing	_	
185-245	35155-35157	in	_	
185-246	35158-35161	the	_	
185-247	35162-35169	nucleus	_	
185-248	35170-35179	accumbens	_	
